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Background: New surgical approaches for apical prolapse have gradually been introduced, with few
prospective randomised controlled trial data to evaluate their safety and efficacy compared with
traditional methods.
Objective: To compare surgical uterine preservation with vaginal hysterectomy in women with uterine
prolapse and abdominal procedures with vaginal procedures in women with vault prolapse in terms of
clinical effectiveness, adverse events, quality of life and cost-effectiveness.
Design: Two parallel randomised controlled trials (i.e. Uterine and Vault). Allocation was by remote
web-based randomisation (1 : 1 ratio), minimised on the need for concomitant anterior and/or posterior
procedure, concomitant incontinence procedure, age and surgeon.
Setting: UK hospitals.
Participants: Uterine trial – 563 out of 565 randomised women had uterine prolapse surgery. Vault trial –
208 out of 209 randomised women had vault prolapse surgery.
Interventions: Uterine trial – uterine preservation or vaginal hysterectomy. Vault trial – abdominal or
vaginal vault suspension.
Main outcome measures: The primary outcome measures were women’s prolapse symptoms
(as measured using the Pelvic Organ Prolapse Symptom Score), prolapse-specific quality of life and
cost-effectiveness (as assessed by incremental cost per quality-adjusted life-year).
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Results: Uterine trial – adjusting for baseline and minimisation covariates, the mean Pelvic Organ Prolapse
Symptom Score at 12 months for uterine preservation was 4.2 (standard deviation 4.9) versus vaginal
hysterectomy with a Pelvic Organ Prolapse Symptom Score of 4.2 (standard deviation 5.3) (mean difference
–0.05, 95% confidence interval –0.91 to 0.81). Serious adverse event rates were similar between the
groups (uterine preservation 5.4% vs. vaginal hysterectomy 5.9%; risk ratio 0.82, 95% confidence interval
0.38 to 1.75). There was no difference in overall prolapse stage. Significantly more women would recommend
vaginal hysterectomy to a friend (odds ratio 0.39, 95% confidence interval 0.18 to 0.83). Uterine preservation
was £235 (95% confidence interval £6 to £464) more expensive than vaginal hysterectomy and generated
non-significantly fewer quality-adjusted life-years (mean difference –0.004, 95% confidence interval
–0.026 to 0.019). Vault trial – adjusting for baseline and minimisation covariates, the mean Pelvic Organ
Prolapse Symptom Score at 12 months for an abdominal procedure was 5.6 (standard deviation 5.4)
versus vaginal procedure with a Pelvic Organ Prolapse Symptom Score of 5.9 (standard deviation 5.4)
(mean difference –0.61, 95% confidence interval –2.08 to 0.86). The serious adverse event rates were
similar between the groups (abdominal 5.9% vs. vaginal 6.0%; risk ratio 0.97, 95% confidence interval
0.27 to 3.44). The objective anterior prolapse stage 2b or more was higher in the vaginal group than in
the abdominal group (odds ratio 0.38, 95% confidence interval 0.18 to 0.79). There was no difference in
the overall prolapse stage. An abdominal procedure was £570 (95% confidence interval £459 to £682)
more expensive than a vaginal procedure and generated non-significantly more quality-adjusted life-years
(mean difference 0.004, 95% confidence interval –0.031 to 0.041).
Conclusions: Uterine trial – in terms of efficacy, quality of life or adverse events in the short term, no
difference was identified between uterine preservation and vaginal hysterectomy. Vault trial – in terms
of efficacy, quality of life or adverse events in the short term, no difference was identified between an
abdominal and a vaginal approach.
Future work: Long-term follow-up for at least 6 years is ongoing to identify recurrence rates, need for
further prolapse surgery, adverse events and cost-effectiveness.
Trial registration: Current Controlled Trials ISRCTN86784244.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 13.
See the National Institute for Health Research Journals Library website for further project information.
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Plain English summary
About 1 in 10 women has pelvic organ prolapse (POP) surgery, and around three of these womenrequire a further operation.
The aim of this study was to identify the most appropriate surgery for two different types of POP found
in women: (1) when the uterus itself has come down – the Uterine trial – and (2) when a previous
hysterectomy has resulted in the top of the vagina coming down – the Vault trial.
In the Uterine trial, preserving the uterus was compared with removing it vaginally. In the Vault trial,
uplifting and supporting the vault prolapse using an abdominal approach was compared with a vaginal
approach. Women were asked about their prolapse and other symptoms affecting their quality of life (QoL).
The majority of women reported that their prolapse symptoms and QoL improved after surgery. The women’s
prolapse was also measured by clinical examination before and 12 months after their operation. All of these
results were compared between the different procedures.
It was found that all the surgical procedures were successful within the 12-month review period.
Abdominal surgery in the Vault trial as well as any that was required in the Uterine trial, was, however,
slightly less cost-effective.
Serious complications and the need for further prolapse surgery were similar in all groups. A small number
of women did require additional surgery for prolapse recurrence or for small mesh exposure when
additional or prolapse procedures had involved mesh.
Women in both trials will be followed up for at least 6 years to determine longer-term costs and
consequences.
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Scientific summary
Background
The treatment of women with pelvic organ prolapse is a considerable burden to the UK NHS. Prolapse is a
progressive condition, often initiated by childbirth, with the symptoms appearing many years later. Conservative
treatment with pelvic floor exercises, oestrogens and pessaries might help in the earlier stages, but 6–20% of
affected women will require surgery by the age of 80 years, with a further surgery rate of around 13%.
Surgeons and researchers have suggested that uterine preservation for uterine descent and abdominal
procedures for vault prolapse might provide a better chance of cure and reduce the need for further
surgery. This is important because if the failure rate is reduced, women will be exposed to less risk and the
costs may be less to the NHS. However, there is growing concern about the long-term consequences of
uterine preservation and abdominal procedures, especially if they require augmentation with mesh.
Aims and objectives
The aim of the Vault or Uterine prolapse surgery Evaluation was to compare the clinical effectiveness and
cost-effectiveness of treatment modalities for apical prolapse.
The primary outcome measures were women’s symptoms measured using the Pelvic Organ Prolapse Symptom
Score and prolapse-specific quality-of-life using a visual analogue scale. Cost-effectiveness was assessed as
cost per quality-adjusted life-year gained, based on the EuroQol-5 Dimensions, three-level version.
Secondary objectives were to compare treatments in terms of bladder, bowel and sexual function,
adverse events, objective measurement of anatomical prolapse stage (using the Pelvic Organ Prolapse
Quantification system), further treatment, cost to the health service and patients, and satisfaction with
treatment. Longer-term implications for cost-effectiveness were explored using a Markov probabilistic
decision-analytic model from the perspective of the NHS.
Methods
Research ethics approval and fully informed consent were obtained. The study included women who were
deemed to require apical (vault or uterine) surgery based on symptoms and/or anatomical findings. The study
excluded women who were unable or unwilling to consent or unable to complete study questionnaires.
UK hospitals with surgeons experienced in all procedures participated in the Vault or Uterine prolapse
surgery Evaluation between March 2013 and January 2017.
A total of 563 eligible women participated in the Uterine trial and 208 in the Vault trial.
Randomisation
For both the Uterine and the Vault trials, randomisation involved a computer-generated randomisation
system managed by the Centre for Healthcare Randomised Trials at the University of Aberdeen. Participants
were randomly allocated in a 1 : 1 ratio. The minimisation algorithm included surgeon, age (< 60 years or
≥ 60 years), type of planned apical prolapse repair, planned concomitant continence surgery and anterior
and/or posterior compartment prolapse repair.
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Study interventions
Surgeons were asked to use the surgical techniques with which they were most familiar. As this was a
pragmatic trial, deviation could occur both from the randomised allocation and from their normal practice
for clinical reasons. Details were recorded of concomitant surgery for anterior and/or posterior prolapse
and continence surgery.
Statistical analysis
An intention-to-treat analysis was performed in which participants with observed outcome data were
analysed according to their randomised allocation. Primary and secondary outcomes were compared using
generalised linear mixed models, adjusting for baseline covariates.
Health economics
Two within-trial cost-effectiveness analyses were conducted over the 12-month follow-up. All analyses were
reported on the intention-to-treat principle. NHS and participant perspectives were considered, and all
costs were reported in 2015–16 Great British pounds. Quality-adjusted life-years were calculated based on
responses to the EuroQoL Dimensions, three-level version questionnaire. Results were reported as incremental
cost-effectiveness ratios based on multiple imputations of missing data. Cost-effectiveness acceptability curves
and scatterplots of the cost-effectiveness plane were used to illustrate uncertainty in the data.
A de novo probabilistic Markov cohort model was developed to reflect the treatment pathway for women
requiring prolapse surgery and extrapolated the Uterine trial results over the longer term. The model
assigned a cohort of 1000 women, with an average age of 63 years, to mutually exclusive health states
(failure, complications and well) in monthly cycles over a 30-year time horizon. All-cause mortality was
included in the model as a competing risk. Transition probabilities between health states were based on
time to failure (requiring re-operation) and complications (requiring hospitalisation) observed in the trial and
extrapolated over the longer term using Weibull survival regression models. Utilities and costs of each
modelled health state were obtained from generalised linear regression models to determine the effect of
state membership on costs and quality-adjusted life-years using the trial data. All data were incorporated
into the model probabilistically, sampling from statistical distributions for each model parameter. The model’s
results are reported as discounted (3.5% per annum) incremental costs per quality-adjusted life-year from a
UK NHS perspective.
Results
In total, 2088 women were screened for eligibility. In the Uterine trial, 563 (41%) women were randomised
from 1365 eligible women, and 208 (49%) women were randomised to the Vault trial from 428 eligible
women. The main reason for declining randomisation was the woman’s or the surgeon’s preference for a
specific treatment. The majority of women, 469 (83%) in the Uterine trial and 175 (84%) in the Vault trial,
received their allocated treatment.
In the Uterine trial, 29 (10%) women randomised to uterine preservation underwent a vaginal hysterectomy,
31 (11%) did not receive any apical surgery and five (2%) underwent another apical intervention. Among
those women randomised to vaginal hysterectomy, five (2%) had a uterine preservation, 22 (8%) had no
apical surgery and two (< 1%) had other apical surgery.
In the Vault trial, seven (6.7%) women randomised to an abdominal procedure underwent a vaginal procedure
and 11 (10.6%) had no apical surgery. Among those women randomised to a vaginal procedure, four (3.8%)
had an abdominal procedure and 10 (9.6%) had no apical surgery.
The 12-month follow-up appointment was well attended [i.e. 466 (83%) of those women randomised
in the Uterine trial, and 178 (86%) of those women randomised in the Vault trial] and 478 (85%) of
Uterine trial participants and 177 (85%) of Vault trial participants completed the 12-month questionnaire
(primary outcome).
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Prolapse symptoms reported by women
The primary outcome was women’s report of prolapse symptoms on the Pelvic Organ Prolapse Symptom
Score. The score ranged from 0 to 28 at 12 months after randomisation. After adjusting for baseline scores
and minimisation covariates, the mean Pelvic Organ Prolapse Symptom Score was similar for each comparison:
l Uterine trial: a mean Pelvic Organ Prolapse Symptom Score for the uterine preservation group of 4.2
(standard deviation 4.9) versus a mean Pelvic Organ Prolapse Symptom Score for the vaginal hysterectomy
group of 4.2 (standard deviation 5.3) (mean difference –0.05, 95% confidence interval –0.91 to 0.81).
l Vault trial: a mean Pelvic Organ Prolapse Symptom Score for the abdominal procedure group of 5.6
(standard deviation 5.4) versus a mean Pelvic Organ Prolapse Symptom Score for the vaginal procedure
group of 5.9 (standard deviation 5.4) (mean difference –0.61, 95% confidence interval –2.08 to 0.86).
There was also no statistically significant difference in the prolapse-related quality-of-life score (range 0–10),
measured as the interference of prolapse symptoms with everyday life:
l Uterine trial: a mean prolapse-related quality-of-life score for the uterine preservation group of 1.7
(standard deviation 2.5) versus a mean prolapse-related quality-of-life score for the vaginal hysterectomy
group of 1.5 (standard deviation 2.5) (mean difference 0.12, 95% confidence interval –0.26 to 0.49).
l Vault trial: a mean prolapse-related quality-of-life score for the abdominal procedure group of 2.3
(standard deviation 3.0) versus a mean prolapse-related quality-of-life score for the vaginal procedure
group of 2.6 (standard deviation 2.8) (mean difference –0.25, 95% confidence interval –1.10 to 0.59).
Objective clinical outcomes
There were no clinical differences in the number of women with an overall or residual apical objective
prolapse beyond the hymen at 12 months after their operation:
l Uterine trial: 31.8% of women had an overall objective prolapse in the uterine preservation group
versus 34.1% of women in the vaginal hysterectomy group (odds ratio 0.85, 95% confidence interval
0.55 to 1.32).
Apical objective prolapses occurred in 5.7% of women in the uterine preservation group versus 5.3%
of women in the vaginal hysterectomy group (odds ratio 1.18, 95% confidence interval 0.48 to 2.94).
l Vault trial: 32.6% of women had an overall objective prolapse in the abdominal procedure group versus
46.9% of women in the vaginal procedure group (odds ratio 0.50, 95% confidence interval 0.25 to 1.02).
Apical objective prolapses occurred in 6.0% of women in the abdominal group versus 9.0% of women
in the vaginal group (odds ratio 0.61, 95% confidence interval 0.18 to 2.08). Objective anterior prolapse
stage 2b or more was higher in women in the vaginal group (odds ratio 0.38, 95% confidence interval
0.18 to 0.79).
Adverse events
The number of women with serious adverse events was similar between the groups in the first 12 months,
with blood loss (n = 5) and haematoma (n = 7) being the most common types of adverse event in the Uterine
trial and injury to bladder (n = 3) being the most common in the Vault trial. There were no statistically
significant differences between the randomised groups for any adverse event measure at any time period.
l Uterine trial: 5.4% of women in the uterine preservation group had an adverse event versus 5.9% of
women in the vaginal hysterectomy group (risk ratio 0.82, 95% confidence interval 0.38 to 1.75).
Of the 129 procedures (apical and concomitant) using a mesh implant, one mesh exposure/extrusion
was identified and required surgical treatment in the first 12 months after surgery.
l Vault trial: 5.9% of women in the abdominal procedure group had an adverse event versus 6.0% in
the vaginal procedure group (risk ratio 0.97, 95% confidence interval 0.27 to 3.44).
Of the 106 procedures (apical and concomitant) using a mesh implant, one concomitant continence
mesh exposure/extrusion was identified and required surgical treatment in the first 12 months
after surgery.
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Economic outcomes
l Uterine trial: the base-case analysis shows that, on average, uterine preservation is £235 (95% confidence
interval £6 to £464) more expensive than vaginal hysterectomy and generates non-significantly fewer
quality-adjusted life-years (adjusted mean difference –0.004, 95% confidence interval –0.026 to 0.019).
Uterine preservation was associated with a 15% chance of cost-effectiveness if society is willing to pay
£30,000 for a quality-adjusted life-year. The findings are driven slightly by the use of mesh for the initial
intervention procedure and a greater number of failure procedures over follow-up in the uterine
preservation group.
l Vault trial: abdominal vault repair was £570 (95% confidence interval £459 to £682) more expensive than
vaginal vault repair and generated more quality-adjusted life-years (mean difference 0.004, 95% confidence
interval –0.031 to 0.041), this generation of more quality-adjusted life-years was statistically not significant.
Abdominal repair had a 17% probability of being cost-effectiveness at a threshold of £30,000 per
quality-adjusted life-year.
The base-case model results echo the trial findings over a lifetime horizon. Future analysis will update the
model with longer-term follow-up data to validate the modelling assumptions regarding the trade-offs
between failures and complications following both surgeries.
Conclusions
There was evidence of no benefit from uterine preservation compared with vaginal hysterectomy in terms
of efficacy, quality of life, adverse events or any other outcome in women for uterine prolapse in the short
term. These findings were replicated when a comparison was made between abdominal and vaginal
procedures for vault prolapse. One woman in the Uterine trial required surgery for mesh exposure for the
apical procedure and one woman in the Vault trial required surgery for mesh exposure because of a
concomitant continence procedure using mesh.
Recommendations for future research
Long-term follow-up to at least 6 years after randomisation is ongoing to identify the recurrence rates,
need for further prolapse surgery and adverse events.
Trial registration
This trial is registered as ISRCTN86784244.
Funding
This project was funded by the National Institute for Health Research Technology Assessment programme
and will be published in full in Health Technology Assessment; Vol. 24, No. 13. See the National Institute
for Health Research Journals Library website for further project information.
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Chapter 1 Introduction
In 2012, the UK government’s National Institute for Health Research (NIHR) Health Technology Assessment(HTA) programme funded the Vault or Uterine prolapse surgery Evaluation (VUE) trial. This publication
describes the research.
The study was a major, multicentre, UK-based randomised controlled trial (RCT) investigating the clinical
effectiveness (including safety) and cost-effectiveness of surgical treatment, primarily in terms of improvement
in prolapse symptoms, in women having a uterine or a vault prolapse repair.
Relationship to PROlapse Surgery: Pragmatic Evaluation and randomised
Controlled Trials in women with anterior or posterior pelvic organ
prolapse
The PROlapse Surgery: Pragmatic Evaluation and randomised Controlled Trials (PROSPECT) in women with
anterior or posterior pelvic organ prolapse (POP)1 was a large HTA-funded UK-based RCT of anterior or
posterior prolapse surgery with or without the use of mesh (HTA reference number 07/60/18) that was
also undertaken by the research team (with long-term follow-up under way). The methods developed
in PROSPECT1 were used to inform the design, conduct, analysis and reporting of the VUE trial.
Description of the underlying health problem
Pelvic organ prolapse is the descent of pelvic organs from their normal anatomical position.
Prolapse can occur in three compartments: the anterior (cystocele) vaginal wall, the posterior (rectocele)
vaginal wall and the uterus or the apex (vault in those who have had a hysterectomy). Women can have
prolapsed in one or more compartments at the same time.
There is little epidemiological research into this condition because it has a variety of presentations and
they do not all cause symptoms, particularly in the early stages.2 Commonly reported symptoms include a
feeling of dragging or heaviness in the vagina, an uncomfortable bulge distending the introitus, urinary
symptoms (e.g. incontinence and voiding difficulty), bowel symptoms (e.g. incomplete emptying) and
sexual dysfunction.
The prevalence of prolapse varies depending on age, race and symptoms, with anterior prolapse being the
more prevalent.3–8
Standard management
Women with prolapses may be managed conservatively with pelvic floor muscle training (PFMT), pessaries or
surgery. Management of associated conditions, such as lower urinary tract symptoms (urinary incontinence
or overactive bladder syndrome), bowel problems (constipation or faecal incontinence), sexual dysfunction
and local vaginal atrophy caused by oestrogen deficiency if post-menopausal, may also be required.
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Conservative management for women with prolapses
There is not enough evidence to inform the use of mechanical devices (pessaries or rings), although these
are often used as a first-line treatment or can be used for women who are unfit for surgery or wish to
avoid surgery.9–12
Mechanical devices can be very efficacious, but further research is required to identify the best type of
device, the potential long-term effects and the use of supplementary treatments, such as oestrogen.9,10
Conservative physical treatments, such as PFMT, are also often recommended as first-line management.
The most recent reviews found evidence supporting the use of PFMT to prevent and reduce prolapse
symptoms and severity, as well as improvement in urinary and bowel symptoms.11,13
Vaginal oestrogen can also be used to reduce atrophic symptoms for post-menopausal women,
or for before and after surgery. However, the evidence supporting vaginal oestrogen use is limited
and inconclusive.14,15
Surgical management for women with prolapses
Surgery for POP is common, with recent estimates indicating that women have a lifetime risk of between
6% and 20% of undergoing surgery for prolapse.3,5,16,17
In England and Wales in 2016–17, 24,784 women were admitted to hospital with a main diagnosis of
female genital prolapse, and 29,729 operations were performed (some women had more than one type
of prolapse operation).18 The majority of operations (83%) were in women having an anterior repair
(n = 11,224), posterior repair (n = 6855) or both operations (n = 6502). Around 21% of women (n = 5148)
had an apical procedure. It was identified, from PROSPECT1 and NHS digital data,18 that around one-third
of women with prolapse have a hysterectomy for uterine prolapse.
The demand for surgical prolapse repair may increase given that projections have predicted a rise of around
1.4 million women in the UK aged 50–85 years (most likely to have surgery) between 2017 and 2027.19
Little is known about the long-term effectiveness and safety of different types of operations for uterine
or vault prolapse, although the National Institute for Health and Care Excellence (NICE) has provided
some guidance.11,20,21
Surgical management for women with uterine or vault prolapses
Women may present with an isolated uterine or vault (apical) prolapse or in combination with other
compartments. Numerous surgical techniques now exist for apical prolapse, but none has been properly
evaluated in terms of adequately powered multicentre RCTs.22–24
Uterine prolapse
If there is uterine descent (however small the uterus), removal of the uterus (hysterectomy) is standard
practice at the time of prolapse repair in most parts of the world. Uterine descent is the most common
indication for hysterectomy;25 however, hysterectomy for uterine descent is not an evidence-based practice.
At the onset of the VUE trial, surgery for uterine prolapse was broadly divided into two approaches:
uterine removal (hysterectomy) or uterine preservation.
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Uterine removal (hysterectomy)
When the uterus is removed during hysterectomy, the top of the vagina (the vaginal vault) must be
secured to prevent later descent, which presents as a vault prolapse. The two main options are:
1. vaginal hysterectomy with a vault support procedure, such as plication of uterosacral and
cardinal ligaments
2. subtotal abdominal hysterectomy (supracervical hysterectomy) and sacrocervicopexy (attaching the
cervical stump to the sacrum with mesh).
Uterine preservation
l Amputation of the cervix with shortening and apposition of the cardinal ligaments.
l Hysteropexy (attaching the uterus to the sacrospinous ligaments vaginally or to the sacrum abdominally
with sutures or mesh, or both).
Vault prolapses
After a hysterectomy, vault prolapse occurs in women when the vaginal vault descends into or out of the
vagina despite vault support procedures carried out at the time of hysterectomy.
At the onset of the VUE trial, a variety of techniques to suspend or reposition the vault were available.
The techniques were broadly divided into vaginal or abdominal approaches and included the following:
l Vaginal approaches:
¢ vaginal sacrospinous fixation or sacrospinous colpopexy (vault attachment to the sacrospinous
ligament, either bilaterally or on one side only; this is traditionally performed using sutures,
but mesh could also be used)
¢ transvaginal mesh kits that suspended the vault.
l Abdominal approaches:
¢ abdominal sacrocolpopexy (attachment of the vault to the sacrum, with a mesh bridge); this could
be an open, laparoscopic or robotic laparoscopic procedure.
Current recommendations from the National Institute for Health Care
and Excellence
An interventional procedures review26 and a Cochrane review22 have been conducted on the use of
mesh in uterine or vault prolapse. NICE considered the evidence from independent reviews, RCTs and
non-randomised studies, and in 2017 developed updated guidance on:
l sacrocolpopexy with hysterectomy using mesh for uterine prolapse repair – see Interventional
Procedures Guidance (IPG) 57723
l uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse – see IPG58427
l infracoccygeal sacropexy using mesh to repair uterine prolapse – see IPG58228
l infracoccygeal sacropexy using mesh to repair vaginal vault prolapse – see IPG58129
l sacrocolpopexy using mesh to repair vaginal vault prolapse– see IPG583.24
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Of these procedures, only the standard operation of sacrocolpopexy using mesh for vault prolapse
(IPG583) and uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse
(IPG584) are now considered to have enough evidence for safety and efficacy, such that they can be used
under standard arrangements.24 The uncertainty regarding the other procedures now means they require
strict clinical governance arrangements. A clinical decision-making tool is currently being developed.27
The decision to test uterine and vault prolapse surgical procedures
The most recent Cochrane review included 30 RCTs comparing surgical procedures for women with an
apical vaginal prolapse.22 The reviewers did not, however, separate the results for uterine and vault prolapse.
The reviewers, and others, concluded that there is still insufficient information about any of the surgical
options to guide management of uterine or vault prolapse and identified a need for adequately powered
RCTs.22,26,30 Thus, the evidence base for treating either of these groups of women is clearly inadequate
in terms of patient-reported outcomes [e.g. subjective prolapse symptoms, effect on quality of life (QoL)],
cost-effectiveness and safety.
Questions addressed by the VUE trial
Primary outcomes
To determine the optimal surgical management for women with uterine or vault prolapse, in terms of
clinical effectiveness, cost-effectiveness and adverse events (AEs). The two parallel trials compared:
l Uterine trial – in women having uterine prolapse surgery, the effects of a uterine preservation versus
vaginal hysterectomy
l Vault trial – in women having vault prolapse surgery, the effects of an abdominal vault versus a vaginal
vault suspension.
The Uterine trial and Vault trial participants are reported separately as they are believed to be two distinct
groups with different patient and clinical characteristics. Many studies combine results from both groups
of women with ‘any’ apical prolapse, which makes interpretation of these study results problematic.
Secondary outcomes
1. To determine the differential effects on other outcomes, such as urinary, sexual and bowel function,
QoL, general health, need for secondary surgery and AEs.
2. To identify possible effect modifiers (e.g. concomitant procedures, age, complex prolapse types).
The VUE trial assessed which of the most frequently employed techniques for uterine and vault prolapse
are most clinically effective, safe and cost-effective. This will guide gynaecologists in their surgical practice
and purchasers in their choice of provision of health care.
Given the number of uterine or vault prolapse procedures currently performed (around 5000 annually in
England),18 the potential cost implications for the health service are considerable.
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Chapter 2 Methods and practical arrangements
Study design
The methods developed in PROSPECT1 were used to inform the design, conduct, analysis and reporting
of the VUE trial.
The VUE trial comprised two parallel RCTs (i.e. the Uterine trial and the Vault trial) to determine the
clinical effectiveness (including safety) and cost-effectiveness of surgical treatment, primarily in terms of
improvement in prolapse symptoms in women having either uterine or vault POP surgery.
Participating centres were asked to randomise participants as close to surgery as possible to minimise
participant dropout; therefore, there was a delay from date of consent to date of randomisation. For the
majority of sites, randomisation occurred around 2 weeks prior to surgery. Participant questionnaires were
issued at 6 months after surgery and at 12 months after randomisation. This meant that if a woman did
not receive surgery, no 6-month follow-up questionnaires were issued, but 12-month questionnaires were
issued to all women. Women who received surgery were also reviewed in clinics 12 months after surgery
(Figure 1).
Further details of the study design, methodology and management [eligibility, consent, comparison of health
technologies, treatment allocation, data collection and processing, sample size calculation, avoidance of
bias (and blinding), serious adverse event (SAE) reporting] have been described previously.31 All trial case
report forms (CRFs) and participant completed questionnaires are included in the report methodology
(www.journalslibrary.nihr.ac.uk/programmes/hta/11129183/#/; accessed February 2019).
Study outcome measures
The VUE trial used the International Urogynaecological Association (IUGA)/International Continence
Society’s POP outcome recommendations and definitions.32
Three primary outcome measures were identified (www.journalslibrary.nihr.ac.uk/programmes/hta/
11129183/#/; accessed February 2019):
1. Women’s symptoms of prolapse [as measured using the patient-reported Pelvic Organ Prolapse Symptom
Score (POP-SS)]33 at 12 months after randomisation. This scale was derived from seven questions judged
to be most directly related to prolapse symptoms and has been shown to reflect the range and intensity
of symptoms experienced by women, as well as being responsive to change over time.34 Scores were
determined for each of the seven items (ranging from 0 for ‘never’ to 4 for ‘all of the time’), with an
overall POP-SS out of 28. Women who only partially completed the seven-item response schedule
(defined as having completed six out of seven items in the scale) were assumed to have no symptoms
when no response had been given to that individual item. Participants with more than one missing item
were considered to have a missing overall score. Women were considered to be symptomatic if their
overall score was > 0.
2. Quality of life (condition specific, measured as the woman’s rating of the overall effect of prolapse
symptoms on everyday life on a 0–10 visual analogue scale in which 10 is the worst).
3. The primary economic outcome measure of cost-effectiveness was the incremental cost per quality-
adjusted life-year (QALY), based on the EuroQol-5 Dimensions, three-level version (EQ-5D-3L).35
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Secondary outcomes
Other outcome measures included objective prolapse measurement; urinary, bowel and sexual symptoms
[using the International Consultation on Incontinence (ICI) suite of validated questionnaires];36 intra-operative
and postoperative complications, including the need for additional surgery (repeat surgery for prolapse
recurrence, further prolapse surgery, or incontinence, and surgery required for AEs); cost; and cost-effectiveness
(www.journalslibrary.nihr.ac.uk/programmes/hta/11129183/#/; accessed February 2019).
• Not meeting inclusion
   criteria
Randomised
Women aged ≥ 18 years requiring surgery
for vault or uterine prolapse
Baseline assessment
POP-SS POP-Q health status
Consented to vault trial
(n = 170)
• Do not wish to be
   randomised (50%)
Assessed for eligibility
(n = 1760)
Approached
(n = 1600)
Uterine
preservation
(n = 315)
Surgery
6 months after surgery
• Prolapse symptoms (POP-SS)
• Health status
• Complications
• Further treatment
12 months after randomisation
• Health status
• Complications
• Further treatment
12 months after surgery
• Prolapse signs (POP-Q)
• Complications
• Further treatment
12 months after randomisation
• Health status
• Complications
• Further treatment
12 months after surgery
• Prolapse signs (POP-Q)
• Complications
• Further treatment
6 months after surgery
• Prolapse symptoms (POP-SS)
• Health status
• Complications
• Further treatment
Surgery
Consented to uterine trial
(n = 630)
Vaginal
hysterectomy
(n = 315)
Abdominal vault
procedure
(n = 85)
Vaginal vault
procedure
(n = 85)
Excluded
Primary outcome (POP-SS) Primary outcome (POP-SS)
FIGURE 1 Flow diagram, with anticipated sample sizes. POP-Q, Pelvic Organ Prolapse Quantification System.
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Objective prolapse measurement
Objective prolapse staging was carried out using the Pelvic Organ Prolapse Quantification (POP-Q) system37
and classified from stage 0 to 4 for anterior, posterior and apical at baseline and 12 months after surgery.
The leading edge of the most descended compartment was used to define the overall stage.
The POP-Q system measures the maximum descent of each of the three prolapse compartments (anterior,
posterior and apical) relative to the hymen; measurements inside the vagina are negative, whereas those
outside the vagina are positive. An algorithm was employed to ensure that POP-Q staging was correctly
calculated from the component measurements of the POP-Q (i.e. Aa, Ba, C, D, Bp, Ap and total vaginal
length) in which common recording errors (e.g. Ba less than Aa) were corrected or queried. If data were
discrepant, they were corrected by consultation with the local hospital records to obtain additional data,
to achieve as complete a set of prolapse staging as possible, separately in each compartment. If the POP-Q
data were missing, the surgeon’s qualitative record of stage was accepted for both overall and individual
compartments (i.e. surgeons could specify the individual stage without giving the POP-Q measurements).
Usually, using the classic Bump criteria for the POP-Q system, any measurement from –1 cm (inside the
hymen) to + 1 cm outside the hymen counts as stage 2.37 Stage 2 was further subdivided into prolapse at
the hymen or within (–1 cm to 0 cm, stage 2a or less) compared with prolapse at > 0 cm (stage 2b).38,39
Thus, women were classified as having objective prolapse if the leading edge was at any point outside the
hymen (measured at > 0 cm, stage 2b or more).
Urinary, bowel and sexual symptoms
Symptoms related to other aspects of pelvic floor dysfunction were measured using the ICI suite of
validated questionnaires.36
Urinary incontinence was assessed using the International Consultation on Incontinence Questionnaire (ICIQ) –
urinary incontinence Short Form questionnaire (ICIQ-UI SF). Other urinary symptoms were recorded by the
ICIQ – female lower urinary tract symptoms (ICIQ-FLUTS) instrument. The latter provides subscales for filling,
voiding and incontinence symptoms.
The ICIQ bowel symptom questionnaire was not finalised when the VUE trial began. As in PROSPECT,1 draft
questions were drafted to produce a short summary of relevant bowel symptoms in line with the ROME criteria40
to define constipation (see Appendix 1, Table 39).
Vaginal and sexual symptoms were assessed using the ICIQ – vaginal symptoms (ICIQ-VS) questionnaire.36
The ICIQ-VS provides a brief and robust measure to assess the impact of vaginal symptoms and associated
sexual matters on QoL and the outcome of treatment. The questionnaire provides subscales for vaginal
symptoms, sexual matters and the overall impact of vaginal symptoms on QoL. Women who were sexually
inactive were asked whether this related to their vaginal or prolapse symptoms or for another reason
(including no partner).
Choice of validated outcome measures
Outcome measures were chosen to reflect the current international standards of reporting to ensure that
the findings would be relevant to patients, clinicians and policy-makers.32 The outcomes were measured at
baseline to provide values for later statistical adjustments. The primary measure of prolapse symptoms was
the woman’s subjective report using the POP-SS, developed and validated in a variety of populations for
both research and clinical practice.33
DOI: 10.3310/hta24130 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 13
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hemming et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
Temporary trial suspension
In June 2014, the Scottish Government requested that all Scottish NHS Health Boards considered suspending
the use of transvaginal mesh implants in the surgical treatment of stress urinary incontinence and POP to
enable an independent review to consider the ongoing debate on complication rates and AEs from the use
of transvaginal mesh implants. The VUE trial was temporarily suspended (in Scottish centres only) for a period
of 3 weeks during this time to ensure compliance and sponsor, Trial Steering Committee (TSC) and Data
Monitoring Committee (DMC) satisfaction with all trial processes across Scottish sites. The debate on the use
of transvaginal synthetic mesh continues.41,42
Blinding
Baseline data were reported by women before randomisation using self-completion questionnaires.
Outcome assessors were blinded to randomisation; participants were unblinded if they requested the
information. Surgeons were not blinded to the allocation procedure.
Sample size
Original sample size
The sample size calculations have been reproduced from that described in the original protocol publication.31
In the Uterine trial, 268 women in each arm were required to achieve 90% power to detect a difference
in the primary outcome measure (i.e. POP-SS at 12 months after randomisation) of 0.28 standard deviation (SD)
at a significance level of 5% (two-sided alpha). Allowing for 15% loss to follow-up at 12 months, 315 women
were required to be recruited to each arm (630 in total). The PROSPECT data indicated that a conservative
estimate of the SD of the primary outcome was 7 units and a difference in means of 2 units represented a
clinically important difference in POP-SS. Therefore, a standardised effect size of 2/7 = 0.28 SDs was used.
A smaller number of women were expected to be recruited to the Vault trial. Using data from the women
recruited to PROSPECT,1 the expected number of recruits to the Vault trial was estimated at 27% of that
recruited to the Uterine trial. Therefore, in the time that 630 women were to be recruited to the Uterine
trial, an expected 85 women were to be recruited to each arm of the Vault trial (170 in total). A trial of 170
would have 80% power to detect a difference of 0.43 SDs at a 5% significance level (two-sided alpha).
A standardised effect size of 0.43 equated to a difference in means of 3 units in the POP-SS measure.
In total, based on these assumptions, the number of recruits required across both trials was 800 women.
Important changes to the methods after trial commencement
Recruitment extension and increase in the Vault trial sample size
At steady state, recruitment rate of the Uterine trial was assumed to be approximately 29 women per
month. Recruitment was slower than anticipated, and averaged 15 women per month.
As a result, an extension to the recruitment phase (an additional 15 months) was necessary to achieve the
original target sample size (i.e. 630 women).
The PROSPECT data showed that the number of women requiring vault repair was approximately 27%
of the number presenting with uterine prolapse. Therefore, during the original time period for randomising
630 women to the Uterine trial, it was anticipated that a further 170 women requiring vault repair would
also be randomised to the Vault trial.1
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Recruitment rates to the Vault trial were in line with the original predictions. With an additional 15 months
of recruitment, the Vault trial recruited beyond the original sample size of 170.
Conservatively assuming an average of seven women randomised per month, it was projected that a
revised total of 280 Vault trial women would be recruited, which is 140 per arm or 119 allowing for
15% loss to follow-up. This gave 80% power to detect a difference of 0.36 SDs at 5% significance level
(two-sided alpha). A standardised effect size of 0.36 SDs equated to a difference in means of 2.5 units in
the primary outcome (POP-SS), considering a SD of 7 units. This was a smaller difference than originally
calculated (i.e. 3 units with 80% power). This also equated to a relative reduction in the width of the
confidence interval (CI) of 22% when compared with the precision without the extension. As the POP-SS
at baseline was higher in women with vault prolapse (15.2 vs. 12.0 in women with a uterine prolapse,
data from PROSPECT1) a greater difference after surgery was expected.
Statistical analysis
The predefined statistical analyses are included in the report methodology (www.journalslibrary.nihr.ac.uk/
programmes/hta/11129183/#/; accessed February 2019). These methods apply to both the Uterine and the
Vault trials, but each trial is reported and analysed separately.
A single principal analysis was undertaken 12 months after the last woman was randomised. All main
analyses were based on an intention-to-treat principle in which women with observed outcome data were
analysed according to their randomised allocation. All outcomes in both trials were described with the
appropriate descriptive statistics when relevant: mean and SD for continuous and count outcomes, or
medians and interquartile range if required for skewed data, numbers and percentages for dichotomous
and categorical outcomes.
The analysis of the primary outcome POP-SS estimated the mean difference (MD; and 95% CI) between
intervention and control groups at 12 months after randomisation using a linear mixed model with surgeon
fitted as a random effect that adjusted for the minimisation covariates and the baseline score. The full model
is available in Appendix 1, Table 40. A similar analysis was used to analyse the primary outcome at 6 months
after surgery.
All secondary outcomes were analysed in a similar manner but using the appropriate generalised linear
model (GLM) (logistic regression for dichotomous data, such as subjective prolapse failure) or time to event
methods (Cox regression for time to further surgery). If possible, all models were adjusted for minimisation
variables and baseline values.
Planned subgroup analyses
Subgroup analyses were carried out within the following groups:
l concomitant anterior and/or posterior repair or none
l concomitant continence procedure or not
l age (< 60 or ≥ 60 years).
Subgroup analyses were done as exploratory analyses, including treatment-by-factor interactions in
the model.
Non-compliance with allocated treatment
Non-compliance with allocated treatment was explored by producing descriptive tables of treatment
received versus treatment allocated. Per-protocol analyses were undertaken to estimate treatment effects
for those women who followed the protocol and received the same treatment as allocated.
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Missing data
The primary analysis was undertaken using the observed outcome data for the women. If women did not
have the outcome data they were excluded from the primary analysis; however, mechanisms of missingness
were explored by presenting descriptive tables of baseline characteristics by missing primary outcome status.
Multiple imputation was carried out for the primary outcome as a sensitivity analysis.
Missing outcome data
Although no imputation of missing participant-level outcome data was carried out in the main analysis of
the primary outcome, imputation of instruments was undertaken at item level according to the rules of the
specific instrument.
All randomised women were included in the analysis. Participants deemed ineligible after randomisation
were considered as randomisation exclusions and excluded from the analysis.
Missing outcome baseline data
Centre mean imputation of missing baseline data for continuous variables was undertaken in order to
reduce bias. For categorical variables, an additional category for the missing data was created.
Health economic evaluation
A within-trial economic evaluation assessing the costs, QoL and cost-effectiveness of the interventions
according to a NHS and patient perspective was undertaken for both the Uterine and the Vault trials. All
analyses were completed following the intention-to-treat principle. Trial data were used to populate a
Markov decision-analytic model, developed to extrapolate the 12-month data from the Uterine trial over
a longer time horizon (see Chapter 9). Methods are applicable to both the Uterine (see Chapter 5) and
the Vault (see Chapter 8) trials, that is, within-trial economic evaluations unless otherwise stated.
Health services perspective costs
The NHS resource-use data were collected using CRFs completed by the recruiting officers/research nurses
or gynaecologists and patient-completed questionnaires administered at baseline, at 6 months after surgery
and at 12 months after randomisation (www.journalslibrary.nihr.ac.uk/programmes/hta/11129183/#/;
accessed February 2019). The following categories of resource usage and costs were collected from a
NHS perspective:
l intervention delivery costs [based on a component costing approach for the base case and using
Healthcare Resource Group (HRG) tariffs as a sensitivity analysis]
l inpatient costs (cost of re-admissions for repeat prolapse procedures, incontinence procedures and
treatment of AEs)
l costs of consultations with health-care professionals [outpatient consultations and primary care
consultations, such as general practitioners (GPs), nurses, physiotherapists, etc.]
l medications and treatments relating to prolapse symptoms (e.g. oestrogens, pessaries, antibiotics).
Intervention costs
Two approaches to intervention costing were considered. The base-case analysis used a component
costing approach. Operative details were recorded at the time of surgery using CRFs completed at each
site by the recruiting officer/research nurse or gynaecologist (www.journalslibrary.nihr.ac.uk/programmes/
hta/11129183/#/; accessed February 2019). Resource use data collected included patient time in theatre,
grade of operating gynaecologist, grade of anaesthetist, other nursing staff, type of anaesthetic used and
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the use of prophylactic antibiotics. Details of concomitant surgery and catheterisation were also collected.
Intervention resources included the type of mesh for the apical procedures and for the concomitant
procedures. Detailed information regarding initial hospitalisation length of stay was available and was
used to assign appropriate hospitalisation costs to each group, based on per-night costs for a gynaecology
ward. The component costing approach focused on the costs that were predicted to differ across the
randomised groups. Microcosting information was not collected on items of resource use that were not
expected to differ across groups.
Secondary care resource use over follow-up
Inpatient resource use included further prolapse surgery, further urinary incontinence surgery, further
hospitalisations for complications and any other hospital resource use deemed relevant to the VUE trial.
Data on occurrence of a hospitalisation were primarily collected from participant-administered questionnaires
at 6 months after surgery and at 12 months after randomisation, and supplemented by asking women
about hospitalisations at their final clinic visit (12 months after surgery). The joint approach ensured the
greatest possible level of detail for analysis. All reported hospitalisations were then further investigated in
a post-coding exercise to (1) determine that they were related to the VUE trial, (2) obtain further details
on the category of procedure (e.g. further prolapse procedures: anterior, posterior, apical, combination)
and (3) ensure that procedures were not double counted. The post-coding exercise involved investigation
of site notes to verify the participant-reported data. The number of attendances for outpatient visits at
gynaecology clinics were collected from the patient-administered questionnaires.
Other consultations over follow-up
Participants reported contacts with primary care health professionals for prolapse-related symptoms in the
6- and 12-month questionnaires (after surgery and after randomisation, respectively). This included visits to
the GP, practice nurse, district nurse, physiotherapist (at a GP practice), physiotherapist (at a hospital clinic)
and any other related consultations with health professionals. When collating the data on primary care
resource usage, the following assumptions were made to ensure the best use of available data:
l when women answered ‘no’ to seeing a health professional, resource use was assumed as zero visits
l when women returned a questionnaire and left all items of resource use blank, data were assumed to
be missing
l when women returned a questionnaire and answered one or more categories as ‘yes’, leaving the
remaining blank, it was assumed that unticked boxes related to zero resource use.
Medications and treatments
Data on treatments and medications prescribed to women (i.e. oestrogens, bladder medications, catheters,
pessaries and antibiotics) for prolapse-related symptoms were collected using participant questionnaires.
Total costs to the NHS
Resource use data were multiplied by the relevant national average unit cost. Health services costs were
summed across categories to generate a total cost to the NHS of the intervention and the follow-up care for
each trial participant. Unit cost sources were the British National Formulary (BNF)43 and the NHS Business
Services Authority’s online drug tariff catalogue for medication resource use, Information Services Division
(ISD) Scotland was used for intervention (ward-specific) length of stay,44 NHS Reference Costs 2015–1645
was used to provide information for secondary care procedures and visits and the Personal and Social
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Services Research Unit (PSSRU) provided unit costs of health and social care for other consultations with
health professionals.46 All costs were reported in 2016–17 GBP. No discounting was required because of the
single-year time horizon. Detailed information on unit costs applied to each resource-use item, including any
assumptions that were made are provided in Table 1.
TABLE 1 The unit costs used for the within-trial cost-effectiveness analysis
Resource-use itema Unit
Cost per
unit (£) Comments Source
Operation resource use
Synthetic mesh Per mesh 112.97 Average list price of synthetic mesh
materials used in the PROSPECT
Glazener et al.1
Biological mesh Per mesh 310.41 Average list price of biological graft
materials used in the PROSPECT
Glazener et al.1
Mesh kits Per mesh kit 646.45 Average list price of mesh kits used in the
PROSPECT
Glazener et al.1
Gynaecologist/
anaesthetist time
(consultant)
Per hour 137.00 If surgery was supervised, assume
supervision provided by a consultant
grade. Cost per working hour, includes
qualification costs
Curtis and Burns46
Gynaecologist/
anaesthetist time
(specialty doctor)b
Per hour 71.00 Assume registrar. Cost per working hour,
includes qualification costs
Curtis and Burns46
Band 5 theatre
nurse
Per hour 42.15 Including qualification costs, cost working
hour. Assume three band 5 nurses
present for all procedures
Curtis and Burns;46 and
Glazener et al.1
Band 4 theatre
nurse
Per hour 34.98 Including qualification costs, cost per
working hour. Assume one band 4 nurse
present for duration of all procedures.
Curtis and Burns;46 and
Glazener et al.1
General anaesthesia Per case 20.76 Based on calculation (see Appendix 1,
Table 41) and personal communication
(Dr Christine Hemming, Aberdeen Royal
Infirmary, 2017)
BNF;43 and personal
communication
(Dr Christine Hemming,
Aberdeen Royal
Infirmary, 2017)
Spinal anaesthesia Per case 2.25 Based on calculation
(see Appendix 1, Table 41)
BNF;43 and personal
communication
(Dr Christine Hemming,
Aberdeen Royal
Infirmary, 2017)
Local anaesthesia Per case 0.40 Based on calculation
(see Appendix 1, Table 41)
BNF;43 and personal
communication
(Dr Christine Hemming,
Aberdeen Royal
Infirmary, 2017)
Surgical antibiotics Per case 1.06 Assume augmentin BNF;43 and Glazener
et al.1
Theatre overheads Per hour 420.19 Currently excludes consumables ISD Scotland,47,48
Cost of
catheterisation
Per catheter 6.37 Assume Folysil® (Coloplast Ltd,
Peterborough, UK) all-silicone catheters
(female); EDT, April 2015. Assume no
additional procedure time required if
catheterised during surgery
EDT49
Vaginal pack Per pack 4.67 Sorbsan packing 30 cm/2 g:
£3.47+ Hibitane™ (Derma UK Ltd,
Stotfold, UK) obstetric cream (£1.20)
EDT49
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TABLE 1 The unit costs used for the within-trial cost-effectiveness analysis (continued )
Resource-use itema Unit
Cost per
unit (£) Comments Source
Other treatments during admission for intervention
Return to theatre Per case 923.00 No data available on time in theatre for
returns; conservatively assume duration
was 1 hour
Direct cost, ISD
Scotland50
Laxatives Per pack of
tablets
1.96 5mg of bisacodyl BNF43
Pain relief Infusion 5.00 50mg of fentanyl BNF43
Pain relief Tablets 0.84 Tramadol BNF43
Length of stay
(gynaecology ward)
Per day 179.00 Payment by results tariff of £1433 spread
over 8 days, so £179 per day
Glazener et al.1
Consultations with secondary and primary health-care professionals/procedures for subsequent treatment or
consultations
New apical
procedure
Per procedure 4162.00 Average of appropriate HRG codes for
surgery for uterine and vault prolapse.
See Appendix 1, Table 42 for further
details
NHS Reference Costs
2015–1645
New anterior
procedure
Per procedure 2693.00 Average of appropriate HRG codes for
surgery for anterior prolapse. See
Appendix 1, Table 42 for further details
NHS Reference Costs
2015–1645
New posterior
procedure
Per procedure 2231.00 Average of appropriate HRG codes for
surgery for posterior prolapse. See
Appendix 1, Table 42 for further details
NHS Reference Costs
2015–1645
New anterior and
posterior combined
procedure
Per procedure 3204.00 HRG code for surgery for anterior and
posterior prolapse. See Appendix 1,
Table 42 for further details
NHS Reference Costs
2015–1645
New anterior and
apical procedure
Per procedure 5261.00 Average of appropriate HRG codes for
surgery for complex and major genital
tract procedures. See Appendix 1,
Table 42 for further details
NHS Reference Costs
2015–1645
New posterior and
apical procedure
Per procedure 5261.00 Average of appropriate HRG codes for
surgery complex and major genital tract
procedures. See Appendix 1, Table 42 for
further details
NHS Reference Costs
2015–1645
New anterior and
posterior and apical
procedure
Per procedure 6165.00 HRG code for very major genital tract
procedures with additional comorbidities
and complications to reflect the more
complex procedure. See Appendix 1,
Table 42 for further details
NHS Reference Costs
2015–1645
New sling
incontinence
procedure
Per procedure 2096.00 Average of elective case procedures for
HRG code LB51
NHS Reference Costs
2015–1645
Outpatient
consultation
Per
consultation
131.00 Average of gynaecology consultant and
non-consultant, non-admitted face-to-face
attendance
NHS Reference Costs
2015–1645
GP visit Per visit 36.00 Per 9.22-minute consultation, including
qualification costs
Curtis and Burns46
Practice nurse Per visit 14.47 Unit cost of £56 per hour of patient
contact (with qualification costs);
15.5-minute consultation
Curtis and Burns46
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Participant perspective costs
This wider cost perspective identified the effect of any shifts in the balance of care between the NHS
and the patients and their families. Participant perspective costs included out-of-pocket expenditure on
over-the-counter medications/products and private care to treat prolapse-related symptoms. The opportunity
cost to women (and companions) of attendance at primary and secondary care consultations was also
included, as was the cost of time off work (for those in paid employment).
TABLE 1 The unit costs used for the within-trial cost-effectiveness analysis (continued )
Resource-use itema Unit
Cost per
unit (£) Comments Source
District nurse Per visit 38.00 Average cost of a face-to-face contact Curtis and Burns46
Physiotherapist
(community and
hospital)
Per visit 34.00 Band 5 physiotherapist, cost per working
hour (assume visit duration of 1 hour for
community physiotherapist)
Curtis and Burns46
Other treatments:
Permanent/
indwelling catheter
Per woman
per year
1589.00 Based on a number of assumptions. See
Appendix 1, Table 43 for calculation details
EDT49
Disposable/
intermittent catheter
Per woman:
yearly cost
333.84 Based on a number of assumptions, see
Appendix 1, Table 44 for more details
NHS EDT;49 and NHS
Warrington Trust
documentation for
guidance of care51
Antibiotics Per day 0.28 Average costs of antibiotic drugs
reported by participants. See Appendix 1,
Table 45 for calculation
BNF43
Oestrogen treatment Per week 16.72 Vagifem® (Novo Nordisk, Bagsværd,
Denmark) vaginal tablets, 10-µg estradiol
vaginal pessary in disposable applicators
BNF43
Ring pessary Per pessary 20.09 Average across EDT products. See
Appendix 1, Table 46 for calculation
EDT49
Shelf pessary Per pessary 21.54 Average across EDT products. See
Appendix 1, Table 46 for calculation
EDT49
Drug treatment for
bladder problems
Per 56 tablet
pack
1.82 Assume tolterodine tartrate, generic
version to cover frequency and urgency
symptoms, 2 mg twice daily dose
BNF43
Participant perspective costs
Inpatient visit Per night 81.70 Time and travel costs for attendance to
an inpatient procedure (including index
procedure)
Glazener et al.1
Outpatient visit Per
attendance
50.82 Time and travel costs for attendance to
an outpatient department
Glazener et al.1
Primary care visit Per
attendance
13.75 Time and travel costs for a GP
appointment
Glazener et al.1
Time off work Per day 107.72 Assuming the average earnings/week
(£538.60) and a working week of
39.1 hours and a 5-day working week
ONS52
Other participant
expenses
Per
participant
Various As reported directly by the trial
participants
EDT, Electronic Drug Tariff; ONS, Office for National Statistics.
a Further details of unit cost data are presented in Appendix 1.
b Supervisory costs were also included, that is, an assumption was made that supervision would be performed by a
consultant gynaecologist/anaesthetist.
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To avoid additional patient burden through completion of lengthy questionnaires, it was assumed that the
unit cost of time and travel to health-care professionals was similar to PROSPECT.1 PROSPECT data for all
procedures (primary, secondary and cohort) were used to calculate unit costs of time and travel for inpatient,
outpatient and primary care visits (see Table 1). These unit costs were then multiplied by the number of
appropriate visits observed in the VUE trial to obtain a cost of time and travel tailored to the VUE trial
participants. For time off work, the appropriate national average price of 1 hour of work is used (see Table 1).
For the remaining aspects of personal incurred costs (i.e. private medical costs, over-the-counter medications,
other expenses), data are sourced directly from the participant questionnaires and multiplied by the relevant
participant-reported expense.
A wider cost perspective was obtained by summing together the total NHS and participant perspective
costs and is considered as a sensitivity analysis.
Outcome measurement, quality of life and quality-adjusted life-years
The EQ-5D-3L generic QoL instrument was completed by participants at baseline, at 6 months after surgery
and at 12 months after randomisation.53 The EQ-5D-3L instrument divides health status into five dimensions:
mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of these dimensions have
three levels, so 243 possible health states exist. EQ-5D-3L responses were presented in graphical format
illustrating the percentage of respondents with any problems on each domain, split by randomised arms
of the trial.
Responses to the EQ-5D-3L questionnaire were translated into utility values using the UK general
population tariffs, based on the time trade-off method, generating utility on a scale of worst possible
health state (–0.564) to best possible health state (1).35 Respondents who died during the trial were
assigned a utility of 0 at each time point following death.
The QALYs were then derived by multiplying the utility score at each time point by the length of time in
that health state. An area under the curve approach was used, assuming a linear extrapolation between
utility measurement time points.
Statistical analysis of cost and quality-adjusted life-year data
All components of costs were described with the appropriate descriptive statistics when relevant: mean and
SD for continuous and count outcomes, and numbers and percentages for dichotomous and categorical
outcomes (e.g. numbers reporting problems on EQ-5D-3L). All analyses were conducted using Stata
version 14.1® (StataCorp LP, College Station, TX, USA) software. Cost data were analysed using GLMs,
with adjustment for minimisation covariates specific to each trial and baseline measure when appropriate
(e.g. adjustment of QALYs and costs for baseline utility score).54 All models include a cluster effect for
surgeon. GLMs allow correction for the potential for skewed cost data (i.e. a small proportion of participants
incurring very high costs) by allowing specification of an appropriate distributional family and link function
to best fit the data. Different distributional families offer alternative specifications to reflect the relationship
between the mean and variance of the estimates under consideration.55,56 A modified Park test was used to
select the most appropriate distributional family for each analysis. Then, a combination of tests was run on
the preferred family to identify the most appropriate link function (Pearson correlation test, Pregibon link
test and a modified Hosmer and Lemeshow test). The preferred link function was chosen as the one that
performed best on the greatest number of the three tests, confirmed by examination of the respective
p-values of the tests. The process follows that outlined by Glick et al.55 and was implemented in Stata 14.1
using the user written ‘glmdiag’ command. The coefficient on treatment in the respective analysis models
represents the incremental treatment effect on costs and/or QALYs. When different link functions are used,
marginal effects are estimated on the cost and QALY scale, respectively and CIs calculated using the delta
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method.55,56 The base-case cost data area analysed using a gamma family with a log-link and the base-case
QALY data were analysed with a Poisson family and a power equal to 0.75 link function.
Incremental cost-effectiveness analysis
Cost-effectiveness calculations and interpretation
The primary outcome for the within-trial economic evaluations is incremental cost per QALY gained over
12 months. The mean cost (ΔC) and mean QALY (ΔQ) differences between the randomised groups (see
Statistical analysis of cost and quality-adjusted life-year data) were compared in order to obtain an estimate of
the cost of achieving one additional QALY by implementing the new intervention compared with the control
(e.g. the additional cost of uterine preservation vs. vaginal hysterectomy). This ratio between incremental
costs and QALYs (i.e. ΔC/ΔQ) gives the incremental cost-effectiveness ratio (ICER) for each comparison.
Estimates of the ICER are then compared with the recommended willingness-to-pay decision-making
threshold in the UK, which is currently between £20,000 and £30,000 per QALY gained.57 This means
that any intervention generating additional QALYs for a cost of < £20,000 would usually be considered
cost-effective. Conversely, using a similar decision rule, should an intervention deliver fewer QALYs than
the comparator, then society would need to be compensated to a value of > £20,000 to justify a QALY loss.
Interventions that deliver additional QALYs for lower costs (i.e. cost savings to the NHS) have a negative ICER
and are said to be dominant over the comparator.
Missing data
Missing data can pose significant problems for data analysis, especially surrounding data reported using
participant-administered questionnaires. A decision rule on imputation was taken as follows. If > 10% of
complete-case costs or complete-case QALYs were missing, or if > 15% of complete cost and QALY pairs
were missing, then imputation was considered for the base-case analysis. The analysis meets the prespecified
criteria for imputation and so the base-case analysis was based on multiple imputation of missing data.58
Data were imputed using the iterative chained equations approach within Stata 14.1’s ‘mi impute’ procedure.
Missing EQ-5D-3L data were imputed using predictive mean matching (the mean of five nearest values) to
account for multiple time points per respondent (i.e. at baseline, at 6 months after surgery and at 12 months
after randomisation). Missing cost data were imputed at the category level (operation cost, hospitalisation
cost, consultation cost and other treatment cost) using a multivariate regression approach. All imputation
models were adjusted for minimisation variables specific to each trial and baseline EuroQol 5 Dimensions
(EQ-5D)-derived utility score. Imputations were completed separately for the Uterine and Vault trials. Ten
imputations were considered sufficient to generate stable and reliable estimates for analysis. Imputed data
were then analysed using the appropriately specified GLMs described.
Assessment of uncertainty
Sampling uncertainty
Two types of uncertainty were considered for the analyses. First, the impact of sampling uncertainty on results
by using non-parametric bootstrap loops of the imputed regression models to generate a probability of cost-
effectiveness at commonly accepted threshold values of decision makers’ willingness to pay (WTP) for a QALY
gained (£0, £10,000, £20,000, £30,000 and £50,000) was considered. In all cases, 1000 repetitions of the
model are estimated, and recycled predictions are used to retrieve the mean estimates of incremental costs
and QALYs.59 The bootstrap replications of the models were further used to illustrate sampling uncertainty
as follows. All 1000 replications of the bootstrapped estimates of the differences in costs and QALYs were
plotted on the cost-effectiveness plane. This allows for a visual representation of the joint uncertainty in the
effect sizes for cost and QALY estimates. The quadrant of the cost-effectiveness plane in which the majority
of bootstrapped replications (dots) lies allows for a visualisation of the probability that the new intervention is
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(a) less costly and more effective (dominant, south-east quadrant) versus the comparator; (b) more costly
and less effective (dominated, north-west quadrant) versus the comparator; (c) less costly and less effective
(south-west quadrant); or (d) more costly and more effective (north-east quadrant). To further illustrate
sampling uncertainty, cost-effectiveness acceptability curves (CEACS) were produced. CEACS and scatterplots
are used to represent the probability that different interventions are cost-effective at various threshold values
for society’s WTP for an additional QALY. CEACs present results when the analysis follows a net benefit
approach, in which the net monetary benefit (NMB) of an intervention is calculated as a straight forward
re-arrangement of the cost-effectiveness decision rule used when calculating ICERs such that:
NMB = (λ × ΔQ) –ΔC > 0, (1)
where λ gives the threshold value of WTP for a QALY. If the above expression holds true, the intervention is
considered cost-effective. The NMB is calculated for a range of plausible threshold values of λ. The resultant
CEACs illustrate the probability of cost-effectiveness at different λ values.
Sensitivity analyses
A range of deterministic sensitivity analyses were conducted to assess the impact of important choices
surrounding assumptions and analysis models on the cost-effectiveness findings. All sensitivity analyses
were conducted using data sets with multiple imputation of missing cost and QALY data, and each
analysis is subjected to the same assessment of sampling uncertainty with the production of scatterplots
and CEACs for each sensitivity analysis undertaken. The following sensitivity analyses were explored.
Intervention costing approach
The base-case analysis uses component-based intervention costing using a high level of detail around
resource use and staff time obtained for each trial participant. However, the use of appropriate HRG tariffs
mapped to procedures in the trial was considered as a sensitivity analysis. HRG tariffs more closely reflect
the current best estimate of the NHS costs of different procedures. However, the tariffs do not possess
the intricate level of detail available from a trial study and, as such, may not fully consider the opportunity
costs of resource use, such as consultant time, time in hospital, etc. As such, HRG tariffs may not be
sufficiently sensitive to capture the different resource use for each procedure. Nonetheless, it is important
to understand any potential discrepancies in intervention costing depending on the approach taken.
Choice of analysis model for costs and outcomes
The base-case analysis uses GLMs with family and link functions. To explore uncertainty in the choice
of model on estimates of cost-effectiveness, an alternative seemingly unrelated regression approach
(i.e. the Sureg approach) was used.60 The Sureg approach allows an alternative approach to estimate
cost-effectiveness while accounting for the underlying correlation structure between costs and QALYs.
Use of complete-case (rather than multiply imputed) analysis
The base-case analysis uses multiple imputation of missing data. Sensitivity analyses explored the impact
of rerunning the analyses using complete cost and QALY pairs. Two analyses were completed on the
complete-case data, first using the GLMs specified in the base case and, second, using seemingly unrelated
regression as an alternative approach to account for the correlation between costs and QALYs.60
Quality-adjusted life-year calculation approach
Participants received 6-month questionnaires triggered by the date of surgery and 12-month questionnaires
triggered by the date of randomisation. The differing approach was required to ensure that appropriate
clinical outcome measures that were relevant to the trial intervention were collected. This approach meant
potential existed for women to receive their 12-month follow-up questionnaire prior to their 6 month and
could have implications for QALY estimates, which are based on an area under the curve approach across
time points. The base-case analysis uses data as reported in the questionnaires and makes no further
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adjustment. Sensitivity analysis explores three different configurations. First, the impact of dropping any QALY
data where the 12-month questionnaire was completed before the 6-month questionnaire was explored.
Second, any data when the difference between the 6- and 12-month questionnaires was < 3 months was
dropped. Finally, an analysis in which the exact date of the questionnaire was used as the time point for
QALY calculation was explored.
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Chapter 3 Baseline characteristics: the Uterine trial
Between January 2013 and January 2017, 1544 women were identified as potential participants in theUterine trial of the VUE trial.
This chapter describes how participating women were identified from the women considered for uterine
prolapse surgery in 45 UK hospitals (see Appendix 2, Table 47) and reports the baseline characteristics up
to the point of entry to the Uterine trial. The subsequent findings are described in Chapters 4 and 5.
Study recruitment
The trial outline and methodology for recruitment to the VUE trial have been described previously31 (see
Chapter 2). Women attending gynaecology outpatient clinics who chose to have surgery for symptomatic
uterine POP and women on the waiting list for uterine prolapse surgery were invited to participate in the
Uterine trial. Women were asked if they were willing to be randomised to either a uterine preservation or a
vaginal hysterectomy for their uterine prolapse. The centres and surgeons who participated in the VUE trial,
the numbers recruited, and the rate of recruitment are detailed in Appendix 2 (Table 47 and Figure 19).
Non-recruited women
Of the 1544 women approached to participate in the Uterine trial, 979 did not enter the study because
they declined (n = 774, 50.1%), were ineligible (n = 177, 11.5%) or not timely identified or seen (n = 28,
1.8%; see Appendix 2, Tables 48 and 49 for more details). Women’s preference (n = 431, 55.7%) for a
particular surgery [most commonly the preference was for a vaginal hysterectomy (n = 324, 41.9%; see
Appendix 2, Table 49)], was the most common reason for declining. Ineligible reasons included ‘a specific
operation is necessary’ (n = 77, 43.5%), ‘unsuitable due to medical history’ (n = 28, 15.8%) and ‘not
suitable for surgery’ (n = 13, 7.3%). Other reasons included not wanting to be randomised (n = 149,
19.3%), deciding against surgery (n = 219, 28.3%) and deciding to try a pessary (n = 34, 4.4%).
Recruited women: baseline characteristics
The baseline characteristics of the 563 women who agreed to participate in the Uterine trial and were truly
eligible are described in Table 2 (see also Appendix 2, Table 50 and Figure 3).
Epidemiological characteristics
There was no difference between the randomised groups in respect of age, body mass index (BMI),
parity or delivery mode history (with the majority of women having a normal vaginal delivery; see also
Appendix 2, Table 50).
Previous treatment for prolapse
Overall, around one-third of women had undergone PFMT with the same proportion of women having
used a vaginal pessary (ring or other type) before surgery. Fewer than 1 in 10 women had undergone
previous surgery for prolapse (Table 2).
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Prolapse symptoms at baseline
There were no differences in prolapse symptoms at baseline. Overall, women in the Uterine trial had been
symptomatic for around 4 years, and had been bothered by their symptoms for just over 2 years (Table 3).
The mean POP-SS before surgery was 13.6 out of a maximum score of 28 (Table 3) and the score ranged
from 0 to 28. Using a POP-SS of > 0 to indicate presence of symptoms, around 94% of women had
at least one symptom. The prolapse-related effect on QoL score (‘overall, how much do your prolapse
symptoms interfere with your everyday life?’) ranged from 0 to 10 out of 10, with a mean value of 6.7 out
of 10 (Table 3).
The most common individual prolapse symptom was ‘a feeling of something coming down from or in your
vagina’ reported in 91.7% of women. This was reported ‘most or all of the time’ in 72.0% of women and
was the most bothersome symptom in around half (49.7%) of the women.
Around one-third (33.0%) of women found that the prolapse caused hygiene problems, and almost one in
five (17.8%) needed to relieve pressure or discomfort from the prolapse using their fingers (Table 3).
TABLE 2 Baseline characteristics of Uterine trial participants
Characteristic
Treatment
Uterine preservation Vaginal hysterectomy
Age (years), mean (SD); n 63.4 (10.5); 280 63.9 (9.9); 283
BMI (kg/m2), mean (SD); n 27.7 (4.1); 233 27.1 (4.1); 239
BMI category, n (%)
Normal weight 60 (21.4) 72 (25.4)
Overweight 104 (37.1) 100 (35.3)
Obese 59 (21.1) 59 (20.8)
Morbidly obese 10 (3.6) 8 (2.8)
Missing 47 (16.8) 44 (15.5)
Parity, median (P25–75),a n 2 (2–3); 280 2 (2–3); 283
Number of normal vaginal deliveries, mean (SD); n 2.3 (1.3); 271 2.3 (1.1); 277
Previous conservative treatment, n (%)
Vaginal pessary 81 (28.9) 86 (30.4)
Physiotherapy for prolapse 73 (26.1) 73 (25.8)
Physiotherapy for urinary incontinence 27 (9.6) 32 (11.3)
Drugs for UI 20 (7.1) 21 (7.4)
Previous surgery, n (%)
Previous anterior repair 6 (2.1) 12 (4.2)
Previous posterior repair 8 (2.9) 9 (3.2)
Vaginal repair, but compartment unknown 2 (0.7) 10 (3.5)
Previous incontinence 5 (1.8) 12 (4.2)
BMI, body mass index; UI, urinary incontinence.
a P25–75 is the 25th to the 75th percentile range.
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TABLE 3 Prolapse symptoms and generic QoL at baseline
Symptom
Treatment
Uterine preservation Vaginal hysterectomy
Duration of symptoms (years), mean (SD); n 4.1 (5.7); 264 4.0 (6.3); 256
Duration of bother (years), mean (SD); n 2.2 (2.8); 257 2.2 (2.9); 249
POP-SS at baseline, mean (SD); n 13.7 (6.4); 268 13.5 (5.9); 265
Number of women symptomatic, n (%) 266 (95.0) 264 (93.3)
Prolapse-related effect on QoL score, mean (SD); n 6.8 (2.7); 273 6.5 (2.9); 270
Individual prolapse symptoms, n (%)
Something coming down (any) 258 (92.1) 258 (91.2)
Something coming down (most/all of the time) 201 (71.8) 204 (72.1)
Bladder not empty (any) 238 (85.0) 225 (79.5)
Bladder not empty (most/all of the time) 114 (40.7) 102 (36.0)
Uncomfortable feeling or pain when standing (any) 217 (77.5) 214 (75.6)
Uncomfortable feeling or pain when standing (most/all of
the time)
102 (36.4) 109 (38.5)
Dragging in abdomen (any) 213 (76.1) 210 (74.2)
Dragging in abdomen (most/all of the time) 92 (32.9) 97 (34.3)
Strain to empty bladder (any) 203 (72.5) 187 (66.1)
Strain to empty bladder (most/all of the time) 94 (33.6) 74 (26.1)
Bowel not empty (any) 199 (71.1) 198 (70.0)
Bowel not empty (most/all of the time) 67 (23.9) 54 (19.1)
Dragging in back (any) 171 (61.1) 175 (61.8)
Dragging in back (most/all of the time) 63 (22.5) 61 (21.6)
Most bothersome symptom, n (%)
Something coming down 133 (47.5) 147 (51.9)
Bladder not empty 36 (12.9) 22 (7.8)
Uncomfortable feeling or pain when standing 23 (8.2) 27 (9.5)
Strain to empty bladder 18 (6.4) 10 (3.5)
Bowel not empty 18 (6.4) 16 (5.7)
Dragging in abdomen 17 (6.1) 13 (4.6)
Dragging in back 9 (3.2) 15 (5.3)
Symptom causing most bother not applicable 12 (4.3) 11 (3.9)
Missing 26 (9.3) 33 (11.7)
Actions necessitated by prolapse symptoms, n (%)
Extra hygiene measures 88 (31.4) 98 (34.6)
Fingers to ease discomfort 46 (16.4) 54 (19.1)
Digitally evacuate bowel 10 (3.6) 13 (4.6)
continued
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Generic quality of life
The mean QoL score and visual scales (EQ-5D-3L) were 0.752 and 75.1 points, respectively.
Preoperative objective prolapse measurements
The leading edge of the most descended compartment relative to the hymen was used for the overall
POP-Q stage. The majority (94.1%) of women had an overall objective prolapse and 53.5% had a uterine
prolapse beyond the hymenal ring [stages 2b or more (Table 4; see also Appendix 2, Table 51)]. Around half
(49.4%) of the women had an overall stage 3 prolapse of any compartment (see Appendix 2, Table 51), with
43.2% of women specifically having a stage 2 uterine prolapse.
TABLE 3 Prolapse symptoms and generic QoL at baseline (continued )
Symptom
Treatment
Uterine preservation Vaginal hysterectomy
Fingers to help empty bladder 4 (1.4) 6 (2.1)
Fingers to help empty bowel 2 (0.7) 5 (1.8)
EQ-5D, mean score (SD); n 0.728 (0.232); 270 0.775 (0.187); 266
EQ-5D visual scale, mean score (SD); n 74.2 (18.6); 266 76.2 (17.7); 267
Note
Bold text highlights differences between severity of symptom for that particular problem.
TABLE 4 Preoperative objective prolapse measurements
Stage
Treatment, n (%)
Uterine preservation
(N= 280)
Vaginal hysterectomy
(N= 283)
Overall stage 2b or more 261 (93.2) 269 (95.1)
Apical stage
0 1 (0.4) 1 (0.4)
1 89 (31.8) 68 (24.0)
2a 43 (15.4) 46 (16.3)
2b 76 (27.1) 78 (27.6)
3 57 (20.4) 71 (25.1)
4 4 (1.4) 15 (5.3)
Missing 10 (3.6) 4 (1.4)
Stage 2b or more 137 (48.9) 164 (58.0)
Anterior prolapse stage 2b or more 249 (88.9) 265 (93.6)
Posterior prolapse stage 2b or more 76 (27.1) 91 (32.2)
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Planned concomitant surgery
Planned surgery was based on preoperative findings on clinical examination and women remained in the
group to which they were allocated, irrespective of the actual procedure performed (Table 5). In order to
take into account minimisation criteria, centres were asked to specify in advance which concomitant
surgery was also thought to be necessary.
All women were expected to undergo a uterine prolapse procedure. Most women (85.5%) were expected
to undergo a concomitant prolapse repair. Planned procedures were equally distributed between the two
randomised groups.
Vaginal and sexual symptoms at baseline
Vaginal and sexual symptoms were measured using the ICI-validated instruments36 (www.journalslibrary.
nihr.ac.uk/programmes/hta/11129183/#/; accessed February 2019). These symptoms were common and
had effects on QoL. The majority of women were not sexually active (70.0%) and in around one in five of
the women this was most often because of their prolapse symptoms. Among the women who were
sexually active, or whose reason for no sex life was not ‘due to prolapse symptoms,’ a few (n = 5) had
dyspareunia (pain with intercourse) at baseline (Table 6).
Urinary and bowel symptoms at baseline
Urinary symptoms were relatively common and affected QoL. Women were counted as symptomatic if they
had the symptom ‘most or all of the time’. Nocturia and urgency were common types of urinary symptom.
Overall, around one in five (22.6%) women reported at least some urinary incontinence (using the ICIQ-UI
SF)36 and this was slight or moderate in the majority (68.9%) of cases (see Appendix 2, Table 52). The
mean QoL because of urinary symptoms was 3.9 out of 10 (Table 7).
Few women reported bowel symptoms, and these did not appear to have a large impact on QoL with the
mean 2.7 out of 10 (Table 7). Around one-third (30.2%) of all women reported faecal incontinence at
least occasionally [defined as loss of solid or liquid stool, but not including loss of flatus (wind)] and this
was severe in < 9% of women. Few women (6.2%) reported constipation.
TABLE 5 Planned concomitant surgery
Planned concomitant surgery
Treatment, n (%)
Uterine preservation (N= 280) Vaginal hysterectomy (N= 283)
None 40 (14.3) 40 (14.1)
Anterior repair 114 (40.7) 135 (47.7)
Anterior and posterior repair (both) 114 (40.7) 99 (35.0)
Posterior repair 11 (3.9) 8 (2.8)
Enterocele repair 13 (4.6) 10 (3.5)
Concomitant continence surgery 11 (3.9) 10 (3.5)
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TABLE 6 Vaginal and sexual symptoms at baseline
Vaginal/sexual symptom
Treatment
Uterine preservation
(N= 280)
Vaginal hysterectomy
(N= 283)
ICI Vaginal Symptoms Score, mean (SD); n 21.6 (9.9); 249 21.7 (8.4); 244
QoL due to vaginal symptoms, mean (SD); n 5.2 (3.4); 264 4.9 (3.4); 265
ICI Sexual Matters Score,a mean (SD); n 28.4 (18.1); 89 24.1 (16.4); 79
QoL due to effect on sex life, mean (SD); n 5.4 (3.1); 89 5.0 (3.2); 79
Vagina too loose or lax, n (%) 41 (14.6) 31 (11.0)
Reduced sensation, n (%) 17 (6.1) 18 (6.4)
Number having intercourse, n (%) 89 (31.8) 80 (28.3)
Pain with intercourse,a n (%) 4 (4.5) 1 (1.3)
Missing, n (%) 0 (0) 1 (1.3)
Reasons for not being sexually active, n (%)
Prolapse symptoms 59 (21.1) 63 (22.3)
No partner 51 (18.2) 56 (19.8)
Vaginal symptoms 12 (4.3) 13 (4.6)
Other reasons 45 (16.1) 47 (16.6)
Reason not given 113 (40.4) 104 (36.7)
a Out of sexually active women.
TABLE 7 Urinary and bowel symptoms at baseline
Symptom
Treatment
Uterine preservation
(N= 280)
Vaginal hysterectomy
(N= 283)
Urinary symptoms, n (%)
Urgency 72 (25.7) 42 (14.8)
Nocturia 71 (25.4) 52 (18.4)
Frequency 29 (10.4) 34 (12.0)
All the above 9 (3.2) 5 (1.8)
Any incontinence, n (%) 66 (23.6) 61 (21.6)
Severe 20 (7.3) 12 (4.2)
Missing 9 (3.2) 17 (6.0)
Incontinence-related QoL score, mean (SD); n 3.9 (3.3); 231 3.9 (3.3); 231
ICI Urinary Incontinence Score, mean (SD); n 8.0 (5.2); 223 7.7 (5.2); 226
ICIQ-FLUTS Filling Score, mean (SD); n 5.4 (3.0); 269 4.8 (2.6); 271
ICIQ-FLUTS Voiding Symptoms Score, mean (SD); n 3.4 (2.6); 272 3.3 (2.6); 271
ICIQ-FLUTS Incontinence Score, mean (SD); n 5.6 (4.1); 233 5.4 (3.9); 232
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Discussion
Summary of findings
The participating women in the Uterine trial were around 64 years old, with a median of two previous vaginal
deliveries (see Table 2). Their mean BMI was around 27 kg/m2 (although 18 women with morbid obesity were
included). This was the first prolapse repair surgery in any compartment for the majority of the women.
Prolapse symptoms and measurements
Women had a mean POP-SS of 13.6 out of a maximum score of 28. The most common symptom was a
feeling of ‘something coming down’ (reported in 91.7%), which was the most bothersome symptom in
almost half (49.2%) of the women (see Table 3).
Objective outcome measures
When prolapse was redefined as the leading edge beyond the hymen (stage 2b or more), 94.2% of
women had a protruding prolapse overall and 53.5% had a protruding uterine prolapse (see Table 4).
The majority of women (85.8%) were also expected to undergo a concomitant prolapse repair in another
compartment (anterior, posterior or both) at the same time. This was most likely to be an anterior (44.2%)
or both an anterior and a posterior repair (37.9%) (see Table 5).
The study was able to ascribe a prolapse stage to 94% of women at baseline (5% had no POP-Q measure).
Results data were adjusted for the 10% difference in apical POP-Q staging at baseline. Just over one-quarter
(28.2%) of women appeared to have no significant objective uterine prolapse (i.e. stage 0 or 1). Similarly to
PROSPECT,1 it is proposed that this could be a result of these measurements being recorded:
l without the use of provocation, such as the Valsalva manoeuvre or coughing
l without the use of position and gravity to demonstrate the maximum descent
TABLE 7 Urinary and bowel symptoms at baseline (continued )
Symptom
Treatment
Uterine preservation
(N= 280)
Vaginal hysterectomy
(N= 283)
Bowel symptoms
Bowel frequency, n (%)
Normal 252 (90.0) 255 (90.1)
Frequent 11 (3.9) 6 (2.1)
Infrequent 8 (2.9) 9 (3.2)
Missing 9 (3.2) 13 (4.6)
Faecal incontinence (occasionally or more often), n (%) 93 (33.2) 77 (27.2)
Passive 77 (27.5) 64 (22.6)
Active 16 (5.7) 13 (4.6)
Severe 24 (8.6) 25 (8.8)
Bowel urgency (most or all of the time), n (%) 19 (6.8) 14 (4.9)
Constipation (most or all of the time), n (%) 17 (6.1) 18 (6.4)
Bowel symptoms QoL Score, mean (SD); n 2.8 (3.1); 269 2.6 (2.9); 266
Note
Bold text highlights differences between severity of symptom for that particular problem.
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l at a time when the prolapse was not evident (e.g. in the morning)
l in theatre under anaesthetic (without manual pulling)
l with a pessary in place or recently removed
l successful intervening treatment (intensive physiotherapy, weight loss etc.)
l incorrect diagnosis (full bladder or bowel).
Other clinical symptoms
Vaginal and sexual symptoms were common and had an impact on QoL. Around one-third of women were
sexually active at baseline and 2.9% reported dyspareunia (see Table 6). Nocturia (21.9%) and urgency
(20.3%) were common urinary symptoms. Around one-fifth (22.6%) of women reported urinary incontinence,
and this was slight or moderate in the majority of cases (68.9%; see Appendix 2, Table 52). Few women were
expected to undergo concomitant continence surgery or had already undergone previous continence surgery
(see Tables 2 and 5). Around one-third (30.2%) of women had faecal incontinence, at least occasionally, and
this was severe in around 8.7% of women (see Table 7).
These findings will serve as a benchmark for future research in women with uterine prolapse. The messages
regarding symptoms and findings in relation to clinical practice may be helpful in improving prolapse
assessment in the UK and internationally.
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Chapter 4 Uterine trial results
This chapter reports the outcomes for women participating in the Uterine trial at 12 months.
The flow of women in the Uterine trial is shown in the CONSORT (Consolidated Standards of Reporting
Trials) flow diagram (Figure 2), in line with CONSORT recommendations.61 Two post-randomisation
exclusions were not included in the study analyses (both had no significant uterine descent), leaving 563
randomised women analysed in the Uterine trial of the VUE trial.
The women were recruited in 45 centres across the UK (see Appendix 2, Table 47) and received surgery as
shown in Figure 3.
Surgery actually received
Of the 563 women included, 469 received their randomised allocation (76.8% in the uterine suspension
group and 89.8% in the vaginal hysterectomy group) (Table 8). Reasons for not having the allocated
treatment were the woman’s choice (n = 27), no apical descent [with alternative prolapse surgery (n = 17)
and without surgery (n = 5)], alternative apical procedure (n = 7), other clinical factors (n = 10) or reason
unknown (n = 28).
Uterine preservation 
(n = 282)
Post-randomisation exclusion, n = 2
Treatment
• Treated as allocated, n = 215
• Vaginal hysterectomy, n = 29
• Other apical intervention, n = 5
• No apical surgery, n = 31
Follow-up (12 months)
• Provided primary outcome, n = 230
• Died, n = 0
• Declined further follow-up, n = 18
• Did not respond, n = 32
Vaginal hysterectomy 
(n = 283)
Excluded
Randomised 
(n = 565)
Eligible patients 
(n = 1367)
Ineligible patients 
(n = 177)
Patients screened 
(n = 1544)
Post-randomisation exclusion, n = 0
Treatment
• Treated as allocated, n = 254
• Uterine preservation, n = 5
• Other apical intervention, n = 2
• No apical surgery, n = 22
Follow-up (12 months)
• Provided primary outcome, n = 238
• Died, n = 0
• Declined further follow-up, n = 15
• Did not respond, n = 30
• Declined, n = 774
• Other, n = 28
FIGURE 2 The CONSORT flow diagram of women recruited to the Uterine trial of the VUE study.
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FIGURE 3 Uterine trial: breakdown of the different surgeries received/or none. UIS, urinary incontinence surgery.
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The use of mesh for the apical or concomitant procedure was recorded and is detailed in Appendix 3, Table 53.
In relation to the randomised groups, more women in the vaginal hysterectomy group received a
concomitant anterior repair (50.2%) than in the uterine preservation group (40.4%). Overall, the numbers
receiving a concomitant procedure in other compartments or for incontinence were similar between the
groups (see Table 8).
Description of surgical characteristics
Most procedures were performed by a consultant gynaecologist (73.6%) with the patient under general
anaesthesia (80.3%), and most patients received prophylactic antibiotics (92.0%) (see Appendix 3, Table 54).
The operation was significantly longer in the uterine preservation group (114 minutes) than the vaginal
hysterectomy group (103 minutes, MD 9.79 minutes, 95% CI 3.50 to 16.07 minutes). Women in the
vaginal hysterectomy group had significantly higher blood loss (166 ml) than those randomised to uterine
preservation (125 ml, MD –42 ml, 95% CI –62.68 to –21.73 ml). There was no difference in length of
hospital stay (1.9 days, see Appendix 3, Table 55). There was no difference in time from the woman’s
randomisation to her surgery between the groups (see Appendix 3, Table 55).
Outcomes
Response rates and clinical attendance
A total of 237 out of the 282 (84.0%) women randomised to the uterine preservation group and 241 out
of the 283 (85.2%) in the vaginal hysterectomy group responded to the questionnaire at 12 months after
randomisation. The clinic assessment 12 months after surgery was completed for 258 out of 262 women
TABLE 8 Surgery received
Surgery
Treatment, n (%)
Uterine preservation (N= 280) Vaginal hysterectomy (N= 283)
Apical surgery received
Vaginal hysterectomy 29 (10.4) 254 (89.8)
Uterine suspension 215 (76.8) 5 (1.8)
Vaginal 146 (52.1) 3 (1.1)
Abdominal (laparoscopic) 66 (23.6) 2 (0.7)
Abdominal (open) 3 (1.1) 0 (0)
Other apical surgerya 5 (1.8) 2 (0.7)
No apical surgery 31 (11.1) 22 (7.8)
Concomitant surgery received
Anterior repair 113 (40.4) 142 (50.2)
Both (anterior and posterior) 82 (29.3) 85 (30.0)
Posterior repair 21 (7.5) 22 (7.8)
Continence procedure 7 (2.5) 9 (3.2)
a Other apical surgery included abdominal hysterectomy (n = 2), subtotal hysterectomy (n = 1), cervical amputation (n = 2),
colpocleisis (n = 1) and wedge resection of the cervix (n = 1).
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in the uterine preservation group who received any type of surgery (98.5%) and 262 out of 269 women in
the vaginal hysterectomy group (97.4%).
Women’s prolapse symptoms and effect on everyday life
At 6 months after surgery, women reported a reduction in their POP-SS from a mean score of 13.7 out
of 28 to 4.9 out of 28 in the uterine preservation group and from 13.5 out of 28 to 4.0 out of 28 in the
vaginal hysterectomy group (MD 0.85, 95% CI 0.00 to 1.71). The effect of prolapse on QoL also improved
at 6 months after surgery and again there was no significant difference between the groups.
The primary outcome was POP-SS at 12 months after randomisation; there was no statistically significant
difference between the groups. The MD in the POP-SS for uterine preservation (4.2, SD 4.9) compared
with vaginal hysterectomy (4.2, SD 5.3) adjusted for baseline variables was –0.05 (95% CI –0.91 to 0.81)
(Table 9 and Figure 4).
TABLE 9 The POP-SS and prolapse-related effect on QoL
Symptoms and effects
Treatment, mean (SD); n
Effect sizea (95% CI); p-valueUterine preservation Vaginal hysterectomy
POP-SS
Baseline 13.7 (6.4); 268 13.5 (5.9); 265
6 months after surgery 4.9 (5.7); 238 4.0 (4.7); 246 0.85 (0.00 to 1.71); 0.05
12 months after randomisation 4.2 (4.9); 230 4.2 (5.3); 238 –0.05 (–0.91 to 0.81); 0.91
Prolapse-related effect on QoL
Baseline 6.8 (2.7); 273 6.5 (2.9); 270
6 months after surgery 2.2 (3.1); 239 1.6 (2.6); 243 0.47 (–0.01 to 0.96); 0.06
12 months after randomisation 1.7 (2.5); 237 1.5 (2.5); 239 0.12 (–0.26 to 0.49); 0.54
a Effect size presented is a MD (uterine preservation vs. vaginal hysterectomy), adjusted for baseline and minimisation
variables.
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FIGURE 4 Mean and standard error POP-SSs at baseline and follow-up.
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There was also no significant difference on the effect of prolapse on QoL at 12 months after randomisation
[uterine preservation 1.7 (SD 2.5) vs. vaginal hysterectomy 1.5 (SD 2.5); MD 0.12, 95% CI –0.26 to 0.49].
The intracluster correlation for the surgeon was 0.04 (95% CI 0.00 to 0.44).
Distribution of individual POP-SSs and prolapse-related effects on QoL are also given in Appendix 3,
Figures 20 and 21.
Each individual prolapse symptom also improved at 12 months after randomisation (Table 10) and was
already apparent at 6 months after surgery (see Appendix 3, Table 56).
TABLE 10 Individual prolapse symptoms and EQ-5D at 12 months after randomisation
Symptoms and EQ-5D
Treatment
Uterine preservation Vaginal hysterectomy
Symptomatic, n (%); N
Number of women with symptoms 178 (77.4); 230 188 (79.0); 238
Individual prolapse symptoms, n (%); N
Bowel not empty (any) 133 (56.6); 235 132 (55.5); 238
Bowel not empty (most/all of the time) 22 (9.4); 235 14 (5.9); 238
Bladder not empty (any) 133 (56.6); 235 121 (50.6); 239
Bladder not empty (most/all of the time) 21 (8.9); 235 24 (10.0); 239
Strain to empty bladder (any) 76 (32.6); 233 75 (31.5); 238
Strain to empty bladder (most/all of the time) 13 (5.6); 233 19 (8.0); 238
Something coming down (any) 71 (30.7); 231 69 (28.9); 239
Something coming down (most/all of the time) 17 (7.4); 231 22 (9.2); 239
Dragging in abdomen (any) 65 (28.0); 232 62 (26.2); 237
Dragging in abdomen (most/all of the time) 9 (3.9); 232 9 (3.8); 237
Dragging in back (any) 63 (27.4); 230 70 (29.4); 238
Dragging in back (most/all of the time) 10 (4.3); 230 8 (3.4); 238
Uncomfortable feeling or pain when standing (any) 40 (17.6); 227 50 (21.0); 238
Uncomfortable feeling or pain when standing
(most/all of the time)
10 (4.4); 227 12 (5.0); 238
Most bothersome symptom, n (%); N
Bowel not empty 50 (36.8); 136 51 (40.5); 126
Bladder not empty 31 (22.3); 136 18 (14.3); 126
Something coming down 23 (16.9); 136 28 (22.2); 126
Dragging in back 10 (7.4); 136 11 (8.7); 126
Dragging in abdomen 10 (7.4); 136 4 (3.2); 126
Uncomfortable feeling or pain when standing 7 (5.1); 136 7 (5.6); 126
Strain to empty bladder 5 (3.7); 136 7 (5.6); 126
Which symptom causes most bother not applicable 82 (37.6); 218 96 (43.2); 222
continued
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The most bothersome symptoms across both groups at 6 months after surgery and at 12 months after
randomisation were different from those at baseline. The most bothersome symptom at baseline, ‘a feeling
of something coming down’ reduced overall from 49.7% to 19.5%. Symptoms of incomplete emptying of
either bladder or bowel became more common, but ‘actions necessitated by prolapse symptoms’ were
improved (see Table 10, see also Appendix 3, Table 56).
Secondary outcomes
Objective prolapse outcomes
Women who had any prolapse procedure were invited back for a clinical assessment 12 months after surgery
and, overall, 97.9% attended. The objective prolapse measure (POP-Q) improved in all compartments (see
Appendix 3, Table 57). There was no difference in either group for objective overall prolapse stage 2b or
more [uterine preservation 31.8% vs. 34.1% vaginal hysterectomy; odds ratio (OR) 0.85, 95% CI 0.55 to
1.32]. More specifically, the overall number of women with an objective apical prolapse (i.e. stage 2b or
more) fell to 5.7% in the uterine preservation group compared with 5.3% in the vaginal hysterectomy group
12 months after surgery [adjusted for baseline values (Table 11)]. Again, this reduction was not significant.
Objective anterior and posterior prolapse outcomes also improved.
Vaginal and sexual symptoms
Both the mean vaginal symptoms and the QoL scores decreased (improved) for both treatment groups
(Table 12). More women were sexually active after surgery than before surgery (from around 30.0% at
baseline to 44.1% in the uterine preservation group and 40.1% in the vaginal hysterectomy group), and
fewer women cited prolapse symptoms as a reason for not being sexually active. For those women who
were not sexually active, 17 (17.4%) women in the uterine preservation group and 12 (11.5%) in the
vaginal hysterectomy group gave vaginal or prolapse symptoms as the reason.
There were no statistically significant differences in vaginal and sexual symptoms between the uterine
preservation and vaginal hysterectomy groups at 12 months after randomisation.
TABLE 10 Individual prolapse symptoms and EQ-5D at 12 months after randomisation (continued )
Symptoms and EQ-5D
Treatment
Uterine preservation Vaginal hysterectomy
Actions necessitated by prolapse symptoms, n (%); N
Extra hygiene measures 10 (4.4); 225 9 (3.9); 230
Digitally evacuate bowel 8 (3.5); 237 5 (2.1); 231
Fingers to help empty bowel 2 (0.9); 224 2 (0.9); 234
Fingers to help empty bladder 1 (0.4); 230 2 (0.9); 235
Fingers to ease discomfort 0 (0); 225 2 (0.9); 229
EQ-5D, mean score (SD); N
EQ-5D 0.865 (0.200); 227 0.886 (0.187); 235
EQ-5D visual scale 81.0 (15.6); 228 82.7 (16.3); 235
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TABLE 11 Objective prolapse outcomes at 12 months after surgery
Stage
Treatment, n (%); N
Effect size,a OR (95% CI);
p-value
Uterine
preservation
Vaginal
hysterectomy
Overall stage 2b or more 74 (31.8); 233 78 (34.1); 229 0.85 (0.55 to 1.32); 0.48
Apical stage
Stage 0 161 (70.0); 230 181 (80.1); 226
Stage 1 51 (22.2); 230 30 (13.3); 226
Stage 2a 5 (2.2); 230 3 (1.3); 226
Stage 2b 9 (3.9); 230 3 (1.3); 226
Stage 3 4 (1.7); 230 3 (1.3); 226
Stage 4 0 (0); 230 6 (2.7); 226
Stage 2b or more 13 (5.7); 230 12 (5.3); 226 1.18 (0.48 to 2.94); 0.72
Anterior stage 2b or more 67 (28.8); 233 66 (28.8); 229 0.97 (0.62 to 1.51); 0.88
Posterior stage 2b or more 12 (5.2); 232 19 (8.4); 227 0.61 (0.28 to 1.35); 0.22
Development of new prolapse at
another site
10 (4.3); 231 12 (5.0); 238 0.86 (0.36 to 2.06); 0.74
a Effect size presented is an OR (uterine preservation vs. vaginal hysterectomy), adjusted for baseline and minimisation
variables.
Note
Bold text highlights differences between severity of symptom for that particular problem.
TABLE 12 Vaginal and sexual symptoms at 12 months after randomisation
Symptoms
Treatment
Effect sizea (95% CI);
p-value
Uterine
preservation
Vaginal
hysterectomy
ICI Vaginal Symptoms Score, mean (SD); N 5.9 (6.7); 208 5.5 (7.1); 215 0.54 (–0.67 to 1.76); 0.38
QoL due to vaginal symptoms, mean (SD); N 1.2 (2.2); 212 1.1 (2.1); 218 0.03 (–0.36 to 0.42); 0.89
ICI Sexual Matters Score, mean (SD); N 7.8 (13.2); 93 8.7 (12.9); 88 –2.47 (–6.78 to 1.85); 0.26
QoL due to effect on sex life, mean (SD); N 1.4 (2.4); 93 1.8 (2.6); 88 –0.53 (–1.34 to 0.27); 0.20
Reduced sensation, n (%); N 5 (2.3); 219 5 (2.2); 229
Vagina too loose or lax, n (%); N 2 (0.9); 218 7 (3.1); 228
Number of women having intercourse,
n (%); N
98 (44.1); 222 93 (40.1); 232
Pain with intercourse 0 (0); 98 2 (2.2); 93
Reasons for not being sexually active, n (%); N
No partner 49 (50.0); 98 57 (54.3); 105
Vaginal symptoms 9 (9.2); 98 7 (6.7); 105
Prolapse symptoms 8 (8.2); 98 5 (4.8); 105
Other reason 32 (32.7); 98 36 (34.3); 105
a Effect size presented is a MD for continuous variables and an OR for binary variables (uterine preservation vs. vaginal
hysterectomy), adjusted for baseline (when available) and minimisation variables.
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Urinary and bowel symptoms
Overall, at 12 months after randomisation, the proportion of women who had any urinary incontinence
increased from 22.6% at baseline to 35.8%, although the proportion with severe urinary incontinence
decreased from 13.0% to 1.6% (Table 13). Significantly more women reported urge incontinence at
12 months after randomisation in the uterine preservation group (n = 32, 13.9%) than in the vaginal
hysterectomy group (n = 12, 5.0%; MD 2.71, 95% CI 1.32 to 5.55). Following surgery, de novo urinary
incontinence was similar across both groups and reported in around one-quarter of the women. Further
urinary symptoms can be found in Appendix 3, Table 58.
TABLE 13 Urinary and bowel symptoms at 12 months after randomisation
Symptoms
Treatment
Effect sizea (95% CI);
p-value
Uterine
preservation
Vaginal
hysterectomy
Urinary symptoms, n (%); N
Urgency 32 (13.9); 230 12 (5.0); 238 2.71 (1.32 to 5.55); 0.01
Nocturia 34 (14.8); 229 29 (12.2); 238
Frequency 11 (4.8); 230 9 (3.8); 238
All the above 3 (1.3); 230 0 (0); 238
Persistent incontinence, n (%); N 40 (18.0); 222 35 (15.8); 222 1.16 (0.70 to 1.91); 0.57
Any incontinence, n (%); N 87 (36.7); 237 84 (34.9); 241 1.09 (0.72 to 1.66); 0.68
Severe incontinence 3 (1.6); 184 3 (1.6); 187 1.00 (0.18 to 5.71); > 0.99
De novo incontinence, n (%); N 44 (25.6); 172 44 (26.2); 168 1.04 (0.63 to 1.70); 0.89
Incontinence-related QoL Score, mean (SD); N 1.8 (2.5); 175 1.6 (2.3); 176 0.19 (–0.27 to 0.65); 0.41
ICI Urinary Incontinence Score, mean (SD); N 5.1 (4.3); 164 4.6 (3.9); 168 0.41 (–0.36 to 1.19); 0.30
ICIQ-FLUTS Filling Score, mean (SD); N 3.7 (2.7); 228 3.3 (2.0); 237 0.18 (–0.19 to 0.54); 0.35
ICIQ-FLUTS Voiding Symptoms Score, mean (SD); N 1.6 (1.7); 230 1.6 (1.8); 237 0.00 (–0.29 to 0.30); 0.97
ICIQ-FLUTS Incontinence Score, mean (SD); N 3.7 (3.2); 184 3.6 (3.1); 187 0.23 (–0.33 to 0.79); 0.42
Bowel symptoms
Bowel frequency (normal), n (%); N 222 (96.5); 230 229 (95.8); 239 1.38 (0.46 to 4.17); 0.56
Faecal incontinence (occasionally or more often),
n (%); N
59 (26.0); 227 61 (26.0); 235 0.97 (0.59 to 1.57); 0.89
Passive 43 (18.3); 235 38 (16.9); 225
Active 18 (7.7); 235 19 (8.4); 225
Severe 15 (6.6); 227 7 (3.0); 235 4.64 (1.49 to 14.42); 0.01
Bowel urgency (most or all of the time), n (%); N 31 (14.4); 216 32 (14.2); 225 0.97 (0.56 to 1.68); 0.90
Constipation (most or all of the time), n (%); N 9 (3.9); 231 10 (4.2); 238 0.94 (0.36 to 2.46); 0.90
Bowel symptoms QoL score, mean (SD); N 1.8 (0.9); 231 1.7 (0.8); 238 0.05 (–0.10 to 0.20); 0.51
a Effect size presented is a MD for continuous variables and an OR for binary variables (uterine preservation vs. vaginal
hysterectomy), adjusted for baseline (when available) and minimisation variables.
Note
Bold text highlights differences between severity of symptom for that particular problem.
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Although bowel urgency increased to 14.3% across both treatment groups at 12 months after randomisation,
the presence of severe faecal incontinence was slightly improved. However, significantly more women in the
uterine preservation group (n = 15, 6.6%) had severe faecal incontinence than in the vaginal hysterectomy
group (n = 7, 3.0%), though these were small numbers (MD 4.64, 95% CI 1.49 to 14.42).
There was no evidence of a difference in any other urinary or bowel symptoms outcomes between the
randomised groups.
Satisfaction with treatment at 12 months after randomisation
At 12 months after randomisation, most women reported that they were better than before surgery, with
no statistically significant difference between the groups (90.8% vs. 95.3%; OR 0.49, 95% CI 0.22 to 1.05)
(Table 14). Similarly, the proportions of women completely or fairly satisfied were not statistically significantly
different (85.6% vs 90.6%; OR 0.62, 95% CI 0.34 to 1.13). However, significantly more women (95.0%)
in the vaginal hysterectomy group would recommend it to a friend compared with women in the uterine
preservation group (88.3%) (OR 0.39, 95% CI 0.18 to 0.83).
Further treatment required for failure or adverse events at 6 and at
12 months
When women reported that they had been re-admitted to hospital, the information was verified with the
centres and post-coded accordingly to ensure accuracy of data and resolution of discrepancies. A hospital
re-admission was counted as a SAE if it was related to the initial prolapse surgery. Further surgery for prolapse
(recurrence if in the same compartment), or for continence surgery, was differentiated from re-admission for
surgery-related complications, such as bleeding or infection (Table 15).
Overall, 29 women were re-admitted for further surgery in the first 12 months (Table 15). Twenty-three
women had further prolapse surgery within 12 months [uterine preservation (n = 15) vs. vaginal hysterectomy
(n = 8)]. Ten women in the uterine preservation group had a further apical procedure compared with three
women in the vaginal hysterectomy group during that time. More women in the uterine preservation group
(n = 8) had a re-admission for an anterior repair compared with those women in the vaginal hysterectomy
group (n = 1). Overall, there was no evidence of a difference between the groups regarding further treatment.
One woman did not have her VUE procedure (or any procedure) at the time of admission (clinical decision),
but pursued the apical procedure by another health-care provider 12 months later.
TABLE 14 Participant recovery and satisfaction
Recovery and satisfaction
Treatment, n (%); N
Effect sizea (95% CI);
p-valueUterine preservation Vaginal hysterectomy
Prolapse is better now compared
with 1 year ago
208 (90.8); 229 221 (95.3); 232 0.49 (0.22 to 1.05); 0.07
Completely or fairly satisfied 196 (85.6); 229 211 (90.6); 233 0.62 (0.34 to 1.13); 0.12
Recommend to a friend 196 (88.3); 222 211 (95.0); 222 0.39 (0.18 to 0.83); 0.01
a Effect size presented is an OR (uterine preservation vs. vaginal hysterectomy), adjusted for minimisation variables.
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Serious and related adverse events in the first 12 months after surgery
Overall, there were 30 SAEs (5.7%) reported in the first 12 months following surgery (more than one SAE
could be reported per woman) (Table 16). Hospitalisation was the most common type of SAE. There were
no differences between the groups in any SAEs.
Specifically, of the 129 procedures (apical and concomitant) using a mesh implant one mesh exposure/
extrusion was identified and required surgical treatment in the first 12 months after surgery.
Non-serious and related adverse events in the first 12 months after
surgery
Non-serious AEs or complications were also recorded (Table 17). Overall, there was a total of 18 (3.6%)
within the 12 months after surgery. There were no differences between the groups in any non-serious AEs.
TABLE 15 Further treatment required at 12 months after surgery
Further treatment
Treatment
Effect sizea (95% CI);
p-value
Uterine
preservation
Vaginal
hysterectomy
Further surgery, n (%); N 18 (7.4); 244 11 (4.5); 242 1.70 (0.78 to 3.71); 0.182
Further prolapse surgery, n (%); N 15 (6.1); 244 8 (3.3); 242 2.01 (0.81 to 4.95); 0.130
Anterior 8 (3.3); 243 1 (0.4); 242 8.10 (1.00 to 65.57); 0.050
Posterior 3 (1.2); 242 5 (2.1); 242 0.60 (0.14 to 2.53); 0.484
Apical 10 (4.1); 243 3 (1.2); 242 3.43 (0.93 to 12.64); 0.064
Continence surgery, n (%); N 3 (1.2); 242 4 (1.7); 242
Time to further surgery (days), mean (SD); Nb 290.1 (149.6); 16 263.2 (91.7); 10 1.66 (0.80 to 3.44); 0.177c
Need for conservative treatment, n (%); N
Any conservative treatment 75 (26.8); 280 73 (25.8); 283 1.06 (0.73 to 1.54); 0.77
Absorbent pads 49 (24.3); 202 61 (27.4); 223
Physiotherapy 17 (11.4); 149 12 (7.4); 162
Ring pessary 14 (7.6); 185 9 (4.4); 205
Shelf or Gellhorn pessary 8 (4.4); 181 4 (2.0); 205
Disposable or reusable catheter 5 (2.7); 180 4 (2.0); 204
Permanent catheter 1 (0.6); 177 2 (1.0); 201
Seen health professional, n (%); N
Gynaecology out patients (GOPD) 73 (39.9); 183 49 (25.5); 192
GP for prolapse 62 (32.5); 191 54 (27); 203
Practice nurse 13 (8.6); 151 9 (5.5); 165
District or continence nurse 7 (4.8); 145 4 (2.5); 159
a Effect sizes presented are ORs (uterine preservation vs. vaginal hysterectomy), adjusted for minimisation variables.
b See also Appendix 3, Table 59 for median values.
c Effect size is a hazard ratio adjusted for minimisation variables and fitting surgeon as a random effect.
UTERINE TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
TABLE 16 Serious and related AEs in the first 12 months after surgery
Serious and related AEs
Treatment, n (%)
Effect sizea (95% CI);
p-value
Uterine preservation
(N= 262)
Vaginal hysterectomy
(N= 269)
Any SAE 14 (5.4) 16 (5.9) 0.82 (0.38 to 1.75); 0.60
Type of SAEb
Hospitalisation 10 (3.8) 9 (3.3)
Considered medically significant by
the investigator
4 (1.5) 4 (1.5)
Prolongation of hospitalisation 3 (1.2) 5 (1.9)
Life-threatening 1 (0.4) 0 (0)
Intraoperative occurrencesc
Excessive blood lossd 1 (0.4) 3 (1.1)
Injury to blood vessel 0 (0) 1 (0.4)
Blood transfusion 0 (0) 1 (0.4)
Anaesthetic complications 0 (0) 1 (0.4)
Postoperative occurrencesc
Haematoma 2 (0.8) 5 (1.9)
Pain 2 (0.8) 4 (1.5)
Excessive blood loss 1 (0.4) 5 (1.9)
Other infections 3 (1.2) 2 (0.7)
Constipation 2 (0.8) 2 (0.7)
Granulation tissue 1 (0.4) 3 (1.1)
Urinary retention/voiding difficulties
requiring conservative intervention
5 (2.0) 1 (0.4)
Suture removal 2 (0.8) 0 (0)
Urinary tract infection 0 (0) 2 (0.7)
Bowel obstruction 1 (0.4) 0 (0)
Thrombosis 1 (0.4) 0 (0)
Wound infection 0 (0) 1 (0.4)
Vaginal adhesions 1 (0.4) 0 (0)
Urinary retention/voiding difficulties
requiring surgery
1 (0.4) 0 (0)
Mesh exposure/extrusion that
requires surgical treatment
1 (0.4) 0 (0)
New or persistent lower urinary tract
symptoms
0 (0) 1 (0.4)
a Effect size presented is an OR (uterine preservation vs. vaginal hysterectomy).
b A SAE could be classified as more than one type.
c A SAE could be composed of more than one occurrence.
d Defined as in excess of 500 ml and considered medically significant.
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Subgroup analysis
There was no evidence of a difference between treatment groups in any of the planned subgroup analyses
(age < 60 and ≥ 60 years, previous anterior or posterior surgery or previous incontinence surgery) (see
Appendix 3, Table 60).
Sensitivity analyses
A multiple imputation model was used to impute missing values in the primary outcome, assuming a
missing-at-random mechanism. No evidence of a difference between the two groups after the imputation
(uterine preservation vs. vaginal hysterectomy; MD –0.02, 95% CI –0.83 to 0.78; p = 0.96) was found.
Per-protocol analysis
A per-protocol analysis including only the participants who followed protocol (i.e. received the allocated
treatment) was done and no evidence of a difference between groups (uterine preservation vs. vaginal
hysterectomy; MD 0.19, 95% CI –0.70 to 1.08; p = 0.68) was found.
Discussion
Summary of findings
Surgical planning and procedure
In addition to their apical surgery, concomitant surgery was planned for the majority (85.8%) of women in
the Uterine trial. The randomised surgical allocation was performed in most of the women (76.8% in the
TABLE 17 Other related non-serious AEs in first 12 months after surgery
Non-serious AE
Treatment, n (%)
Effect sizea (95% CI);
p-value
Uterine preservation
(N= 262)
Vaginal hysterectomy
(N= 269)
Any non-serious AE 6 (2.3) 2 (0.7) 3.30 (0.63 to 17.19); 0.16
Intraoperative non-serious AEb
Anaesthetic complications 1 (0.4) 0 (0)
Blood loss of > 500ml 1 (0.4) 0 (0)
Blood transfusion 0 (0) 1 (0.4)
Postoperative complicationsb
Treatment for postoperative
infection with antibiotics
3 (1.2) 1 (0.4)
Infection 2 (0.8) 1 (0.4)
Pyrexia, unknown origin 1 (0.4) 1 (0.4)
UTI 1 (0.4) 0 (0)
Blood transfusion 0 (0) 1 (0.4)
Other 3 (1.2) 1 (0.4)
UTI, urinary tract infection.
a Effect size presented is an OR (uterine preservation vs. vaginal hysterectomy).
b An AE could be composed of more than one occurrence.
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uterine preservation group and 89.8% in the vaginal hysterectomy group). The woman’s choice was the
most common reason for not receiving the randomised allocation. Women in the vaginal hysterectomy
group were more likely to receive a concomitant anterior repair (50.2%) compared with those in the uterine
preservation group (40.4%), but all other concomitant procedures were similar between the groups.
Most procedures were performed by a consultant gynaecologist under general anaesthesia with prophylactic
antibiotics (92.0%). The duration of the uterine preservation surgery was significantly longer (mean duration
114 minutes, SD 50 minutes) than vaginal hysterectomy (mean duration 103 minutes, SD 33 minutes; MD
9.79 minutes, 95% CI 3.50 to 16.07 minutes)]. Women in the vaginal hysterectomy group had significantly
higher blood loss (mean blood loss 166 ml) than those women randomised to uterine preservation
[mean blood loss 125 ml, MD –42 ml, 95% CI –62.3 to 21.7 ml)], though postoperative hospital stay was
not different.
Primary and secondary outcomes
Around 85% of women responded to the 12-month questionnaire, with more women (97.9%) attending
for the 12-month clinic assessment.
The primary outcome was POP-SS at 12 months after randomisation and there was no difference between
women in the uterine preservation and vaginal hysterectomy groups. The MD in the POP-SS for uterine
preservation (4.2 points, SD 4.9 points) compared with vaginal hysterectomy (4.2 points, SD 5.3 points),
adjusted for baseline variables, was –0.05 points (95% CI –0.91 to 0.81 points) and suggests that both are
equally effective in improving uterine prolapse symptoms at 12 months.
At 12 months after randomisation, prolapse-related effects on QoL scores had improved and were apparent
at 6 months after operation. The most bothersome symptom at baseline, ‘a feeling of something coming
down’, reduced from 49.7% to 19.5%. Incomplete emptying of the bladder or bowel was the most
bothersome symptoms at both 6 and 12 months for both randomised groups, but did not affect ‘actions
necessitated by prolapse symptoms’, which were reduced from baseline.
Overall, objective prolapse stage (POP-Q) improved for both randomised groups, particularly in terms of
prolapse protrusion beyond the hymen (stage 2b or more: 31.8% after uterine preservation vs. 34.1%
after vaginal hysterectomy). Objective apical prolapse (stage 2b or more) fell to < 6% for both groups
12 months after surgery (adjusted for baseline values). These values were not statistically different between
the groups.
More women were sexually active after surgery. There were no statistically significant differences in vaginal
and sexual symptoms between randomised groups at 12 months.
Overall, at 12 months after randomisation the proportion of women who had any urinary incontinence
increased from around one in five women to one in three, although severe urinary incontinence decreased.
Significantly more women reported urge incontinence at 12 months in the uterine preservation group than
in the vaginal hysterectomy group. De novo urinary incontinence was similar across both groups of women
and reported in around one in four women. Few women had continence surgery to alleviate their
symptoms within the first 12 months (n = 7).
Although bowel urgency increased to 14.3% across both randomised groups at 12 months after
randomisation, the presence of faecal incontinence was slightly reduced. However, significantly more
women in the uterine preservation group (n = 15, 6.6%) had severe faecal incontinence at 12 months
than in those women in the vaginal hysterectomy group (n = 7, 3.0%), though these are small numbers
(MD 4.64%, 95% CI 1.49% to 14.42%). There were no other significant differences in bowel symptoms
between the groups of women.
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At 12 months after randomisation, 93.1% of women reported that their prolapse symptoms were better
compared with baseline, and the proportion of satisfaction was not statistically significantly different.
However, significantly more women (95.0%) in the vaginal hysterectomy group would recommend the
treatment to a friend compared with 88.3% of those in the uterine preservation group (OR 0.39, 95% CI
0.18 to 0.83).
Overall, 29 women were re-admitted for further surgery in the first 12 months after surgery (see Table 16).
Twenty-three women had further prolapse surgery within 12 months [uterine preservation (n = 15) vs.
vaginal hysterectomy (n = 8)] and this was not statistically significant. Ten women in the uterine preservation
group had a further apical procedure compared with three women in the hysterectomy group in that time
(again, this was not statistically significant). More women in the uterine preservation group (n = 8) had a
re-admission for an anterior repair compared with those in the vaginal hysterectomy group (n = 1; OR 8.10,
95% CI 1.00 to 65.57).
There were 30 SAEs reported in the first 12 months following surgery and there were no differences
between the groups of women in any SAEs. Of the 129 procedures (apical and concomitant), using a
mesh implant there was one mesh exposure/extrusion in the first 12 months after surgery. This was treated
surgically by removal of the exposed mesh.
Conclusion
Vaginal hysterectomy and uterine preservation surgeries are equally effective in relieving uterine prolapse
in relation to symptoms and objective descent, although vaginal hysterectomy was more likely to be
recommended to a friend. The presence of urinary incontinence may worsen after either procedure, but
severe incontinence appears to remain static; however, an increased risk of re-operation for an anterior
pelvic floor repair in those women having preservation procedures was identified.
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Chapter 5 Uterine trial within-trial
cost-effectiveness analysis
This chapter presents the results of the within-trial cost–utility analysis for women in the Uterine trial.Further details of the cost-effectiveness data are provided in Appendix 4, Tables 61–5.
NHS perspective resource use and costs
Intervention costs
Intervention costs are calculated for all women entering theatre for an operative procedure (regardless of
whether or not they received a completed surgery). Intervention delivery was £92 more expensive in the
uterine preservation group than in the vaginal hysterectomy group (95% CI –£5 to £178). The potential
for additional costs in the uterine preservation group is because of a slightly longer operation on average
(around 10 minutes) and the use of mesh in a greater number of procedures. Mesh was used in the apical
procedure for 86 out of 264 (33%) women randomised to the uterine preservation group, compared
with 9 out of 270 (3%) women randomised to the vaginal hysterectomy group. All other resource use
contributing to the intervention cost was similar across the groups. Full details of the component costing
approach underpinning these numbers can be found in Appendix 4, Table 61.
Follow-up care costs
More women required further prolapse surgery in the uterine preservation group (n = 16) than in the
vaginal hysterectomy group (n = 8). No difference between the groups was evident regarding either
continence procedure or SAEs requiring hospitalisation. Average hospitalisation costs (excluding the index
procedure) were £320 in the uterine preservation group compared with £179 in the vaginal hysterectomy
group (adjusted MD £166, 95% CI –£39 to £370). Consultations with health-care professionals (e.g.
outpatient doctors, GPs, community-based nurses, physiotherapists) were similar across the groups,
as were the costs of medications and devices (e.g. oestrogens, pessaries, antibiotics). Full details of all
follow-up care resource use reported in the trial are provided in Appendix 4, Tables 62–5.
Total NHS costs
Overall, total costs to the NHS were calculated for 207 out of 279 (74%) and 217 out of 283 (77%)
women in the uterine preservation and vaginal hysterectomy groups, respectively (randomised women
after post-randomisation exclusions). Missing data are primarily because of the non-return of participant
questionnaires. Based on the complete-case costs available for analysis, the total costs to the NHS were
£1643 (SD £1302) in the uterine preservation group and £1345 (SD £754) in the vaginal hysterectomy
group. Uterine preservation was significantly more costly to the NHS (MD £292, 95% CI £68 to £517).
This cost difference is driven by higher average intervention costs and the greater proportion of women
experiencing a repeat prolapse procedure over 12-months’ follow-up in the uterine preservation group.
Patient participant perspective resource use and costs
Women with prolapse symptoms have a high rate of contact with health-care professionals, including a
large number of consultations in both primary and secondary care. The opportunity costs of time and
travel, purchase of over-the-counter medications and other related expenses were similar across the
groups. A small number of women reported private care, and the cost was higher for women in the
uterine preservation group.
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The number of women reporting that they had to take time off from work, as a proportion of the trial
population, was small. In total, in the Uterine trial 130 out of 572 (23%) randomised women reported the
need to take time off work for prolapse symptoms [64/279 (23%) and 66/283 (23%) of those randomised to
the uterine preservation and vaginal hysterectomy groups, respectively]. Among those women who required
sick leave from work, the average number of days of leave required was 35 days (SD 65 days) and 22 days
(SD 40 days) in the uterine preservation and vaginal hysterectomy groups, respectively, but differences were
not statistically significant. See Appendix 4, Table 65 for full details of all costs incurred by the women.
Among the women with complete data for participant-incurred costs (46% in the uterine preservation
group vs. 54% in the vaginal hysterectomy group), the average costs were £1266 (SD £4127) and
£460 (SD £1505) in the uterine preservation and vaginal hysterectomy groups, respectively (MD £609,
95% CI £47 to £1172). The large SDs in both groups indicate that some women experienced very high
personal costs.
When summing participant and NHS perspective costs together to inform a wider-perspective analysis of
prolapse costs, the uterine preservation group remains significantly more costly (MD £911, 95% CI £359
to £1463).
Generic quality-of-life outcomes
The proportion of women reporting any health problems on each EQ-5D-3L domain (i.e. a score of 2 or
3 points) at baseline, at 6 months after surgery and at 12 months after randomisation is presented in Figure 5.
Data are presented as reported in the respective questionnaires. Missing data are not reported in the
figure. At baseline, < 70% of the women in both groups reported problems related to pain and discomfort
and between one-quarter and one-third of women had at least some problems with usual activities or anxiety
and depression. The reporting of any pain or discomfort fell to about 30% for all women by 12 months after
randomisation, with fewer than one in five women reporting problems with usual activities or anxiety/
depression. The fewest number of problems were experienced in self-care, with a small proportion of women
reporting any problems by 12 months after randomisation. There are no obvious differences between the
groups evident from the graphical presentations. The proportion of women experiencing problems decreased
in both groups, indicating that both procedures had a positive impact on generic QoL. This finding echoes the
findings from the condition-specific QoL data (see Chapter 4).
Full details of the utility scores resulting from EQ-5D-3L responses at each time point and calculated QALYs
are reported in Table 18. In terms of covariates included within the analysis model, baseline utility was the
only significant predictor of overall QALYs, re-enforcing the importance of adjusting for this baseline
measure.54
Complete data were available across domains and time points, enabling QALY calculation for 198 out
of 279 (71%) and 209 out of 283 (74%) women in the uterine preservation and vaginal hysterectomy
groups, respectively. There were no differences in QALYs between the uterine preservation (0.845 years)
and vaginal hysterectomy (0.866 years) groups (MD 0.006 years, 95% CI –0.016 to 0.028 years). Multiple
imputation of missing EQ-5D data underpinning the QALY calculation indicates a similar lack of difference
across the groups.
Cost-effectiveness results
Complete-case cost and complete-case QALY data are presented (Table 18), making best use of all available
data. For the base-case analysis, multiple imputed missing data are used because only 372 out of 562 (66%)
participants had fully complete profiles of costs and QALYs to enable calculation of the ICER. A range
of deterministic sensitivity analyses are also reported. All analyses of cost-effectiveness also indicate the
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probability that uterine preservation is a cost-effective use of NHS resources at five alternative threshold
values (£0, £10,000, £20,000, £30,000 and £50,000) of WTP for a QALY gained.
Base-case analysis
The base-case analysis using the imputed data set shows significant additional costs for the uterine
preservation group (MD £235; 95% CI £6 to £464), for no significant difference in QALYs (MD –0.004
years, 95% CI –0.026 to 0.019 years). As uterine preservation is associated with additional costs for a
negative point estimate of the impact on QALYs, uterine preservation is therefore dominated by vaginal
hysterectomy. The scatterplot (Figure 6) illustrates this finding visually. There is little uncertainty regarding
the additional cost of uterine preservation, with almost all of the increments from the bootstrap lying
above the horizontal line. However, regarding QALYs, the scatterplot indicates substantial uncertainty,
with no clear evidence of one strategy being preferable.
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FIGURE 5 Percentage of respondents with any problems on each EQ-5D-3L domain at (a) baseline, (b) 6 months
after surgery and (c) 12 months after randomisation.
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TABLE 18 Costs, QALYs and cost-effectiveness for the Uterine trial
Costs, QALYs
and cost-
effectiveness
Treatment, mean (SD); N
Uterine preservation vs. vaginal
hysterectomy
Uterine
preservation
(N= 280)
Vaginal hysterectomy
(N= 283) MD 95% CI
Costsa,b
Intervention £1213.04 (£472.08);
264
£1116.18 (£371.28);
270
£91.59 £5.16 to £178.01
Hospital resource
use
£319.69 (£1073.49);
265
£178.71 (£839.97);
269
£165.72 –£39.00 to £370.45
Other
consultations
£112.59 (£179.45);
219
£85.83 (£169.92);
227
£21.74 –£17.96 to £61.45
Other treatments £13.74 (£64.71);
215
£24.22 (£108.51);
224
–£11.66 –£28.92 to £5.60
Total NHS costs £1642.73 (£1302.29);
207
£1344.68 (£754.37);
217
£292.41 £67.66 to £517.17
QALYsb,c
EQ-5D
Baseline 0.738 (0.221); 264 0.781 (0.178); 263
6 monthsd 0.855 (0.211); 225 0.880 (0.188); 243
12 monthsd 0.871 (0.187); 225 0.886 (0.187); 235
Total QALYs 0.845 (0.158); 198 0.866 (0.140); 209 0.006 –0.016 to 0.028
Cost-effectiveness
N ΔC (95% CI) ΔE (95% CI) ICERe
Probability that uterine preservation is
cost-effective compared with vaginal
hysterectomy at different WTP thresholds
for a QALY gained (%)
£0 £10,000 £20,000 £30,000 £50,000
Imputed data set
(base case)f
562 £235
(£6 to £464)
–0.004
(–0.026 to 0.019)
Dominated 2 5 10 15 20
Imputed data set
(SUR)
562 £235
(£41 to £429)
–0.002
(–0.025 to 0.021)
Dominated 0 3 9 14 19
Wider-perspective
costing analysis
562 £770
(£23 to £1517)
–0.004
(–0.026 to 0.019)
Dominated 2 2 4 5 8
Use of HRG tariffs
for intervention
procedure
g,h
534 –£395
(–£619 to –£171)
–0.004
(–0.026 to 0.019)
£98,750 100i 100i 94i 85i 70i
Assumptions
regarding QALY
calculation (1)
545 £235
(£6 to £464)
–0.003
(–0.025 to 0.020)
Dominated 1 13 32 43 54
Assumptions
regarding QALY
calculation (2)
481 £235
(£6 to £464)
–0.000
(–0.024 to 0.024)
Dominated 1 10 25 34 42
Assumptions
regarding QALY
calculation (3)
378 £235
(£6 to £464)
–0.031
(–0.071 to 0.009)
Dominated 1 0 1 1 2
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TABLE 18 Costs, QALYs and cost-effectiveness for the Uterine trial (continued )
Costs, QALYs
and cost-
effectiveness
Treatment, mean (SD); N
Uterine preservation vs. vaginal
hysterectomy
Uterine
preservation
(N= 280)
Vaginal hysterectomy
(N= 283) MD 95% CI
Complete-case
analysisi
372 £292
(£64 to £520)
0.004
(–0.026 to 0.033)
£71,250 0 7 20 31 40
Complete-case
analysis, SUR
372 £297
(£90 to £505)
–0.002
(–0.024 to 0.020)
Dominated 0 6 19 30 40
ΔC, difference in costs; ΔE difference in effectiveness; SUR, seemingly unrelated regression.
a Represents complete-case data for costs.
b All models are adjusted for minimisation covariates and baseline EQ-5D score.
c Represents complete-case data for QALYs.
d Includes imputation of EQ-5D score = 0 for one participant who died during the trial.
e The ICER was calculated using incremental costs to the nearest whole pound and incremental QALYs rounded to three
decimal places.
f Imputed data set, QALYs estimated using OLS linear regression model; costs estimated using gamma family, identity link
using GLMs.
g HRG codes applied to uterine procedures are reported in Table 1.
h The probabilities should be interpreted as the probability that uterine preservation is cost-effective if society requires
compensation of at least the threshold value (e.g. £30,000) to compensate for a QALY loss.
i Complete-case cost and QALY pairs.
Note
Bold text highlights differences between severity of symptom for that particular problem.
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FIGURE 6 Scatterplot of the cost-effectiveness plane (imputed data set).
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The CEAC (Figure 7) shows that, based on the NMB, there is a high probability that vaginal hysterectomy
is the most cost-effective treatment option, with little evidence to support the cost-effectiveness of uterine
preservation. This is driven by the additional costs of delivering the uterine preservation intervention, and
the higher re-operation rate, for no QALY benefit. The probability of uterine preservation being considered
to be cost-effective is 15% if society is willing to pay up to £30,000 for 1 QALY gained. A full set of
scatterplots and CEACs for each analysis undertaken can be found in Appendix 4, Figures 22–9.
Deterministic sensitivity analyses
The study has produced a range of additional deterministic sensitivity analyses to address areas of
uncertainty in assumptions, data collection and analysis modelling approaches. All deterministic analyses
are based on the imputed data set unless otherwise stated (e.g. complete-case analysis). See Chapter 2
for the rationale behind each of the analyses. A number of observations have been made on the results.
First, the findings are not sensitive to the type of model used in the imputed data set with very similar results
for the base case and a sensitivity analysis using seemingly unrelated regression, in which the probability of
cost-effectiveness at a threshold of £30,000 per QALY gained reduces from 15% (base case) to 14%.
Additionally, it is reassuring that the results are not sensitive to missing data assumptions, with similar
findings for both the imputed and the complete-case analyses. The probability of uterine preservation being
cost-effective at a threshold of £30,000 per QALY gained remains < 20% for both the imputed and the
complete-case scenarios.
Second, the estimates of incremental costs are highly sensitive to the approach taken to intervention
costing. The base-case component costing approach estimated additional costs because of the use of
mesh and the slightly longer (around 10 minutes) operation time. However, when mapping Office of
Population, Censuses and Surveys (OPCS) codes onto HRGs, using national reference cost spell-based
tariffs, uterine preservation attracts a lower cost compared with vaginal hysterectomy. The use of a HRG
approach to costing the intervention means that total costs to the NHS over follow-up are lower in the
uterine preservation group, MD –£395; 95% CI –£619 to –£171. Considering that cost savings may be
achieved for marginal (non-significant) reductions in QALYs, the base-case ICER is £98,750. The commonly
accepted maximum price society would be willing to pay to get one additional QALY of benefit is between
£20,000 and £30,000. The threshold could also be interpreted as the maximum amount of money that
would need to be freed up in the NHS to compensate for a QALY loss. Using a HRG-based costing
approach indicates that society would save £98,750 for every QALY lost, indicating a cost-effective use
0.0
0 10 20 30 40 50 60 70 80 90 100
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
WTP per QALY (£000)
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
Vaginal hysterectomy
Uterine preservation
Treatment
FIGURE 7 Cost-effectiveness acceptability curve (imputed data set).
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of resources. The probability that uterine preservation is cost-effective increases from 15% in the base case
to 85% under this scenario, illustrating that the results are highly sensitive to the choice of intervention
costing approach taken.
Third, because of differences in time points for questionnaire triggers (i.e. at 6 months after surgery and at
12 months after randomisation) and the potential for comparatively long periods of time to elapse between
randomisation and surgery, it is possible that respondents received their 12-month questionnaire before
their 6-month questionnaire. The sensitivity analyses show that estimates of cost-effectiveness are not
sensitive to any of the following assumptions in sensitivity analysis:
1. an analysis dropping the 6-month EQ-5D data, if the 6-month questionnaire is returned on or after the
12-month date
2. an analysis dropping any 6-month EQ-5D data within 3 months of the 12-month data
3. an analysis using the exact date of questionnaire report as the measure of time used in the calculation
of QALYs.
Finally, the incorporation of a wider-perspective costing analysis, including both NHS and participant-
incurred and reported costs, does not alter the estimates of cost-effectiveness. The probability that uterine
preservation is cost-effective remains very low (5%) at a threshold of £30,000 per QALY.
Discussion
The findings of the economic evaluation indicate that uterine preservation is unlikely to be cost-effective
compared with vaginal hysterectomy over a 12-month time horizon. Although the findings are unfavourable
for uterine preservation, there are a number of factors that need to be considered when arriving at a
decision on cost-effectiveness. First, the cost-effectiveness results are sensitive to the costing approach taken
for the intervention. Arguments can be made for the use of either a component-costing or HRG approach.
Component costing is chosen as the base case because it is grounded in the economic concepts of resource
scarcity and opportunity cost. Therefore, component costing more accurately reflects the resources displaced
for each surgery, and explicitly accounts for differences in operation times, length of stay and materials costs
(e.g. mesh implants) between the groups observed in the trial. However, the HRG costing approach is more
reflective of the way in which hospitals are paid for carrying out procedures, and it could be argued that
HRGs reflect the true cost outlay to the NHS under current payment mechanisms. The disadvantage of the
HRG approach is that it groups many similar surgeries together. It does not directly consider the opportunity
cost of consultant time, etc. for these specific procedures. That is because HRGs are not based on the
intricate level of detail that can be obtained from the trial data. Although the choice of intervention costing
has a substantial impact on overall costs and cost-effectiveness for the trial-based analysis, the choice may
be less influential in determining lifetime cost-effectiveness from the decision model (see Chapter 2).
Second, the validity of any policy recommendations based solely on the within-trial economic evaluation
could be correctly criticised because the time horizon is very short. Indeed, it is highly unlikely that a
12-month time horizon is sufficient to capture the important costs and QoL impact of different surgical
treatments. The economic modelling (see Chapter 9) aims to address this concern by extrapolating the trial
results over a woman’s lifetime. Additionally, it is planned to follow-up women for a longer period to get
a better understanding of the costs and the outcomes associated with treatment. These data will be used
to validate and update the trial and economic modelling results in the future.
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Chapter 6 Baseline characteristics: Vault trial
Between January 2013 and January 2017, 544 women were identified as potential participants for theVault trial.61
This chapter describes how participating women were identified from the women identified for vault
prolapse surgery in UK hospitals (see Appendix 5, Table 66), 36 of which recruited women to the
Vault trial of the VUE trial. Chapter 6 reports the baseline characteristics up to the point of entry to
the Vault trial of the VUE trial. The subsequent findings are described in Chapters 7 and 8.
Study recruitment
The trial outline and methodology for recruitment have been described previously31 (see Chapter 2).
Women who attended gynaecology outpatient clinics with symptomatic vault POP and then chose to have
surgery, and women on the waiting list for vault prolapse surgery, were invited to participate in the Vault
trial of the VUE trial. Women were asked if they were willing to be randomised to either a vaginal or
abdominal vault procedure. The centres and surgeons who participated in the VUE trial, the numbers they
recruited and the rate of recruitment are detailed in Appendix 5 (Table 66 and Figure 30).
Non-recruited women
Of the 544 women approached regarding trial participation, 335 women did not enter the study because
they declined (n = 211), were ineligible (n = 115) or not timely identified or seen (n = 9) (see Appendix 5,
Tables 67 and 68). Reasons for declining to participate included decided against surgery (n = 58, 27.5%),
did not want mesh (n = 8, 3.8%) and preference for the route of surgery (n = 85, 40.3%), with more
women preferring an abdominal (n = 53, 25.1%) rather than a vaginal procedure (n = 32, 15.2%). Clinical
reasons for non-participation included ‘specific operation is necessary’ (n = 73, 63.5%) and ‘unsuitable due
to medical history’ (n = 21, 18.3%).
Recruited women: baseline characteristics
The baseline characteristics of the 208 women included in the Vault trial are described in Table 19
(see also Appendix 5, Table 69).
Epidemiological characteristics
There was no difference between the randomised groups in respect of age, BMI, parity or delivery mode
history [with the majority of women having a normal vaginal delivery (see Appendix 5, Table 69)].
Previous conservative treatment
Around one-quarter to one-third (29.8%) of women had PFMT supervised by a physiotherapist for prolapse
symptoms and around one in five (20.2%) women had previously used a vaginal pessary (ring or other type)
before surgery (Table 19).
Overall, around 1 in 10 women (13.0%) had previous supervised PFMT or used drug treatment (9.7%)
for urinary incontinence.
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TABLE 19 Baseline characteristics, by randomised allocation
Characteristics
Treatment
Abdominal vault (N= 104) Vaginal vault (N= 104)
Age (years), mean (SD); N 65.1 (8.0); 104 66.4 (8.3); 104
BMI (kg/m2), mean (SD); N 28.1 (4.0); 87 27.8 (3.7); 86
BMI category, n (%)
Underweight 1 (1.0) 0 (0)
Normal weight 17 (16.3) 17 (16.3)
Overweight 42 (40.4) 49 (47.1)
Obese 19 (18.3) 18 (17.3)
Morbidly obese 8 (7.7) 2 (1.9)
Missing 17 (16.3) 18 (17.3)
Parity, median (P25–75);a n 2 (2–3); 101 2 (2–3); 104
Number of normal vaginal deliveries, n (%); N 2.4 (1.2); 100 2.5 (1.2); 101
Previous conservative treatment, n (%)
Physiotherapy for prolapse 38 (36.5) 24 (23.1)
Vaginal pessary 24 (23.1) 18 (17.3)
Physiotherapy for urinary incontinence 16 (15.4) 11 (10.6)
Drugs for UI 11 (10.6) 9 (8.7)
Previous surgery, n (%)
Vaginal hysterectomy 58 (55.8) 56 (53.8)
For prolapse 41 (39.4) 35 (33.7)
Other reason 8 (7.7) 9 (8.7)
Reason unknown 9 (8.7) 12 (12.5)
Abdominal hysterectomy 47 (45.2) 49 (47.1)
For prolapse 1 (1.0) 4 (3.8)
Other reason 32 (30.8) 34 (32.7)
Reason unknown 14 (13.5) 11 (10.6)
Previous vault repair for prolapse
For prolapse 3 (2.9) 1 (1.0)
Other reason 0 (0) 1 (1.0)
Previous anterior repair
1 28 (26.9) 29 (27.9)
2 4 (3.8) 0 (0)
Previous posterior repair
1 18 (17.3) 14 (13.5)
2 1 (1.0) 0 (0)
Vaginal repair, but compartment unknown 4 (3.8) 6 (5.8)
Previous continence surgery 10 (9.6) 5 (4.8)
UI, urinary incontinence.
a P25–75 is the 25th to the 75th percentile range.
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Previous surgery
All women in the Vault trial had a previous hysterectomy. Slightly more women had had a vaginal
hysterectomy (54.8%) than an abdominal hysterectomy (46.2%) (Table 19). Of those women with a
previous vaginal hysterectomy, in just over one-third (36.6%) of the women this was for prolapse symptoms.
A previous abdominal hysterectomy was rarely undertaken for prolapse reasons and was most likely due
to ‘other reasons’ (31.8%), for example menorrhagia or fibroids. The reason for a previous hysterectomy
(vaginal or abdominal) was unknown in around 12% of women (Table 19).
In four women, their VUE vault repair was a repeat vault procedure, having already had a previous vault
repair (three of which were for prolapse and one for ‘other reasons’).
Just over one-quarter (27.4%) of all women had previously had an anterior repair and four women (3.8%)
had two previous anterior repairs. Fewer women (approximately 15%) had a previous posterior repair,
and one woman had two previous posterior repairs. Previous vaginal repair was noted in an additional
10 women, but the compartment of previous surgery was unknown (see Table 19).
Overall, approximately 7% of women had undergone previous continence surgery.
Prolapse symptoms at baseline
Women in the Vault trial had been symptomatic for approximately 3 years, and were bothered by their
symptoms for approximately 2 years. The overall mean POP-SS was 15 out of 28 (and ranged from 1 to 28).
Using a POP-SS of > 0 to indicate presence of symptoms, 100% of women who completed these questions
had at least one symptom (this section was missing for seven women). The effect on QoL score (‘overall,
how much do your prolapse symptoms interfere with your everyday life?’) was high and ranged from 0 to
10 out of 10, with a mean of 7 out of 10 (Table 20).
The most common individual prolapse symptom was ‘a feeling of something coming down from or in your
vagina’, reported in 94.7% of women. This was reported ‘most or all of the time’ in over three-quarters
(78.9%) and was the most bothersome symptom for almost half (47.2%) of the women.
Over one-third (36.6%) of women found the prolapse caused hygiene problems, and 15.9% needed to
relieve pressure or discomfort from the prolapse using their fingers (Table 20).
Generic quality of life
The mean score for generic QoL and visual scales (EQ-5D) were 0.735 and 74.1 points, respectively.
Preoperative objective measurements
Over one-third (38.9%) of women had a stage 0 or 1 vault prolapse. Using a more clinically meaningful
definition of leading edge of prolapse beyond the hymen (POP-Q stage 2b or more), 91.4% of women
had an overall objective prolapse (see Appendix 5, Table 70), and 39.4% had an objective vault prolapse
[stages 2b or more (Table 21)]. The stage of vault prolapse was missing in 3.9% of women.
More women had an objective (stage 2b or more) anterior (80.3%) than a posterior (52.4%) prolapse
(Table 21).
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TABLE 20 Prolapse symptoms at baseline
Symptom
Treatment
Abdominal vault
(N= 104)
Vaginal vault
(N= 104)
Duration of symptoms (years), mean (SD); N 3.7 (4.8); 95 2.4 (2.4); 98
Duration of bother (years), mean (SD); N 2.5 (3.9); 95 1.9 (2.4); 95
POP-SS at baseline, mean (SD); N 15.1 (6.5); 101 14.8 (5.7); 100
Number of women symptomatic, mean (SD); N 101 (97.1) 100 (96.2)
Prolapse-related effect on QoL score, mean (SD); N 7.1 (2.6); 100 7.0 (2.6); 103
Individual prolapse symptoms, n (%)
Something coming down (any) 98 (94.2) 99 (95.2)
Something coming down (most/all of the time) 81 (77.9) 83 (79.8)
Bladder not empty (any) 90 (86.5) 94 (90.4)
Bladder not empty (most/all of the time) 44 (42.3) 43 (41.3)
Uncomfortable feeling or pain when standing (any) 89 (85.6) 92 (88.5)
Uncomfortable feeling or pain when standing (most/all of the time) 50 (48.1) 51 (49.0)
Dragging in abdomen (any) 81 (77.9) 86 (82.7)
Dragging in abdomen (most/all of the time) 45 (43.3) 40 (38.5)
Bowel not empty (any) 81 (77.9) 84 (80.8)
Bowel not empty (most/all of the time) 27 (26.0) 27 (26.0)
Strain to empty bladder (any) 74 (71.2) 76 (73.1)
Strain to empty bladder (most/all of the time) 33 (31.7) 32 (30.8)
Dragging in back (any) 73 (70.2) 75 (72.1)
Dragging in back (most/all of the time) 37 (35.6) 23 (22.1)
Most bothersome symptom
Something coming down 48 (46.2) 50 (48.1)
Uncomfortable feeling or pain when standing 12 (11.5) 19 (18.3)
Bladder not empty 11 (10.6) 8 (7.7)
Dragging in abdomen 7 (6.7) 5 (4.8)
Strain to empty bladder 6 (5.8) 6 (5.8)
Bowel not empty 5 (4.8) 6 (5.8)
Dragging in back 4 (3.8) 4 (3.8)
Symptoms cause most bother not applicable 3 (2.9) 2 (1.9)
Missing 11 (10.6) 6 (5.8)
Actions necessitated by prolapse symptoms
Extra hygiene measures 34 (32.7) 42 (40.4)
Fingers to ease discomfort 17 (16.3) 16 (15.4)
Fingers to help empty bladder 5 (4.8) 1 (1.0)
Fingers to help empty bowel 3 (2.9) 0 (0)
Digitally evacuate bowel 2 (1.9) 5 (4.8)
Quality of life, mean (SD); count
EQ-5D 0.726 (0.209); 95 0.744 (0.197); 101
EQ-5D visual scale 74.8 (18.0); 99 73.4 (17.5); 103
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Planned concomitant surgery
Planned surgery was based on preoperative findings on clinical examination (Table 22). The VUE trial was
designed so that women would remain in the group to which they were allocated, irrespective of the actual
procedure performed. In order to randomise women appropriately, taking account of minimisation criteria,
gynaecologists were asked to specify in advance which concomitant surgery would also be necessary.
All women were expected to undergo a vault prolapse procedure from the preoperative clinical planning.
A concomitant anterior prolapse repair was planned more frequently (32.7%) than either posterior repair
(13.5%) or both anterior and posterior repair (21.7%). Surgery for incontinence was rarely planned (2.9%).
Planned procedures were equally distributed between the two randomised groups.
TABLE 21 Preoperative objective measures of prolapse
Prolapse stage
Treatment, n (%)
Abdominal vault (N= 104) Vaginal vault (N= 104)
Overall stage 2b or more 92 (88.5) 98 (94.2)
Vault stage
0 3 (2.9) 5 (4.8)
1 38 (36.5) 35 (33.7)
2a 19 (18.3) 18 (18.3)
2b 19 (18.3) 15 (14.4)
3 21 (20.2) 23 (22.1)
4 1 (1.0) 3 (2.9)
Missing 3 (2.9) 5 (4.8)
Stage 2b or more 41 (39.4) 41 (39.4)
Anterior prolapse stage 2b or more 86 (82.7) 81 (77.9)
Posterior prolapse stage 2b or more 51 (49.0) 58 (55.8)
TABLE 22 Planned concomitant surgery
Planned concomitant surgery
Treatment, n (%)
Abdominal vault (N= 104) Vaginal vault (N= 104)
None 30 (28.8) 32 (30.8)
Anterior repair 32 (30.8) 36 (34.6)
Anterior plus posterior repair 24 (23.1) 21 (20.2)
Posterior repair 14 (13.5) 14 (13.5)
Enterocele repair 7 (6.7) 4 (3.8)
Concomitant UI surgery 3 (2.9) 3 (2.9)
UI, urinary incontinence.
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Vaginal and sexual symptoms at baseline
Vaginal and sexual symptoms were measured using the ICI-validated instruments36 (Table 23) (www.
journalslibrary.nihr.ac.uk/programmes/hta/11129183/#/; accessed February 2019). These were common
and had important effects on QoL. The majority of women were not sexually active (72.6%) and for about
one-quarter of women this was most often because of their prolapse symptoms. No women reported
dyspareunia at baseline.
Urinary and bowel symptoms at baseline
Urinary symptoms also had some impact on QoL (the overall mean QoL due to urinary symptoms was
4/10) (Table 24). Around one in six (16.8%) of all women reported at least some urinary incontinence,
as measured using the ICIQ-UI SF;36 however, this was slight or moderate in the majority (79.3%) of cases
(Appendix 5, Table 71). Urgency was the most common type of urinary symptom, reported in around 28.9%
of all women. Women were counted as symptomatic if they had the symptom ‘most or all of the time’.
Over one-third (38.0%) of all women had faecal incontinence at least occasionally [defined as loss of solid
or liquid stool, but not including loss of flatus (wind)], and this was severe in around 12.0% of women.
Few women (8.2%) reported constipation.
TABLE 23 Vaginal and sexual symptoms at baseline
Symptom
Treatment
Abdominal vault (N= 104) Vaginal vault (N= 104)
ICI Vaginal Symptoms Score, mean (SD); n 23.9 (9.5); 87 24.4 (9.5); 93
QoL due to vaginal symptoms, mean (SD); n 5.6 (3.1); 95 5.9 (3.1); 100
ICI-Sexual Matters Score, mean (SD); n 26.1 (17.3); 28 25.7 (17.4); 29
QoL due to effect on sex life, mean (SD); n 4.7 (3.1); 28 5.6 (3.1); 29
Vagina too loose or lax, n (%) 18 (17.3) 16 (15.4)
Reduced sensation, n (%) 4 (3.8) 8 (7.7)
Number having intercourse, n (%) 28 (26.9) 29 (27.9)
Pain with intercoursea – most or all of the time 0 (0.0) 0 (0.0)
Reasons for not being sexually active, n (%)
Prolapse symptoms 26 (25.0) 27 (26.0)
No partner 24 (23.1) 19 (18.3)
Vaginal symptoms 2 (1.9) 3 (2.9)
Other reason 15 (14.4) 17 (16.3)
Reason not given 37 (35.6) 38 (36.5)
a Out of sexually active women.
BASELINE CHARACTERISTICS: VAULT TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
54
Discussion
Summary of findings
The participating women in the Vault trial were around 66 years old, with a median of two babies. Their
mean BMI was around 28 kg/m2 (though eight women in the abdominal group and two in the vaginal
group were morbidly obese and did receive surgery). All women had a previous hysterectomy (abdominal
or vaginal), with more having had a previous vaginal hysterectomy for prolapse symptoms than for other
reasons. Those women with a previous abdominal hysterectomy were more likely to have had this for
non-prolapse reasons.
Women were more likely to have had a previous anterior than posterior repair, and few (7%) had a
previous incontinence procedure (see Table 19).
TABLE 24 Urinary and bowel symptoms at baseline
Symptom
Treatment
Abdominal vault (N= 104) Vaginal vault (N= 104)
Urinary symptoms, n (%)
Urgency 32 (30.8) 28 (26.9)
Nocturia 26 (25.0) 27 (26.0)
Frequency 13 (12.5) 8 (7.7)
Any incontinence, n (%) 20 (19.2) 15 (14.4)
Severe 2 (1.9) 1 (1.0)
Incontinence-related Qol score, mean (SD); N 4.1 (3.3); 88 4.0 (3.4); 91
ICI-UI score, mean (SD); N 8.1 (5.1); 85 7.8 (5.1); 89
ICIQ-FLUTS filling score, mean (SD); N 5.7 (2.7); 98 5.5 (2.7); 101
ICIQ-FLUTS voiding symptoms score, mean (SD); N 3.5 (2.9); 102 3.4 (2.4); 103
ICIQ-FLUTS incontinence score, mean (SD); N 5.5 (3.5); 87 5.1 (3.2); 93
Bowel symptoms
Bowel frequency, n (%)
Normal 93 (89.4) 98 (94.2)
Frequent 3 (2.9) 1 (1.0)
Infrequent 6 (5.8) 1 (1.0)
Missing 2 (1.9) 4 (3.8)
Faecal incontinence (occasionally or more often), n (%) 39 (37.5) 40 (38.5)
Passive 14 (13.5) 5 (4.8)
Active 25 (24.0) 35 (33.7)
Severe 17 (16.3) 8 (7.7)
Bowel urgency (most or all of the time), n (%) 16 (15.4) 5 (4.8)
Constipation (most or all of the time), n (%) 11 (10.6) 6 (5.8)
Bowel symptoms QoL score, mean (SD); N 3.1 (3.3); 98 3.1 (2.9); 101
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Prolapse symptoms and measurements
Women had POP-SSs of around 15 out of a maximum score of 28. The most common symptom was a
feeling of something coming down, reported by 94.7%, which was most bothersome in 47.2% of women
(see Table 20).
When prolapse was redefined as the leading edge beyond the hymen (i.e. stage 2b or more), most (91.3%)
women had an overall protruding prolapse and 39.4% had a vault prolapse specifically (see Table 21).
In the study it was possible to ascribe a prolapse stage to 96% of women at baseline. It is difficult to
explain why a small minority of women appeared not to have significant vault prolapse (i.e. stage 0 or 1)
yet were listed for vault surgery (see also Chapter 3 for reasons for this).
The majority of women (70.2%) were also expected to undergo a concomitant prolapse in another
compartment (anterior, posterior or both) at the same time (see Table 22). This was more likely to be an
anterior repair (32.7%) rather than a posterior repair (13.5%).
Other clinical symptoms
Vaginal and sexual symptoms were common and impacted on QoL (see Table 23). Just over one-quarter
(27.4%) of the women were sexually active at baseline and none reported dyspareunia (see Table 23).
Urgency (28.9%) and nocturia (25.5%) were common urinary symptoms. Just under one-fifth of women
had urinary incontinence, and this was severe in 1.5% of women (see Table 24). Few women were
expected to undergo concomitant continence surgery or had already undergone previous continence
surgery. Over one-third (38%) of women had faecal incontinence, at least occasionally, and this was
severe in around 1 in 10 women (see Table 24).
The Vault trial was recruited alongside the Uterine trial, but the Vault trial was not powered in the same
way. The Vault trial was considered more an opportunistic sample given the lower prevalence of vault to
uterine prolapse in the population. As a result, any differences may appear larger because of the lower
number of participants.
The findings in this chapter will serve as a benchmark for future research in women with a vault prolapse.
The clinical messages regarding symptoms and clinical practice may be helpful in improving prolapse
management in the UK and internationally.
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Chapter 7 Vault trial results
This chapter reports the outcomes for women who participated in the Vault trial at 12 months.
The flow of women through the trial is shown in the CONSORT flow diagram (Figure 8), in line with
CONSORT recommendations.61
There was one post-randomisation exclusion (further review concluded that this woman had a previous
subtotal hysterectomy, which was an exclusion criteria) not included in the study analyses, leaving 208
randomised women analysed in the Vault trial.
The women were recruited in 45 centres across the UK (see Appendix 5, Table 66) and received surgery as
shown in Figure 9.
Of the 208 women included, 175 received their randomised allocation (81.8% in the abdominal group
vs. 86.5% in the vaginal group) and 11 crossed over (Figure 9) (Table 25). Reasons for not having the
allocated treatment were that the vault procedure was no longer appropriate (n = 12), pelvic adhesions
(n = 4), other clinical reasons (n = 10), woman’s choice (n = 3) or unknown reasons (n = 3).
A small number of women (n = 16) had no vault surgery (Figure 9) but did receive a prolapse procedure in
a different compartment [anterior (n = 8), posterior (n = 6) or both an anterior and a posterior (n = 2)].
One woman reported that she had undergone surgery (the surgery type was not detailed), but this has not
been verified with the recruiting centre.
Abdominal 
(n = 105)
Post-randomisation exclusion, n = 1
Treatment
• Treated as allocated, n = 85
• Vaginal, n = 7
• Other apical intervention, n = 0
• No apical surgery, n = 11
• Unknown, n = 1
Follow-up (12 months)
• Provided primary outcome, n = 88
• Died, n = 1
• Declined further follow-up, n = 5
• Did not respond, n = 10
Vaginal 
(n = 104)
Excluded
Randomised 
(n = 209)
Eligible patients 
(n = 429)
Ineligible patients 
(n = 115)
Patients screened 
(n = 544)
Post-randomisation exclusion, n = 0
Treatment
• Treated as allocated, n = 90
• Abdominal, n = 4
• Other apical intervention, n = 0
• No apical surgery, n = 10
• Unknown, n = 0
Follow-up (12 months)
• Provided primary outcome, n = 86
• Died, n = 1
• Declined further follow-up, n = 6
• Did not respond, n = 11
• Declined, n = 211
• Other, n = 9
FIGURE 8 The CONSORT flow diagram of women recruited to the Vault trial of the VUE study.
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(n = 209)
Abdominal
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Abdominal
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Vaginal
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(n = 11)
Vaginal
(n = 90)
Abdominal
(n = 4)
No apical
surgery
(n = 10)
Yes
(n = 19)
No
(n = 18)
Yes
(n = 72)
No
(n = 1)
Yes
(n = 10)
No
(n = 0)
Yes
(n = 7)
No
(n = 66)
Yes
(n = 1)
No
(n = 3)
Yes
(n = 6)
No
(n = 4)
Anterior
(n = 6)
Posterior
(n = 6)
Both
(n = 7)
Anterior
(n = 4)
Posterior
(n = 5)
Both
(n = 1)
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(n = 3)
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Both
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FIGURE 9 Treatment received diagram for the Vault trial: breakdown of the different surgeries received or no surgery actually received. a, One participant’s surgery status is
unknown. UIS, urinary incontinence surgery.
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The use of mesh for the apical surgery in the abdominal group (88.0%) was higher than in the vaginal
group (6.4%). Concomitant surgery was around 4% overall (see Appendix 6, Table 72).
Description of surgical characteristics
Most procedures were performed by a consultant gynaecologist (87.5%), were performed under general
anaesthesia (90.4%) and most patients received prophylactic antibiotics (91.8%) (Appendix 6, Table 73).
The duration of the operation was significantly longer in the abdominal group (146 mean duration,
SD 54 minutes) than in the vaginal group (82 mean duration, SD 34 minutes; MD 60.48, 95% CI 49.80
to 71.16 minutes). There was no difference in blood loss (98 ml in the abdominal group vs. 108 ml in the
vaginal group) or length of hospital stay (2.1 days in the abdominal group vs. 1.8 days in the vaginal group)
between the groups (Appendix 6, Table 74).
There was no difference in time from the woman’s randomisation to her surgery between the groups
(Appendix 6, Table 74).
Outcomes
Response rates and clinical attendance
Of the 104 women randomised to the abdominal group, 89 (85.6%) responded to the 12 months after
randomisation questionnaire, and 88 (84.6%) out of the 104 participants randomised to the vaginal group
responded. Clinical outcomes were collected at 12 months after surgery for 96 out of the 104 (92.3%)
women in the abdominal group and 99 out of the 104 (95.1%) women in the vaginal group.
TABLE 25 Surgery actually received
Surgery received
Treatment, n (%)
Abdominal vault (N= 104) Vaginal vault (N= 104)
Apical surgery received
Vaginal vault suspensiona 7 (6.7) 90 (86.5)
Abdominal suspension (laparoscopicb) 61 (58.7) 4 (3.8)
Abdominal suspension (openc) 24 (23.1) 0 (0)
No apical surgery 11 (10.6) 10 (9.6)
Unknown 1 (1.0) 0 (0)
Concomitant surgery received
None 66 (63.5) 21 (20.2)
Anterior repair 11 (10.6) 27 (26.0)
Posterior repair 16 (15.4) 24 (23.1)
Both (anterior and posterior) 9 (8.7) 28 (26.9)
Continence surgery 3 (2.9) 2 (1.9)
a Vaginal sacrospinous fixation.
b Laparoscopic sacrocolpopexy.
c Open sacrocolpopexy.
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Women’s prolapse symptoms and effect on everyday life
At 6 months after surgery, women reported a reduction in their POP-SS (maximum score 28) from an
overall mean score of 15 out of 28 at baseline to 5.3 out of 28 in the abdominal group and 6.1 out of 28
in the vaginal group (Table 26). The between-group difference was not statistically significant (MD –1.17;
95% CI –2.64 to 0.31). The effect of prolapse on QoL also improved at 6 months after surgery and there
was no significant difference between the groups.
The primary outcome was POP-SS at 12 months after randomisation; there was no statistically significant
difference between the groups. The MD in the POP-SS for abdominal (5.6, SD 5.4) compared with vaginal
(5.9, SD 5.4) adjusted for baseline variables was –0.61 (95% CI –2.08 to 0.86) (see Figure 10, and
Appendix 6, Figure 31). The intracluster correlation for surgeon was 0.04 (95% CI 0.01 to 0.12).
0
Baseline
Time point
6-months
post-clinic
Vaginal vault
Abdominal vault
12-months
post-randomisation
2
4
6
8
10
12
14
PO
P-
SS 16
18
20
22
24
26
28
Treatment
FIGURE 10 The mean and standard error POP-SSs at baseline and follow-up (6 months after surgery and 12 months
after randomisation).
TABLE 26 The POP-SS and prolapse-related effect on QoL
Time point
Treatment, mean (SD); N
Effect sizea (95% CI); p-valueAbdominal vault Vaginal vault
POP-SS
Baseline 15.1 (6.5); 101 14.8 (5.7); 100
6 months after surgery 5.3 (5.5); 83 6.1 (5.5); 93 –1.17 (–2.64 to 0.31); 0.12
12 months after randomisation 5.6 (5.4); 88 5.9 (5.4); 86 –0.61 (–2.08 to 0.86); 0.42
Prolapse-related effect on QoL
Baseline 7.1 (2.6); 100 7.0 (2.6); 103
6 months after surgery 2.5 (3.2); 84 2.9 (2.9); 93 –0.56 (–1.41 to 0.30); 0.20
12 months after randomisation 2.3 (3.0); 87 2.6 (2.8); 87 –0.25 (–1.10 to 0.59); 0.56
a The effect sizes presented represent the MD (abdominal vs. vaginal), adjusted for baseline and minimisation variables.
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There was also no significant difference on the effect of prolapse on QoL at 12 months after
randomisation [abdominal 2.3 (SD 3.0) vs. vaginal 2.6 (SD 2.8); MD –0.25, 95% CI –1.10 to 0.59].
The distribution of individual POP-SSs and prolapse-related effects on QoL are also given in Appendix 6,
Figures 31 and 32.
Each individual prolapse symptom also improved at 12 months after randomisation (Table 27) and was
already apparent at 6 months after surgery (see Appendix 6, Table 75).
TABLE 27 Prolapse symptoms at 12 months after randomisation
Symptoms
Treatment
Abdominal vault Vaginal vault
Symptomatic, n (%); N
Number of women with symptoms 78 (88.6); 88 75 (87.2); 86
Individual prolapse symptoms, n (%); N
Bowel not empty (any) 62 (69.7); 89 56 (64.4); 87
Bowel not empty (most/all of the time) 13 (14.6); 89 8 (9.2); 87
Bladder not empty (any) 54 (60.7); 89 54 (62.1); 87
Bladder not empty (most/all of the time) 11 (12.4); 89 8 (9.2); 87
Strain to empty bladder (any) 38 (43.7); 87 37 (42.5); 87
Strain to empty bladder (most/all of the time) 7 (8.0); 87 6 (6.9); 87
Dragging in back (any) 36 (41.4); 87 39 (45.3); 86
Dragging in back (most/all of the time) 6 (6.9); 87 7 (8.0); 86
Something coming down (any) 31 (34.8); 89 41 (47.1); 87
Something coming down (most/all of the time) 13 (14.6); 89 15 (17.2); 87
Dragging in abdomen (any) 29 (33.3); 87 32 (36.8); 87
Dragging in abdomen (most/all of the time) 2 (2.3); 87 7 (8.0); 87
Uncomfortable feeling or pain when standing (any) 28 (32.2); 87 32 (37.2); 86
Uncomfortable feeling or pain when standing (most/all of the time) 7 (8.1); 87 7 (8.1); 86
Most bothersome symptom
Bowel not empty 27 (45.8); 59 18 (32.1); 56
Something coming down 6 (10.2); 59 19 (33.9); 56
Bladder not empty 14 (23.7); 59 6 (10.7); 56
Strain to empty bladder 4 (6.8); 59 3 (5.4); 56
Uncomfortable feeling or pain when standing 3 (5.4); 59 4 (7.1); 56
Dragging in back 4 (6.8); 59 2 (3.6); 56
Dragging in abdomen 1 (1.7); 59 4 (7.1); 56
Which symptom causes most bother not applicable 24 (28.9); 83 23 (29.1); 79
continued
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The most bothersome symptoms across both treatment groups at both 6 months after surgery and 12 months
after randomisation were different from those at baseline. The most bothersome symptom at baseline,
‘a feeling of something coming down’, reduced overall from 47.2% to 10% in the abdominal versus 34% in
the vaginal group. Symptoms of incomplete emptying of either bladder or bowel became more common, but
‘actions necessitated by prolapse symptoms’ were low (see Table 27, see also Appendix 6, Table 75).
Secondary outcomes
Objective prolapse outcomes
Women who had any prolapse procedure were invited back for a clinical assessment at 12 months after
surgery and, overall, 93.7% attended. The objective prolapse measure (i.e. POP-Q) improved in all
compartments (Table 28).
The objective overall prolapse stage 2b or more fell from 91.4% to 32.6% in the abdominal and 46.9% in
the vaginal group, and this was not significant between the groups (OR 0.50, 95% CI 0.25 to 1.02; see
Appendix 6, Table 76). More specifically, those with an objective vault prolapse (Stage 2b or more) fell
from 39.4% to 6.0% in the abdominal group compared with 9.0% in the vaginal group after surgery
(adjusted for baseline values); this was not significant (OR 0.61, 95% CI 0.18 to 2.08). Objective anterior
prolapse stage 2b or more was found in 24.4% of the abdominal group and 40.7% of the vaginal group
and this was statistically significant (OR 0.38, 95% CI 0.18 to 0.79). Objective posterior prolapse also
improved, with no difference between the treatment groups (Table 28).
Development of new (de novo) prolapse at another site (anterior or posterior) was seen in a few cases and
there was no evidence of a difference between the randomised groups (four in the abdominal group vs.
eight in the vaginal group; OR 0.45, 95% CI 0.13 to 1.56).
Vaginal and sexual symptoms
There was no difference between the groups in terms of vaginal and sexual symptoms (Table 29). Both the
mean vaginal symptoms and the QoL scores decreased (improved) for both groups. Slightly more women
were sexually active after surgery (from around 27.4% at baseline to 36.9% in the abdominal group and
38.4% in the vaginal group), and fewer women cited prolapse symptoms as a reason for not being sexually
active. From those women who were not sexually active, six (14.0%) in the abdominal and seven (17.7%) in
the vaginal group gave vaginal or prolapse symptoms as the reason.
TABLE 27 Prolapse symptoms at 12 months after randomisation (continued )
Symptoms
Treatment
Abdominal vault Vaginal vault
Actions necessitated by prolapse symptoms
Extra hygiene measures 6 (7.3); 82 6 (7.1); 84
Fingers to ease discomfort 3 (3.7); 82 0 (0); 84
Fingers to help empty bowel 3 (3.5); 85 0 (0); 85
Digitally evacuate bowel 1 (1.1); 87 2 (2.3); 87
Fingers to help empty bladder 1 (1.2); 85 0 (0); 87
Quality of life, mean (SD); count
EQ-5D 0.826 (0.217); 82 0.823 (0.175); 86
EQ-5D visual scale 78.2 (16.9); 83 77.5 (17.0); 85
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TABLE 29 Vaginal and sexual symptoms at 12 months after randomisation
Symptoms
Treatment
Effect sizea (95% CI); p-valueAbdominal vault Vaginal vault
ICI Vaginal Symptoms Score, mean (SD); N 8.9 (9.9); 75 8.4 (8.7); 79 0.69 (–1.89 to 3.26); 0.60
QoL because of vaginal symptoms,
mean (SD); N
1.6 (2.4); 79 1.8 (2.3); 80 –0.10 (–0.81 to 0.60); 0.78
ICI-Sexual Matters Score, mean (SD); N 8.8 (10.4); 31 14.5 (16.4); 32 –5.13 (–13.33 to 3.07); 0.22
QoL because of effect on sex life, n (%); N 2.1 (2.7); 31 2.7 (3.2); 32 –0.46 (–2.13 to 1.20); 0.59
Reduced sensation, n (%); N 4 (4.9); 82 2 (2.4); 82
Vagina too loose or lax, n (%); N 3 (3.6); 83 2 (2.4); 83
Number having intercourse, n (%); N 31 (36.9); 84 33 (38.4); 86
Pain with intercourse 1 (3.2); 31 0 (0); 33
Reasons for not being sexually active, n (%); N
No partner 21 (48.8); 43 17 (41.5); 41
Prolapse symptoms 4 (9.3); 43 7 (17.7); 41
Vaginal symptoms 2 (4.7); 43 0 (0); 41
Other reason 16 (37.2); 43 17 (41.5); 41
a The effect sizes presented represent the MD or OR depending on the type of variable (abdominal vs. vaginal), adjusted
for baseline when available and minimisation variables.
TABLE 28 Objective prolapse outcomes
Compartment stage
Treatment, n (%); N
Effect size,a OR (95% CI); p-valueAbdominal vault Vaginal vault
Overall stage 2b or more 28 (32.6) 86 38 (46.9) 81 0.50 (0.25 to 1.02); 0.06
Apical stage
Stage 0 68 (81.0); 84 54 (69.2); 78
Stage 1 11 (13.1); 84 14 (17.9); 78
Stage 2a 0 (0); 84 3 (3.8); 78
Stage 2b 4 (4.8); 84 4 (5.1); 78
Stage 3 0 (0); 84 1 (1.3); 78
Stage 4 1 (1.2); 84 2 (2.6); 78
Stage 2b or more 5 (6.0); 84 7 (9.0); 78 0.61 (0.18 to 2.08); 0.43
Anterior stage 2b or more 21 (24.4); 86 33 (40.7); 81 0.38 (0.18 to 0.79); 0.01
Posterior stage 2b or more 10 (11.6); 86 11 (13.6); 81 0.71 (0.27 to 1.85); 0.48
Development of new prolapse at another site 4 (4.4); 90 8 (9.2); 87 0.45 (0.13 to 1.56); 0.21
a The effect size is presented as an OR (abdominal vs. vaginal), adjusted for baseline and minimisation variables.
Note
Bold text separates and highlights the different prolapse staging of the different vaginal compartments.
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There were no statistically significant differences in vaginal and sexual symptoms between the abdominal
and vaginal groups at 12 months after randomisation.
Urinary and bowel symptoms
Overall, at 12 months after randomisation the proportion of women who had any urinary incontinence
increased from 16.8% at baseline to 30.8% in the abdominal versus 24.0% in the vaginal group [and this
was not significantly different (OR 1.39, 95% CI 0.68 to 2.86)] (Table 30). The proportion of women with
severe urinary incontinence remained low.
More women reported urge incontinence at 12 months after randomisation in the vaginal group than in
the abdominal group, but this was not significantly different (MD 0.49, 95% CI 0.17 to 1.47). De novo
urge incontinence following surgery was similar across both treatment groups and was reported in around
one-quarter of the women.
TABLE 30 Urinary symptoms at 12 months after randomisation
Symptoms
Treatment
Effect sizea (95% CI); p-valueAbdominal vault Vaginal vault
Urinary symptoms, n (%); N
Urgency 6 (6.9); 87 10 (11.6); 86 0.49 (0.17 to 1.47); 0.20
Frequency 5 (5.7); 87 5 (5.9); 85
Nocturia 8 (9.2); 87 15 (17.4); 86
All of the above 0 (0); 87 0 (0); 85
Any incontinence, n (%); N 32 (37.6); 85 25 (29.1); 86 1.39 (0.68 to 2.86); 0.37
Severe incontinence 2 (2.8); 71 2 (2.6); 78 1.10 (0.15 to 8.03); 0.92
De novo incontinence, n (%); N 17 (25.4); 67 15 (21.1); 71 1.27 (0.57 to 2.85); 0.56
Incontinence-related QoL score, mean (SD); count 2.0 (2.7); 70 2.2 (2.5); 77 –0.03 (–0.79 to 0.72); 0.93
ICI UI Score, mean (SD); count 5.1 (4.7); 68 5.7 (4.6); 74 –0.42 (–1.77 to 0.94); 0.55
ICIQ-FLUTS Filling Score, mean (SD); count 3.7 (2.2); 87 3.9 (2.0); 83 –0.28 (–0.83 to 0.28); 0.33
ICIQ-FLUTS Voiding Symptoms Score, mean (SD);
count
1.8 (2.0); 86 1.7 (2.0); 87 0.05 (–0.47 to 0.58); 0.84
ICIQ-FLUTS Incontinence Score, mean (SD); count 3.9 (3.4); 71 4.3 (3.6); 78 –0.58 (–1.55 to 0.39); 0.24
Persistent incontinence, n (%); N 14 (16.7); 84 9 (10.8); 83 1.67 (0.66 to 4.20); 0.28
Bowel symptoms
Bowel frequency (normal), n (%); N 82 (94.3); 87 83 (96.5); 86 0.84 (0.09 to 8.01); 0.88
Faecal incontinence (any), n (%); N 30 (35.3); 85 29 (33.7); 86 1.36 (0.57 to 3.26); 0.49
Passive 17 (19.8); 86 15 (18.1); 83
Active 12 (14.0); 86 13 (15.7); 83
Severe 9 (10.6); 85 9 (10.5); 86 0.55 (0.16 to 1.84); 0.33
Constipation 4 (4.6); 87 2 (2.3); 87 1.85 (0.32 to 10.65); 0.49
Bowel urgency 18 (22.2); 81 17 (20.5); 83 0.75 (0.33 to 1.74); 0.51
Bowel symptoms QoL score, mean (SD); count 2.0 (1.0); 87 1.8 (0.9); 87 0.22 (–0.04 to 0.47); 0.10
a The effect sizes presented represent the MD or OR depending on the type of variable (abdominal vs. vaginal), adjusted
for baseline when available and minimisation variables.
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There were no statistically significant differences between the treatment groups in terms of urinary or
bowel symptoms at 12 months after randomisation (see Appendix 6, Table 77).
Satisfaction with treatment at 12 months after randomisation
There were no differences between the treatment groups in terms of satisfaction with treatment at
12 months after randomisation (Table 31).
Further treatment required for failure or adverse events at 6 and at 12 months
Most women reported that they felt better than before surgery (92.8% abdominal procedure vs. 86.2%
vaginal procedure) and this was not statistically significant (OR 1.97, 95% CI 0.69 to 5.60) (Table 32).
The proportions of women completely or fairly satisfied were also similar (87.8% abdominal procedure
vs. 82.6% vaginal procedure; OR 1.56, 95% CI 0.63 to 3.86). The majority of women would recommend
the surgery to a friend (86.3% abdominal procedure vs. 88.0% vaginal procedure).
When women reported that they had been re-admitted to hospital, the information was verified with the
centres and post-coded accordingly to ensure accuracy of data and resolution of discrepancies. A hospital
re-admission was automatically counted as a SAE if it was related to the initial prolapse surgery. Further
surgery for prolapse (failure if same compartment), or for continence surgery, was differentiated from
re-admission for surgery-related complications, such as bleeding or infection.
Fewer than 1 in 10 women had a re-admission for further surgery in the first 12 months (Table 32). Eleven
women had further prolapse surgery within 12 months [abdominal (n = 5) vs. vaginal (n = 6)], this was not
statistically significant. Four women in the vaginal group had a further apical procedure compared with
one in the abdominal group in that time (again, this was not statistically significant).
There was no evidence of a difference in further use of health services between the randomised groups of
women.
Serious and related adverse events in the first 12 months
Overall, there were 12 SAEs (6.0%) reported in the first 12 months following surgery (more than one SAE
could be reported per woman) (Table 33). Hospitalisation was the most common type of SAE. There were
no differences between the treatment groups for any SAEs.
Specifically, of all the 106 procedures using a mesh implant, one concomitant continence mesh exposure/
extrusion was identified and required surgical treatment in the first 12 months after surgery.
TABLE 31 Participant recovery and satisfaction
Recovery and satisfaction
Treatment group, n (%); N
Effect sizea (95% CI); p-valueAbdominal vault Vaginal vault
Prolapse is better now compared with 1 year ago 77 (92.8); 83 75 (86.2); 87 1.97 (0.69 to 5.60); 0.20
Completely or fairly satisfied 72 (87.8); 82 71 (82.6); 86 1.56 (0.63 to 3.86); 0.33
Recommend to a friend 69 (86.3); 80 73 (88.0); 83 0.84 (0.32 to 2.18); 0.72
a Effect sizes presented represent ORs (abdominal vs. vaginal), adjusted for baseline when available and minimisation
variables.
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Non-serious and related adverse events in the first 12 months after surgery
Non-serious AEs/complications were also reported (Table 34). Overall, four were identified within
the 12-month follow-up period. There were no differences between the treatment groups in any
non-serious AEs.
Subgroup analysis
There were no differences in any of the planned subgroup analyses [aged < 60 years and ≥ 60 years,
previous anterior or posterior surgery, or previous incontinence surgery (see Appendix 6, Table 79)].
Sensitivity analyses
A multiple imputation model was used to impute missing values in the primary outcome, POP-SS, assuming
a missing-at-random mechanism. No evidence of a difference between the two treatment groups after the
imputation was found (abdominal vs. vaginal: MD –0.32, 95% CI –1.71 to 1.06; p = 0.65).
TABLE 32 Further treatment required at 12 months after surgery
Further treatment
Treatment group
Effect sizea (95% CI); p-valueAbdominal vault Vaginal vault
Further surgery, n (%); N 8 (7.8); 102 7 (7.0); 100 1.08 (0.37 to 3.12); 0.892a
Further prolapse surgery, n (%); N 5 (4.9); 102 6 (6.0); 100 0.79 (0.23 to 2.68); 0.702a
Anterior 3 (2.9); 102 2 (2.0); 100 1.45 (0.24 to 8.89); 0.687a
Posterior 3 (2.9); 102 0 (0); 100
Apical 1 (1.0); 102 4 (4.0); 100 0.23 (0.02 to 2.11); 0.192a
Continence surgery, n (%); N 3 (2.9); 102 1 (1.0); 100
Time to further surgery (days), mean (SD); Nb 337.7 (206.3); 7 310.0 (190.8); 7 0.94 (0.31 to 2.87); 0.921c
Need for conservative treatment, n (%); N
Any conservative treatment 29 (27.9); 104 33 (31.7); 104 0.83 (0.46 to 1.51); 0.54a
Absorbent pads 24 (31.2); 77 28 (34.6); 81
Physiotherapy 8 (13.3); 60 9 (18.0); 50
Disposable or reusable catheter 3 (4.1); 74 4 (6.0); 67
Had a ring pessary 3 (4.0); 75 3 (4.4); 68
Had a shelf or Gellhorn pessary 0 (0.0); 73 3 (4.4); 69
Permanent catheter 0 (0.0); 71 2 (3.1); 64
Seen health professional, n (%); N
GOPD 27 (37.0); 73 39 (54.2); 72
GP for prolapse 21 (29.2); 72 26 (37.7); 69
Practice nurse 8 (14.3); 56 4 (8.0); 50
District or continence nurse 2 (3.5); 57 5 (10.0); 50
a Effect sizes presented represent ORs (abdominal vs. vaginal), adjusted for minimisation variables.
b See also Appendix 6, Table 78 for median values.
c Effect size is a hazard ratio adjusted for minimisation variables and fitting surgeon as a random effect.
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TABLE 34 Non-serious and other related AEs in first 12 months after surgery
Non-serious and other related AEs
Treatment group), n (%)
Effect sizea (95% CI); p-value
Abdominal vault
(N= 102)
Vaginal vault
(N= 100)
Any complications 1 (1.0) 2 (2.0) 0.49 (0.04 to 5.44); 0.56
Postoperative complications
Haematoma 1 (1.0) 0 (0)
Treatment for postoperative infection with
antibiotics
0 (0) 2 (2.0)
Other adverse postoperative events 0 (0) 1 (1.0)
a Effect size presented represents ORs (abdominal vs. vaginal), adjusted for minimisation variables.
TABLE 33 Serious and related AEs in the first 12 months after surgery
Serious and related AEs
Treatment group), n (%)
Effect sizea (95% CI); p-value
Abdominal vault
(N= 102)
Vaginal vault
(N= 100)
Any SAE 6 (5.9) 6 (6.0) 0.97 (0.27 to 3.44); 0.96
Type of SAE
Hospitalisation 3 (2.9) 4 (4.0)
Prolongation of hospitalisation 3 (2.9) 1 (1.0)
Considered medically significant by the
investigator
1 (1.0) 2 (2.0)
Intraoperative occurrences
Injury to organs (bladder or bowel) 3 (2.9) 1 (1.0)
Postoperative occurrences
Constipation 2 (2.0) 1 (1.0)
Urinary retention/voiding difficulties requiring
conservative intervention
1 (1.0) 1 (1.0)
Urinary tract infection 1 (1.0) 0 (0)
Pain 1 (1.0) 0 (0)
Catheterisation required for > 10 days post
operation
0 (0) 1 (1.0)
Vaginal adhesions 0 (0) 1 (1.0)
Perineal scarring/tightness requiring surgery 0 (0) 1 (1.0)
Granulation tissue 0 (0) 1 (1.0)
Mesh exposure/extrusion that requires surgical
treatment
0 (0) 1 (1.0)b
a Effect size presented represents ORs (abdominal vs. vaginal), adjusted for minimisation variables.
b Mesh exposure from concomitant continence tension-free vaginal tape surgery at time of the VUE surgery.
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Per-protocol analysis
A per-protocol analysis for the primary outcome, POP-SS, including only the participants that followed
protocol (received the allocated treatment) found no evidence of a difference between treatment groups
(abdominal vs. vaginal: MD –0.99, 95% CI –2.59 to 0.60; p = 0.22).
Discussion
Summary of findings
Surgical planning and procedure
In addition to their apical surgery, concomitant surgery was planned for the majority (70.2%) of women in
the Vault trial. The randomised surgical allocation was performed in most of the participants (81.8% in the
abdominal group and 86.5% in the vaginal group). In those women who did not obtain their allocated
surgery, 7.7% were found to have no apical prolapse following an anterior or posterior procedure.
Women in the vaginal group were more likely to receive a concomitant anterior and/or posterior repair
(76.0%) than those women in the abdominal group (34.7%).
Most procedures were performed by a consultant gynaecologist under general anaesthesia with prophylactic
antibiotics (91.8%). The duration of the abdominal procedure was significantly longer (mean duration
146 minutes, SD 54 minutes) than the vaginal procedure (82 minutes, SD 34 minutes; MD 60.48 minutes,
95% CI 49.80 to 71.16 minutes). There was no difference in the level of blood loss or postoperative hospital
stay between the treatment groups.
Primary and secondary outcomes
Around 85.5% of women responded to the 12-month questionnaire, with slightly more women attending
for the 12-month clinic assessment.
The primary outcome was POP-SS at 12 months after randomisation, and there was no difference between
an abdominal and a vaginal procedure. The MD in the POP-SS for the abdominal group was 5.6 (SD 5.4)
compared with a MD of 5.9 (SD 5.4) in the vaginal group. Adjusted for baseline variables, the MD was
–0.61 (95% CI –2.08 to 0.86) and suggests that both procedures are equally clinically effective in
improving vault prolapse symptoms at 12 months.
At 12 months after randomisation, prolapse-related effects on QoL scores had improved and were apparent
at 6 months after operation. The most bothersome symptom at baseline, ‘a feeling of something coming
down’, reduced from 47.2% overall at baseline to 10% in the abdominal group and 34% in the vaginal
group. Incomplete emptying of the bladder or bowel were the most bothersome at both 6 and 12 months
for both randomised groups of women, but did not affect ‘actions necessitated by prolapse symptoms’,
which were reduced from baseline.
Overall, objective prolapse scores (i.e. POP-Q) improved for both randomised groups, particularly in terms
of prolapse protrusion beyond the hymen (stage 2b or more: 32.6% after an abdominal vs. 46.9% after
a vaginal procedure; this was not statistically significant). Objective vault prolapse (stage 2b or more) fell
to 6.0% in the abdominal group and 9.0% in the vaginal group 12 months after surgery (adjusted for
baseline values). Again, this was not statistically significant.
More women were sexually active after surgery. There were no statistically significant differences in vaginal
and sexual symptoms between either of the randomised groups of women at 12 months.
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Overall, at 12 months after randomisation, the proportion of women who had any urinary incontinence
increased from around one in six women to one in three in the abdominal and one in four in the vaginal
group; severe urinary incontinence remained the same as baseline. In addition, de novo urinary incontinence
following surgery was found in one in four women in the abdominal group and one in five in the vaginal
group. Few women had continence surgery to alleviate their symptoms within the first 12 months (n = 4).
There was no evidence of a difference in any urinary symptom outcomes between the randomised groups
of women.
There were no other significant differences in bowel symptoms between the randomised groups of women.
There were no differences between the randomised groups of women in terms of satisfaction with
treatment at 12 months after randomisation. Most women reported that they were better than before
surgery (92.8% vs. 86.2%). The majority of women were completely or fairly satisfied (87.8% vs. 82.6%)
and would recommend the surgery to a friend (87.2%).
Overall, 15 women were re-admitted for further surgery in the first 12 months after surgery (see Table 32).
Eleven women had further prolapse surgery within 12 months [abdominal preservation (n = 5) vs. vaginal
(n = 6)], and this was not statistically significant. One woman in the abdominal group had a further apical
procedure compared with four women in the vaginal group in that time (again, this was not statistically
significant). There was no difference in re-admission rates for anterior repair between both groups. Three
women in the abdominal group had a re-admission for a posterior repair.
Overall, 12 SAEs (5.8%) were reported in the first 12 months following surgery and there were no
differences between the groups in any serious adverse effects. Specifically, of all the 106 procedures using
a mesh implant one mesh exposure/extrusion from a concomitant continence procedure was identified
requiring surgical treatment in the first 12 months after surgery relating to a risk ratio (RR) of around 1%
for mesh exposure.
Conclusion
Both abdominal and vaginal surgeries are equally clinically effective in relieving symptoms of vault prolapse
in the short term. There is no statistically significant difference for the apical measurements. The objective
descent measured by POP-Q is significantly different in relation to the anterior wall prolapse 12 months
after surgery (though the numbers were small). This, however, did not affect re-admissions for anterior
wall prolapse in the first 12 months. The presence of urinary incontinence may worsen after either
procedure, but severe incontinence appears to remain static.
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Chapter 8 Vault trial cost-effectiveness analysis
Overview
This chapter presents the results of the within-trial cost–utility analysis for women in the Vault trial.
A single table of all results is presented (Table 35), with separate sections for summary data on costs,
QALYs and cost-effectiveness (including deterministic sensitivity analysis results). Further details of the
cost-effectiveness data are provided in Appendix 7, Tables 80–84.
NHS perspective resource use and costs
Intervention costs
Intervention costs are calculated for all women entering theatre for an operative procedure (regardless
of whether or not they received surgery). The overall intervention cost was £582 more expensive in the
abdominal group compared with the vaginal group (95% CI £472 to £692) using the component costing
approach. The significant additional procedure cost is predominantly driven by a longer time in surgery,
but also by the additional use of apical mesh for 80% of women in the abdominal group, compared with
6% in the vaginal group. All other resource use (e.g. length of stay, use of drugs in surgery) were similar
across groups. A complete list of items used for the component-based costing of each intervention is
reported in Appendix 7, Table 80.
Follow-up care costs
There is no evidence of any differences across the groups in terms of re-admission to hospital for further
prolapse procedures, incontinence procedures or for the treatment of SAEs. The average total cost of
hospitalisation (excluding the index procedure admission) is £241 in the abdominal group and £287
in the vaginal group (MD –£19.69, 95% CI –£252 to £212). Consultations with health professionals
(e.g. outpatient doctors, GPs, community-based nurses, physiotherapy) are similar across the groups, as is
the cost of medications and devices (e.g. oestrogens, pessaries, antibiotics). Full details of all resource use
over follow-up for hospitalisations, contact with health professionals and use of medications/devices are
reported in Appendix 7, Tables 81–84.
Total NHS costs
Overall, total costs were calculated for 74 out of 104 (71%) and 81 out of 104 (78%) women in the
abdominal and vaginal groups, respectively. Missing data are due primarily to participant non-return of
questionnaires. Based on the complete-case costs available, the abdominal group cost £1999 and the
vaginal group cost £1370. The abdominal approach was significantly more expensive overall, with a MD of
£672 (95% CI £372 to £973) per patient, representing a substantial additional cost to the NHS, compared
with the vaginal group over the short 12-month time horizon considered.
Patient participant perspective resource use and costs
Women with prolapse symptoms have a high rate of contact with health professionals, including a large
number of consultations in both primary and secondary care. The costs to women of time spent attending
appointments is substantial, with costs per women of £252 in the abdominal group compared with £201
in the vaginal group.
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TABLE 35 Costs, QALYs and cost-effectiveness for the Vault trial
Costs, QALYs and
cost-effectiveness
Treatment
Abdominal vault vs. vaginal vaultAbdominal vault (N= 104) Vaginal vault (N= 104)
Mean SD na Mean SD na MD 95% CI
Costsb,c
Intervention £1541.55 £500.02 102 £935.22 £351.74 100 £582.31 £472.32 to £692.30
Hospital resource use £241.14 £777.74 103 £286.89 £932.08 97 –£19.69 –£251.73 to £212.35
Other consultations £116.69 £183.22 81 £141.54 £154.69 84 –£43.21 –£94.87 to £8.44
Other treatments £56.46 £190.41 76 £27.86 £109.60 84 £61.19 –£8.25 to £130.63
Total NHS costs £1999.05 £1056.23 74 £1369.86 £993.39 81 £672.36 £372.21 to £972.51
QALYsc,d
Baseline EQ-5D 0.735 0.192 95 0.760 0.184 97
6 months EQ-5D 0.835 0.206 79 0.828 0.176 90
12 months EQ-5D 0.833 0.210 81 0.832 0.157 85
Total QALYs 0.824 0.143 67 0.825 0.109 78 –0.009 –0.049 to 0.032
Cost-effectiveness
N ΔC (95% CI) ΔE (95% CI) ICERe
Probability that abdominal vault is cost-effective compared with
vaginal vault at different WTP for 1 QALY gained (%)
P(C/E)
at £0
P(C/E) at
£10,000
P(C/E) at
£20,000
P(C/E) at
£30,000
P(C/E) at
£50,000
Imputed data set (base case)f 208 £570 (£459 to £682) 0.004 (–0.031 to 0.041) £142,500 0 1 6 17 29
Imputed data set (SUR) 208 £552 (£262 to £843) 0.004 (–0.030 to 0.039) £138,000 0 1 8 18 31
Wider-perspective costing
analysis
208 £498 (–£262 to £1259) 0.004 (–0.031 to 0.041) £124,500 6 8 14 21 32
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Costs, QALYs and
cost-effectiveness
Treatment
Abdominal vault vs. vaginal vaultAbdominal vault (N= 104) Vaginal vault (N= 104)
Mean SD na Mean SD na MD 95% CI
Use of HRG tariffs for
intervention procedure
g
202 £1212 (£916 to £1508) 0.004 (–0.031 to 0.041) £303,000 0 0 0 2 11
Assumptions regarding QALY
calculation (1)
195 £570 (£459 to £682) 0.002 (–0.035 to +0.039) £285,000 0 1 5 11 19
Assumptions regarding QALY
calculation (2)
176 £570 (£459 to £682) 0.006 (–0.030 to 0.042) £95,000 0 1 4 10 19
Assumptions regarding QALY
calculation (3)
142 £570 (£459 to £682) –0.004 (–0.055 to 0.048) Dominated 0 4 14 23 29
Complete-case analysish 129 £695 (£403 to £987) –0.025 (–0.060 to 0.010) Dominated 0 2 16 33 50
Complete-case analysis, SUR 129 £693 (£324 to £1064) –0.015 (–0.050 to 0.020) Dominated 0 2 17 34 51
SUR, seemingly unrelated regression.
a The n reported refers to the number of women for whom it was possible to generate time point-specific EQ-5D and category costs. Further details on assumptions regarding non-response
are provided in Chapter 2.
b Represents complete-case data for costs.
c All models for the Vault trial are adjusted for minimisation co-variates, baseline EQ-5D score and previous vault repair.
d Represents complete-case data for QALYs.
e The ICER was calculated using incremental costs to the nearest whole pound and incremental QALYs rounded to three decimal places.
f Imputed data set, QALYs estimated using Poison regression model with a power link function of 0.75; costs estimated using gamma family, log–link using GLMs.
g HRG codes applied to vault procedures are reported in Table 1.
h Complete-case cost and QALY pairs.
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The number of women reporting that they had to take time off from work, as a proportion of the trial
population, was small. In total, 38 women, 19 per group, representing 18% of trial participants reported
needing to take sick leave. The low proportion requiring sick leave is likely to be because of the proportion
in paid employment (c. 25%) and the average age of the trial participants having passed the standard
retirement age. Among those women needing to take sick leave, the average number of days off work
was 24, with no differences across the groups.
The costings include a few women who incurred a small amount of cost for over-the-counter medications
and other related expenses. No women in the Vault trial report any use of private health-care services for
prolapse-related symptoms. Full details of all costs incurred by women, collected through the study are
reported in Appendix 7, Table 84.
The total average costs to women over the trial follow-up period is substantial, but there were no
differences across the groups (MD –£53, 95% CI –£400 to £294). High SDs contribute to wide CIs and
indicate that there is substantial variability in the experience of personal costs, with some women
experiencing substantially greater financial burden than others.
When summing participant and NHS perspective costs together to inform a wider-perspective analysis of
prolapse costs, the abdominal group remains significantly more costly with a MD of £825 (95% CI £208
to £1443).
Generic quality-of-life outcomes
The proportion of women reporting any health problems on each EQ-5D-3L domain (i.e. a score of two or
three) at baseline, at 6 months and at 12 months is presented in Figure 11. Missing data are not reported on
the graphs. At baseline, a substantial proportion of women in both groups report problems related to pain
and discomfort. This would be expected given the need for surgery. Those reporting any pain or discomfort
reduces to about half of all women in both groups at 6 months, with similar proportions reporting pain/
discomfort at 12 months. The proportion of women reporting problems with self-care was low.
Full details of the utility scores resulting from these EQ-5D-3L responses at each time point and calculated
QALYs can be found in Table 35. In terms of covariates included within the analysis model, baseline utility
was the only significant predictor of overall QALYs, re-enforcing the importance of adjusting for this
baseline measure.
Complete data were available across EQ-5D domains and time points (baseline, and 6 months and 12 months),
enabling QALY calculation for 67 out of 104 (64%) and 78 out of 104 (75%) women randomised to the
abdominal and vaginal vault groups, respectively. Based on the complete-case data, there are no statistically
significant differences in QALYs between treatment groups, with the abdominal and vaginal vault groups
obtaining an average of 0.824 and 0.825 QALYs per person over 12 months, respectively (MD –0.009, 95% CI
–0.049 to +0.032). Multiple imputation of missing data indicates a similar lack of difference across the groups
(MD 0.002, 95% CI –0.036 to 0.039).
Cost-effectiveness results
Complete-case costs and complete-case QALY data are presented, making best use of all available data (see
Table 35). The base-case analysis uses multiple imputation of missing data. Imputation of missing data was
chosen because (1) only 129 out of 208 (62%) participants had fully complete profiles of costs and QALYs
to enable calculation of the ICER, and (2) missing data for QALYs were imbalanced across the randomised
groups. A range of deterministic sensitivity analyses are also reported. All analyses of cost-effectiveness also
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indicate the probability that abdominal vault repair is a cost-effective use of NHS resources at five alternative
threshold values of WTP for 1 QALY gained (i.e. £0, £20,000, £30,000, £50,000 and £100,000).
Base-case analysis
The multiple imputed data show significant additional costs for the abdominal group (MD £570, 95% CI
£459 to £682) for no significant QALY gain (MD 0.004, 95% CI –0.030 to 0.040). The base-case cost to
the NHS of obtaining one additional QALY is therefore £285,000 per QALY.
The scatterplots (Figure 12) of all bootstrapped replications further illustrates the sampling uncertainty
accrued from the bootstrapped replications of the analysis models. There is little uncertainty regarding the
additional cost of the abdominal procedure when using the base-case component costing approach with
almost all of the increments from the bootstrap lying above the horizontal line. However, regarding QALYs,
the scatterplot indicates substantial uncertainty, with no clear evidence of one strategy being preferable.
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FIGURE 11 Percentage of respondents reporting any problems on each EQ-5D domain (baseline, 6 months after
surgery and 12 months after randomisation).
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The CEAC in Figure 13 shows that at 12 months after randomisation, based on the NMB, there is a high
probability that vaginal repair is the most cost-effective treatment option, with little evidence to support
the cost-effectiveness of abdominal repair. The probability of abdominal repair being considered to be
cost-effective is < 17%, up to a threshold value of WTP for 1 QALY gained of £30,000, increasing to a
29% probability of cost-effectiveness if the threshold was £50,000 per QALY.
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FIGURE 13 Vault trial: CEAC (imputed data set).
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FIGURE 12 Vault trial: scatterplot of the cost-effectiveness plane (imputed data set).
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Deterministic sensitivity analyses
Deterministic sensitivity analyses are conducted to address areas of uncertainty in assumptions, data
collection and analysis-modelling approaches. All deterministic analyses are based on the imputed data
set unless otherwise stated (e.g. complete-case analysis). The rationale behind each of the analyses is
described in Chapter 2 and a number of observations were made on the results. Results of all deterministic
sensitivity analyses are reported in Table 35 and a full set of CEACs and scatterplots for each analysis can
be found in Appendix 7, Figures 33–40.
First, based on an analysis of complete cost and QALY pair data, at the 12-month follow-up, abdominal
vault repair remains significantly more costly and generates non-significantly fewer QALYs and is thus
dominated by vaginal vault repair. Although the additional costs of abdominal vault repair are marginally
greater for the complete-case analysis, the additional costs are surrounded by more uncertainty, with wider
CIs. Probabilities of cost-effectiveness are therefore slightly higher in the complete-case group, which may
initially appear counterintuitive. However, this is because of greater uncertainty around the effect size
on costs in the complete-case group, with a higher proportion of simulations falling to the right of the
threshold line (see Appendix 7). The important point remains that complete-case data show no evidence of
changing the overall findings of the analysis.
Second, it was shown that the findings are robust to the analysis models incorporated. The use of
seemingly unrelated regression as an alternative approach to account for the correlation in costs and
QALYs (abdominal, –0.202; vaginal, –0.066; trial, –0.146) does not change the overall findings.
Third, the estimates of incremental costs in the Vault trial are sensitive to the approach taken to intervention
costing. Using HRG reference costs for intervention procedures increases the MD (abdominal vs. vaginal)
to £1212 (95% CI £916 to £1508) and increases the ICER to > £300,000 per QALY. This analysis further
reduces the probability that abdominal vault repair might be considered cost-effective compared with
vaginal vault repair. Arguments can be made for the use of either approach. Component costing is chosen
as the base case because it is grounded in the economic concepts of resource scarcity and opportunity cost.
It therefore more accurately reflects the resources displaced for each surgery, and explicitly accounts for
differences in operation times, length of stay and materials costs (e.g. mesh and devices) between the
groups observed in the trial. Importantly, the approach to intervention costing does not change the overall
cost-effectiveness conclusions from the Vault trial.
Fourth, because of differences in time points for questionnaire triggers (i.e. at 6 months after surgery and at
12 months after randomisation), and the potential for comparatively long periods of time to elapse between
randomisation and surgery, it is possible that respondents get their 12-month questionnaire before their
6-month questionnaire. The sensitivity analyses show that estimates of cost-effectiveness are not sensitive
to any of the following assumptions in sensitivity analysis:
1. an analysis dropping the 6-month EQ-5D data if the 6-month questionnaire is returned on or after the
12-month date
2. an analysis dropping any 6-month EQ-5D data within 3 months of the 12-month data
3. an analysis using the exact date of questionnaire report as the measure of time used in the calculation
of QALYs.
However, a note of caution on the last analysis is that some women will have QALYs greater than one
over a single year, as some questionnaires were returned well after 12 months (i.e. maximum = 1.80 years).
Fifth, the incorporation of a wider-perspective costing analysis, including both NHS and participant-incurred
and -reported costs, does not alter the estimates of cost-effectiveness or the probability of cost-effectiveness
at alternative threshold values of WTP for 1 QALY gained.
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Discussion
The findings from the Vault trial indicate that there is a low probability that abdominal vault repair is a
cost-effective use of resources when compared with vaginal vault repair. However, it should be noted that
the findings of the trial-based economic evaluation only partially address the question of cost-effectiveness.
To fully understand the cost-effectiveness of an intervention, it is important to capture the longer-term
costs and effects of a surgical intervention. For example, it may not be until many years into the future
when the true impact of failure rates and complications may be realised, and any cross-group differences
observed. Therefore, it is planned to have long-term follow-up of women randomised in the Vault trial to
better understand the long-term costs and outcomes of surgery. The Vault trial provides a rich source of
data to populate the long-term economic model of the most cost-effective treatment pathway combining
the findings of the Uterine and Vault trials into one single model of the treatment pathway. The analysis
will be updated as more mature data become available.
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Chapter 9 Lifetime economic evaluation
Introduction and objective
Chapters 5 and 8 report the results of the within-trial economic evaluations for both the Uterine trial and the
Vault trial over a 12-month time horizon. The data provide useful indications of short-term cost-effectiveness.
Apical prolapse, however, is a chronic condition and the clinical effects of alternative surgical treatments may
persist into the future or emerge over the longer term, well beyond the 12-month follow-up period of the
VUE trial. Recent NICE guidance acknowledges that there is no conclusive evidence about the long-term
clinical effectiveness or cost-effectiveness of different surgical treatments;20,21 hence, little is known about the
most efficient treatment pathway. The VUE trial seeks to address this gap in the evidence base. Longer-term
follow-up of women randomised to the VUE trial is ongoing. However, clinical decision-makers need best
estimates of the long-term cost-effectiveness data to inform treatment decisions now. The objective of this
chapter is to use a decision-analytic model to extrapolate the Uterine trial results over a lifetime horizon to
determine the cost-effectiveness of uterine preservation versus vaginal hysterectomy for treating apical
prolapse from a NHS perspective.
Markov structure and model description
A probabilistic Markov cohort model was developed using TreeAge Pro™ 2016 software (TreeAge Pro 2016,
R1.0.; TreeAge Software, Inc., Williamstown, MA, USA) to represent the treatment pathway for women with
apical prolapse. The model is structured to mimic progression through the pathway of care. A cohort of
1000 women, with an average age of 63 years (trial baseline population), suffering from symptomatic
prolapse requiring surgical intervention enter the model at a treatment decision point (uterine preservation
vs. vaginal hysterectomy). The women then follow a treatment pathway, based on risk of requiring further
surgery. A maximum of four (vaginal hysterectomy followed by a maximum of three repeat procedures) or
five (uterine preservation followed by a maximum of four repeat procedures, including vaginal hysterectomy)
surgeries are modelled depending on the starting arm. Figure 14 describes the model structure for the
uterine preservation arm.
The sequence of surgeries and transitions allowed in the model were developed in discussion with clinicians
and trial collaborators. The model allows the cohort to have further surgery for prolapse in the following
sequence: (1) uterine preservation, (2) vaginal hysterectomy, (3) vaginal vault, (4) abdominal vault and
(5) repeat abdominal vault or other surgical procedure. The treatment pathway described in Figure 14 is
identical for both model arms, the only difference being the number of potential surgical procedures.
After each surgical procedure, the cohort can enter into one of four mutually exclusive states:
1. Well after surgery – this reflects the proportion of the cohort in any given cycle who do not experience
failures or complications requiring surgery, or die naturally. They may, however, still experience some
prolapse-related symptoms or other complications (that do not require hospitalisation). Minor treatment
costs may be incurred, such as physiotherapy, oestrogens, etc. Once entering this state, the cohort
remains there over successive model cycles until they experience failure, complication or die.
2. Complications – the cohort may enter the complications state at any point in the model following
surgery, reflecting on the fact that women may experience complication risks over both the short and
the longer term following prolapse surgery. Complications have been classified in accordance with the
trial reporting of SAEs. The complications state reflects major complications that require hospitalisation.
The duration of the complications state is 6-month cycles, reflecting the average time required to
recover from complications. The model allows the cohort to have multiple complications at any time
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following a surgical procedure. As the cohort progresses through successive surgeries for failures,
each complication state relates to the most recent surgical procedure. For example, it is assumed that
‘complications following vaginal vault’ relate to the vaginal vault procedure, and not the index decision
of uterine preservation versus vaginal hysterectomy.
3. Further surgery for failures – failure requiring a repeat surgical intervention triggers progression of the
cohort along the sequence of surgeries described in Figure 14. A failure requiring surgical repair is
considered to be any repeat prolapse surgery, whether it occurs in the same or a different
compartment.
4. Long-term containment – the proportion of the cohort having progressed through all surgical options
described and still experiencing symptoms indicative of treatment failure are assumed to be managed
conservatively, and so do not receive further surgical intervention. Conservative management includes
the use of pessaries, physiotherapy and regular outpatient consultation.
5. Long-term well – this state reflects the proportion of the cohort who have progressed through the full
sequence of prolapse surgeries and are no longer experiencing symptoms indicative of a failure of the
final procedure. In the absence of any data to confirm the proportion progressing from the final surgery
state to either long-term containment or long-term well, clinical expert opinion is relied on (Dr Christine
Hemming, University of Aberdeen, 2017, personal communication), assuming that approximately
75% of the cohort would have no further problematic symptoms over a 10-year period, with 25%
continuing to be managed conservatively.
6. Dead – the modelled cohort may die at any point in the model, following female-specific general
population all-cause mortality rates.62 No additional surgical mortality rate is included because no
women died during the surgical procedures in the VUE trial.
The cohort of 1000 women progress through the model health states in monthly Markov cycles following
the sequence of surgical treatments and health-state transitions described above. A monthly cycle length
has been chosen to reflect the time increments for which data regarding time of treatment failure and
complications requiring surgery were available. Tunnel states were used to ensure that the proportion of
the cohort in each surgery and complication state remain there for 6 monthly cycles to allow for sufficient
time to recover from treatment, and experience a longer time period of lower utility (QoL). The model time
horizon is 30 years’ duration (equivalent to 360 monthly cycles) in the base case, this is deemed sufficient
to capture the important life-time costs and consequences of an average 63-year-old woman entering the
model. Costs and QALYs occurring beyond the first year of the model are discounted at a rate of 3.5% per
annum in line with current NICE guidelines.63 All costs are reported in 2015–16 GBP and the analysis is
conducted from the perspective of the UK NHS.
Model parameterisation: health-state transition probabilities
Survival analysis is used to estimate transition probabilities to further surgery and complication states using
time-to-failure events observed in both the Uterine and the Vault trials. For example, failure and complications
following uterine preservation are derived from the corresponding arm of the Uterine trial data. Similarly,
transition probabilities following vaginal and abdominal vault procedures are derived from the corresponding
arms of the Vault trial. As noted in the Introduction and objective, long-term follow-up is ongoing. Two-year
follow-up data on complications and failures were available for 208 out of 562 (37%) participants randomised
to the Uterine trial and 140 out of 208 (67%) participants randomised to the Vault trial. The available 2-year
data supplement the existing 1-year follow-up data to generate a richer data set. The methods used to
extrapolate data from both trials are similar.
Treatment failures
Event dates were available by month and so are congruent with the cycle length applied in the model.
Kaplan–Meier curves illustrating the time-to-failure (requiring surgery) event data for the four surgical
procedures are presented in Figure 15.
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Progression-to-treatment failure states (i.e. further prolapse surgery) in the model is based on time-dependent
transition probabilities derived from a set of Weibull regression analyses of time-to-event data from the
respective trials. The results of the survival model for time-to-repeat surgery event, with a Weibull distribution
specified, indicate a hazard ratio of 1.610 (95% CI 0.824 to 3.146) for uterine preservation compared with
vaginal hysterectomy. Treatment effects are not statistically significant, but the point estimate of the hazard
ratio points towards treatment effects favouring vaginal hysterectomy, albeit it with substantial uncertainty.
For the Vault trial, there is greater uncertainty driven by the smaller sample size. The hazard ratio for
abdominal vault failure versus vaginal vault failure is 0.826 (95% CI 0.312 to 2.182).
A systematic approach was taken to choosing appropriate distributions for the survival analyses, in line
with best practice recommendations guidance.64,65 A range of possible survival models to fit the data was
considered. Gamma, log-normal, log–logistic, exponential, Gompertz and Weibull models, as well as Cox
regression models, were all considered. The Weibull model was chosen based on (1) consideration of the
Akaike’s information criterion (AIC) score, with lower values indicating a preferred model fit; (2) overlaying
the estimated survival curves on top of the Kaplan–Meier data; and (3) consideration of the clinical plausibility
of the long-term failure probabilities. All models were estimated using Stata 14 software, using the ‘streg’
command. Cox regression models were not considered further as the proportional hazards assumption was
rejected in all cases for the failure models. For both the Uterine trial and the Vault trial failure models, all
parametric survival models indicated similar AIC scores. After considering the clinical plausibility of the
long-run projections, it was determined that the Weibull function gives the best estimate at the tail of the
curve. Output from the different survival regression models were considered (both unadjusted and adjusted
for minimisation covariates and baseline EQ-5D) and extrapolated survival curves for different models are
reported in detail in Appendix 8, Figures 41–4. The unadjusted regression analyses have been used to
parameterise the decision model.
The survival function (S(t)), representing the probability of a success (i.e. not having a prolapse failure
requiring surgery) at time t (months), is given in Equation 2:
S(t) = exp (–λtγ). (2)
Transition probabilities to failure states in the model are calculated for each monthly cycle according to
Equation 3:
tp = 1–f(exp (–λtγ)/exp(–λ(t –1)γ)g. (3)
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FIGURE 15 Kaplan–Meier curves for failure event
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When λ is the constant parameter from the regression model, this is the scale parameter that shows the
probability that a woman’s prolapse will recur in the next period given the fact that she was successful in
the current period; γ is the shape parameter describing the rate of change in the probability of further
surgery for prolapse failure over time. γ > 1 indicates that the rate increases over time. Conversely, γ < 1
indicates that the rate decreases over time.
Uncertainty surrounding the transition probabilities is incorporated into the model by using the Cholesky
decomposition of the covariance matrix retrieved from the output of the regression models. A multinormal
distribution was used to sample from the correlations between the regressions coefficients and multiplied
by the coefficient of the log of the hazard ratios, lambda and gamma parameters, thus assigning treatment
specific transition probabilities for failures. The process was repeated for both the Uterine and the Vault
trial data.
Complications
The process for incorporating complications into the model was identical to that described for failures
requiring further surgery. For the purposes of the transition probabilities, complications are defined here as
any complication that required admission to hospital. Transitions to complications states were based on
time since the most recent surgical procedure. For the Uterine trial, the adjusted hazard ratio for uterine
preservation versus vaginal hysterectomy was 1.126 (95% CI 0.478 to 2.651); the unadjusted hazard ratio
was 1.077 (95% CI 0.453 to 2.552). For the Vault trial, the hazard ratios for abdominal versus vaginal were
– 0.689 for adjusted (95% CI 0.154 to 3.078) and – 0.885 for unadjusted (95% CI 0.342 to 2.294). Overall,
there were no significant differences between any of the treatments in terms of complications requiring
hospitalisation. CIs were wide, in part due to the relatively low number of complications in both trials.
Figure 16 presents the Kaplan–Meier curves for complications using all available 2-year follow-up data.
As can be seen from the Kaplan–Meier curves and the estimated hazard ratios, there is no evidence to
suggest any differences in time-to-complication events across the groups based on currently available data.
As with the analysis of time to failure, the time-to-complication event is based on Weibull regression models.
A similar process for selecting the models was used. Details of the full set of models considered are available
in Appendix 8, Tables 85–8. Uncertainty surrounding transition probabilities was again incorporated into the
model by fitting multinormal distributions to the correlations between the relevant coefficients, obtained
from the Cholesky decomposition matrix of the regression model.
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FIGURE 16 Kaplan–Meier curves for time to complication requiring hospitalisation.
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Mortality parameters
When women move through the model, the chance that they might die is based on the annual rates of
age-specific all-cause mortality for women (Office for National Statistics interim life tables).62 As there were
no intraoperative deaths reported during the trial, surgical mortality was not included in the model.
Model parameterisation: resource use and costs
Intervention delivery costs are based on the component costing approach used for the trial-based
cost-effectiveness analysis. Sensitivity analysis considers the use of HRGs in the model given the sensitivity
of findings in the trial analyses to the choice of intervention costing approach. Costs for the remaining
health states (failures, complications and well) are obtained from the trial data. Definitions of failures and
complications are as described in Complications for obtaining time-dependent state-transition probabilities.
Women who were not categorised as having complications or failures were categorised as being in the
‘well’ health state. This does not mean that these women were asymptomatic, and so the costs of the ‘well’
state implicitly assumes a proportion of the cohort have costs of consultations with health professionals
and treatments based on the data reported in the trials. To avoid double costing, all regression analyses
were based on total costs over follow-up, less the initial intervention costs. GLM regression models with
robust standard errors (SEs) were then used to determine the impact of health-state membership on costs.
Health-state dummy variables were interacted with the randomised treatment group to obtain treatment-
specific health-state costs. The marginal effects of the relevant coefficients and SEs (estimated using the
delta method) were used to populate the model. Sensitivity analysis considers the impact on results of
assuming that the health-state costs are not treatment specific, that is, calculating health-state costs based
on all trial women, regardless of randomised treatment group. Costs obtained from the trial data are
adjusted to reflect the monthly time cycle of the model. Exceptions to this include full costs applied for
complication and failure states at the point of entry to capture the full resource impact of high-cost surgical/
hospitalisation procedures.
All cost parameters are defined in the model as statistical distributions and are assumed to follow a
gamma distribution. Table 36 reports the mean, SE (SD of the sampling distribution) and the alpha and
beta parameters used to define the gamma distributions.
TABLE 36 Cost parameters used in the economic model
Variable Point estimate (£) Robust SEs (£)
Parameters
Alpha Beta
Uterine trial costs
Intervention: vaginal hysterectomy 1116 22 2511.24 0.44
Intervention: uterine preservation 1213 28 1830.69 0.66
HRG intervention: vaginal hysterectomya 3591 33 12,171.07 0.30
HRG intervention: uterine preservationa 3041 27 12,444.61 0.24
Vaginal hysterectomy: well 82 14 36.09 2.27
Uterine preservation: well 105 20 27.65 3.80
Uterine trial: wella 93 12 59.66 1.56
Vaginal hysterectomy: failure 2362 461 26.22 90.10
Uterine preservation: failure 3160 419 56.93 55.51
Uterine trial: failurea 2756 312 78.06 35.31
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Model parameterisation: utilities
The process of obtaining health-state utilities mirrors that described for the cost parameters. Health-state
membership was determined (failure, complication and well). The utility measure obtained closest to the
time-to-complication/time-to-failure event in the trial was used to reflect the utility of that state specific to
each woman in the trial. GLM regression models were used to obtain the effect of state membership on
utility and interactions between state. Treatment dummies were used to determine treatment-specific
health-state utilities for the base-case analysis. Sensitivity analysis explores the impact of using health-state
utilities that are not treatment specific. All utilities are adjusted for age and gender (female)-specific general
population norms in accordance with best practice guidance66 to allow the average utility of health states
to fall as the cohort ages. The utilities accrued in each health state are adjusted to reflect the monthly time
cycle of the model. All utility data are included in the model as statistical distributions. Uncertainty in utility
parameters is characterised and incorporated by sampling from beta distributions for the utility of each
modelled health state. Alpha and beta parameters are calculated using the method of the moments
approach and the parameters of the distribution are presented in Table 37.
Assessment of cost-effectiveness
The model analysis was conducted using second-order Monte Carlo (probabilistic or second-order) simulation,
with 1000 iterations. Each iteration resampled a value from each input parameter based on the defined
distributions. The model was therefore fully probabilistic, with 1000 expected values of costs and QALYs
generated for each treatment strategy from the sampling distributions. These cost and QALY values were
combined into a single measure of efficiency and reported as incremental costs per QALY gained, commonly
TABLE 36 Cost parameters used in the economic model (continued )
Variable Point estimate (£) Robust SEs (£)
Parameters
Alpha Beta
Vaginal hysterectomy: complication 1164 438 7.06 164.76
Uterine preservation: complication 587 160 13.46 43.62
Uterine trial: complicationa 879 235 13.98 62.90
Vault trial costs
Vaginal vault: well 187 54 12.02 15.55
Abdominal vault: well 125 35 12.83 9.74
Vault trial: wella 156 32 23.78 6.56
Vaginal vault: failure 2362 607 15.14 155.99
Abdominal vault: failure 2684 381 49.63 54.08
Vault trial: failurea 2525 357 50.02 50.47
Vaginal vault: complication 1065 385 7.65 139.18
Abdominal vault: complication 755 376 4.03 187.25
Vault trial: complicationa 908 269 11.38 79.81
Conservative management 167 20 66.88 2.50
Cost of death 0 N/A N/A N/A
N/A, not available.
a Indicates the value that is used in the sensitivity analysis. All cost parameters are included in the model as gamma
distributions, parameterised in TreeAge software as (GAMMA; alpha; 1/beta).
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referred to as the ICER. Interventions reporting an ICER of < £20,000–30,000 per QALY gained are generally
considered cost-effective. Interventions that generate cost savings and higher QALYs than a comparator are
the dominant treatment and offer an even stronger case for cost-effectiveness. Conversely, interventions that
cost more and generate fewer QALYs than a comparator are said to be dominated and are not considered a
cost-effective use of resources.
TABLE 37 Utility parameters used in the economic model
State HSUV SE
Parameters
Alpha Beta
Uterine trial
Utility vaginal hysterectomy: baseline 0.781 0.011 1103.198 309.348
Utility uterine preservation: baseline 0.739 0.014 726.494 256.583
Utility Uterine trial: baseline (SA) 0.760 0.009 1710.647 540.204
Utility vaginal hysterectomy: well 0.904 0.011 647.466 68.757
Utility uterine preservation: well 0.873 0.013 571.851 83.190
Utility Uterine trial: well (SA) 0.889 0.009 1082.144 135.116
Utility vaginal hysterectomy: failure 0.675 0.063 36.634 17.638
Utility uterine preservation: failure 0.728 0.044 73.733 27.548
Utility Uterine trial: failure (SA) 0.701 0.039 95.899 40.904
Utility vaginal hysterectomy: complication 0.674 0.064 35.482 17.162
Utility uterine preservation: complication 0.820 0.036 92.569 20.320
Utility Uterine trial: complication (SA) 0.746 0.037 102.508 34.902
Vault trial
Utility vaginal vault: well 0.835 0.019 317.841 62.807
Utility abdominal vault: well 0.846 0.024 190.509 34.679
Utility Vault trial: well (SA) 0.841 0.015 498.971 94.336
Utility vaginal vault: failure 0.795 0.033 118.181 30.474
Utility abdominal vault: failure 0.684 0.105 12.726 5.879
Utility Vault trial: failure (SA) 0.740 0.055 46.326 16.277
Utility vaginal vault: complication 0.751 0.064 33.535 11.119
Utility abdominal vault: complication 0.697 0.094 15.962 6.939
Utility Vault trial: complication (SA) 0.724 0.057 43.804 16.699
Other
Utility dead 0.000 N/A N/A N/A
Utility long term: containment 0.684 0.105 12.726 5.879
Utility long term: well 0.846 0.024 190.509 34.679
HSUV, health-state utility value; N/A, not applicable.
Note
SA indicates that the value is used in the sensitivity analysis.
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The simulation approach allows fully probabilistic ICERs to be obtained for both the base case and all
sensitivity analyses conducted. CEACs were generated by assessing the probabilistic NMB for each treatment
strategy. The CEACs allow for calculation of the probability that each strategy is cost-effective at alternative
threshold values of WTP for a QALY gained. Similarly, scatterplots of incremental costs and incremental
QALYs were obtained for uterine preservation versus vaginal hysterectomy and report the results on the
cost-effectiveness plane. Both CEACs and the scatterplots illustrate the uncertainty surrounding the optimal
treatment strategy caused by the combined statistical variability in the model’s parameter estimates.
Deterministic sensitivity analysis
Cost-effectiveness acceptability curves illustrate sampling uncertainty, but do not address underlying
uncertainty driven by choice of data, structural assumptions, methodological choices or heterogeneity
across subgroups of the modelled cohorts. A range of deterministic sensitivity analyses were explored to
address the main areas of uncertainty in the model and test the impact of important assumptions on the
cost-effectiveness conclusions. Model parameters for all deterministic sensitivity analyses are sampled from
the statistical distributions, ensuring that all presented ICERs are fully probabilistic. Sensitivity analyses were
conducted to:
1. Explore uncertainty surrounding the choice of model utilities and costs. The base-case analysis uses
treatment-specific utilities and costs for each health state in the model. These data are advantageous
in that they preserve the impact of treatment on the costs and QoL in any given health state. However,
for rare events, they are derived from trial data with small samples and mean values subject to rare but
extremely severe health events. Sensitivity analysis explores the impact of using utilities and costs that are
defined for each modelled health state, but not split according to randomised treatment in the VUE trial.
This increases the sample for estimating costs and utilities, but removes any assumption about treatment-
specific effects on these parameters for the model. The base-case analysis (treatment-specific utilities)
assumes that baseline utility for the cohort may be different across groups. This could potentially limit
generalisability to the wider population. Therefore, a further sensitivity analysis explores keeping
treatment-specific utilities for health states, but ensuring that the baseline utility for the cohort is the
same in both uterine preservation and vaginal hysterectomy (i.e. 0.760).
2. Determine the impact of intervention costing approach on cost-effectiveness. The trial-based analyses
showed that estimates of cost-effectiveness for uterine preservation versus vaginal hysterectomy were
highly sensitive to the costing approach used for the interventions. A similar sensitivity analysis is conducted
for the model-based analysis to determine whether or not the implications of intervention costing approach
remain an important determinant of cost-effectiveness in the longer term.
3. Determine the impact of heterogeneity in the cohort’s characteristics on cost-effectiveness. The mean
age of the women in the Uterine trial was 63 years. Sensitivity analysis explores the implications for
cost-effectiveness of varying the age of women at the point of entry to the model between 53 and
73 years.
4. Determine the impact of methodological uncertainty on the results. Long-term data on the time to
failure and complications are lacking and so estimates have been developed for the model based on
survival models, extrapolating short-term findings over the longer term. Although the models represent
a good fit to the observed trial data and are clinically plausible, the models may nonetheless fail to
accurately capture the true (unknown) long-term complication and failure rates of surgery. The impact
of any modelling inaccuracies on cost-effectiveness is likely to be magnified over longer-term time
horizons. Therefore, sensitivity analysis shortens the time horizon to 5, 10 and 20 years.
5. Determine the impact of methodological uncertainty surrounding the appropriate discount rate to apply
to future costs and QALYs. Sensitivity analyses vary the discount rate between 0% and 6% in line with
NICE best practice guidelines.63
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Cost-effectiveness results
Base-case results
Results from cost-effectiveness analyses are usually reported with treatments ranked in ascending order
of QALYs (or costs). However, as there are only two treatment strategies in this model, to ensure ease of
interpretation, all ICERs are presented for uterine preservation versus vaginal hysterectomy. The base-case
and sensitivity analyses are reported in Table 38. The base-case analysis indicates that uterine preservation
is not a cost-effective use of resources compared with vaginal hysterectomy. This is because uterine
preservation entails an additional surgical procedure in the treatment pathway, with, on average, higher
failure rates compared with vaginal hysterectomy. Therefore, it is associated with additional costs and QoL
decrements associated with having an additional surgery and treatment failure in the treatment pathway.
TABLE 38 Cost-effectiveness results
Sensitivity
analysis Strategy Cost (£)
Incremental
cost (£) QALYs
Incremental
QALYs ICER
Percentage
cost-effective
at £30,000 (%)
1 Base case
Vaginal hysterectomy 4428 12.44 78
Uterine preservation 4814 386 12.29 –0.15 Dominated 22
2 0 discount rate
Vaginal hysterectomy 6012 17.7 70
Uterine preservation 6436 424 17.55 –0.15 Dominated 30
3 6 discount rate
Vaginal hysterectomy 3739 10.10 83
Uterine preservation 4101 362 9.96 –0.14 Dominated 17
4 Age 53 years
Vaginal hysterectomy 4963 14.33 76
Uterine preservation 5357 394 14.22 –0.11 Dominated 24
5 Age 73 years
Vaginal hysterectomy 3513 9.11 86
Uterine preservation 3871 358 8.96 –0.15 Dominated 14
6 HRG-based internal costs
Vaginal hysterectomy 6903 12.43 22
Uterine preservation 6454 –258 12.29 –0.14 £1214.71 78
7 Time horizon 5 years
Vaginal hysterectomy 1962 4.02 96
Uterine preservation 2279 317 3.91 –0.11 Dominated 4
8 Time horizon 10 years
Vaginal hysterectomy 2785 7.13 93
Uterine preservation 3158 373 6.97 –0.16 Dominated 7
9 Time horizon 20 years
Vaginal hysterectomy 3979 11.01 83
Uterine preservation 4342 363 10.85 –0.16 Dominated 17
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The base-case CEAC illustrating sampling uncertainty is reported in Figure 17. Scatterplots of cost-
effectiveness for uterine preservation versus vaginal hysterectomy are reported in Figure 18, with 95%
confidence ellipses illustrated. The results show that, although vaginal hysterectomy is the most likely
cost-effective treatment at a range of plausible values of the decision-maker’s willingness to pay for 1
QALY, there remains a 20–30% chance that vaginal hysterectomy is not a cost-effective use of resources.
TABLE 38 Cost-effectiveness results (continued )
Sensitivity
analysis Strategy Cost (£)
Incremental
cost (£) QALYs
Incremental
QALYs ICER
Percentage
cost-effective
at £30,000 (%)
10 Removing general population utility age adjustment
Vaginal hysterectomy 4428 13.34 79
Uterine preservation 4814 386 13.19 –0.15 Dominated 21
11 Turn off treatment-specific costs
Vaginal hysterectomy 4614 12.43 78
Uterine preservation 4605 –9 12.29 –0.14 £128.57 22
12 Turn off treatment-specific utility
Vaginal hysterectomy 4434 12.28 4
Uterine preservation 4808 374 12.39 0.11 £3318 96
13 Assume equal baseline utility in both arms
Vaginal hysterectomy 4434 12.43 79
Uterine preservation 4808 374 12.29 –0.015 Dominated 21
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FIGURE 17 Cost-effectiveness acceptability curve for base-case results.
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Sensitivity analysis results
The results from all sensitivity analyses undertaken are reported in Table 38 alongside the base-case results.
A full set of CEACs and incremental scatterplots for each analysis undertaken can be found in Appendix 8,
Figures 45–68. In general, the base-case findings are robust to the sensitivity analyses around age adjustment
of health-state utilities, discount rates, starting age and starting utility of the modelled cohort. As illustrated
by sensitivity analyses 7–9, the uncertainty in cost-effectiveness increases over longer time horizons, when
projections of the trade-offs between complications and failures become less clear. For all the time horizons
considered, the model shows vaginal hysterectomy to be the most cost-effective strategy.
The cost projections from the model remain somewhat sensitive to the choice of intervention costing
approach. These results echo the findings of the trial-based economic evaluation, indicating that the
methodology used to assign initial treatment costs is important when projecting total costs. However,
the use of HRG costing does not change the conclusions about the most cost-effective treatment option
unless society were to place zero value on 1 QALY. Under the HRG costing approach, uterine preservation
becomes marginally less costly, but at the expense of QALY losses. Therefore, if society would require
compensation of at least £20,000–30,000 for 1 QALY lost, it is unlikely that this analysis would change the
cost-effectiveness conclusions.
The model is sensitive to the choice of costs and utilities used to populate the health states, in particular the
‘well’ health state. Treatment-specific costs and utilities both tend to favour vaginal hysterectomy, whereas
using averages from the Uterine trial, as a whole, favours uterine preservation. The finding is driven primarily
by the treatment-specific utilities and costs for the proportion of the cohort who are in the ‘well’ state. The
regression analyses indicate slightly lower costs in the ‘well’ state following vaginal hysterectomy and higher
utility compared with vaginal preservation. Turning off treatment-specific costs and utilities removes this
difference between the groups. As failure and complication rates are low and transient in the model (state
duration for failure and complications is 6 months), the majority of the cohort spend most of the model in
some form of ‘well’ state, hence the sensitivity of the results to this assumption.
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Interpretation of the model results
The model describes the important long-term trade-offs between the choice of uterine preservation versus
vaginal hysterectomy. The model is populated with the best available data on failures and complications
following surgery. However, the maximum follow-up to date of 2 years means data are immature, and it is
unlikely that all the important trade-offs between failures and complications have been observed across
the groups. It is therefore crucial that the model analyses are updated once more mature data on time-
to-failure and complication events become available. From a decision-making point of view, the ICER is
therefore sensitive to the true long-term failure and complication rates, and in particular cross-group
differences. In addition, the model describes a set of scenarios and assumptions that favours uterine
preservation and vaginal hysterectomy, respectively.
Within the modelling analysis and structure of the care pathway, advantages of uterine preservation
include:
l Keeping the cohort out of a final health state in which no other options are available apart from
conservative management and long-term containment for longer. This means that the cohort avoid
long-term costs of containment and the QoL implications of having no other potentially curative surgical
options available.
l The use of HRG intervention costing. The implications of HRG compared with component costing have
been discussed in Chapters 4 and 7.
Issues favouring the cost-effectiveness of vaginal hysterectomy include:
l Lower intervention costs, based on a shorter surgical procedure, using the component-based costing
approach described in Chapter 2.
l Potentially lower short-term failure rates. Although differences in time to event are not statistically
significant, point estimates of the hazard ratios favouring hysterectomy are propagated through the
model. Fewer failures mean a lower likelihood of costly surgical procedures and the QoL benefits of
experiencing a failure later than with uterine preservation.
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Chapter 10 Overarching discussion
The lack of long-term information for POP surgery to improve both counselling and information forwomen has been highlighted by NICE, but also to guide clinicians on best practice in terms of surgical
approach, particularly in relation to apical prolapse given the introduction of new techniques over the last
two decades.23,24,27–29
Both the uterine and the Vault trials presented in this report are the largest multicentre RCTs to assess surgical
treatments for apical compartment prolapse to date. They provide information on outcome measures up to
12 months after randomisation and surgery in terms of women’s symptoms, their satisfaction and objective
clinical assessment by POP-Q. The VUE trial will become a major contributor to current evidence and provides
the opportunity to identify the most appropriate surgical care pathway for the majority of women with apical
prolapse in the long term given the variability in surgical practice.16,67–71 An update of recent evidence,
including the VUE trial data, has also been completed (see Appendix 9, Figures 69–84).
Trial recruitment and treatment choice
Around 50% of parous women report symptoms of POP8,72 and have a lifetime risk of between 6% and
20% of undergoing surgery for prolapse,3,5,16,17 this is dependent on symptoms, QoL and functional impact.
Women within the VUE trial had requested surgical treatment for different reasons; the most bothersome
symptom was ‘a feeling of something coming down’ (see Chapters 4 and 7). This symptom has been
found to have a sensitivity of 84% and a specificity of 94% for prolapse at, or beyond, the hymenal ring.73
Other symptoms prompted women to consider surgery, such as faecal incontinence (more common in the
Vault trial), dragging in the abdomen or back or incomplete bladder emptying, although there is no clinical
evidence that confirms that these symptoms have any direct relationship attributable to prolapse74 and
surgery may potentially increase the risk.
A considerable number of eligible women chose not to participate in the Uterine trial during the initial
planned recruitment time, which affected recruitment rate, and a 15-month recruitment extension was
required. The main reason given to recruitment staff for non-participation was of the women’s wish to
have their uterus removed (see Chapter 3). This finding suggests the complex nature of the decision-
making process and it would be interesting to further explore reasons through a qualitative study (see
Appendix 10) given that previous literature suggests that 31–60% would choose uterine preservation.25,75,76
The recruitment rate for the Vault trial was not affected (see Chapter 6).
During the recruitment phase of the VUE trial, debate on the use of mesh implants in POP repair surgery
intensified. The potential insertion of mesh, though not necessarily transvaginally, was an important
decision-making point for many women. However, some women were unaware of the publicity and their
knowledge depended on their own social circle. This also highlights, and reinforces, the need for high-quality
standardised patient information provision on the options available for women before surgery, to allow
informed decision-making and person-centred care.41,42,77 In both the Uterine and the Vault trials, two
women had a mesh exposure from 235 mesh procedures at 12 months after surgery, and both underwent
surgical mesh removal. This provides a mesh exposure rate per procedure of 0.9% for the first 12 months.
One of the two mesh exposures was due to a transvaginal concomitant procedure. Mesh exposure rates
have been considered and reported as much greater for transvaginal mesh41,42,77 and further monitoring of
the VUE trial participants is taking place to identify if the natural timeline when using mesh for apical surgery
is different given the different approach. The exposure rates may also be lower than national statistical data,
as the surgeons involved in the VUE trial are recognised as being highly skilled; therefore, the study rates may
not accurately reflect actual rates.
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Clinical findings before operation
The POP-Q scoring system for objectively quantifying prolapse is considered highly reliable for research
purposes, though whether or not apical prolapse should use the same standards as anterior and posterior
prolapse has been debated. It has been suggested that the scoring system does not allow sufficient detail
for apical descent, such as in women with isolated cervical elongation or a large anterior wall prolapse that
obscures the vault location.78–81 At present it remains unchanged,82 as there is no unanimous view and no
alternative to replace the present system. In the VUE trial, a number of women had minimal apical descent
but were included in the trial (see Chapters 3 and 6), suggesting that there may be some women for
whom scoring by POP-Q has been less accurate.82 Of note, women in the Vault trial were found to have
higher POP-SSs (i.e. symptoms were more bothersome), but their POP-Q scores were not necessarily as
severe as those women in the Uterine trial (see Chapters 3 and 6). This may suggest a reduced tolerance to
prolapse or functional symptoms, or perhaps this cohort actually suffers more from prolapse as a result of
the absent uterus.
In addition to apical descent in the VUE trial population, anterior compartment descent was also present
and not only led to more planned anterior repairs preoperatively, but may have also contributed to increases
in baseline POP-SSs (see Chapters 3 and 6). This anatomical coexistence has been recognised previously in
studies and may possibly be caused by pelvic floor dynamics, irrespective of uterine presence. However,
it is possible that anterior prolapse may have been over diagnosed, particularly in those with vault prolapse,
where the apical and anterior compartment are less well defined,83,84 and highlights the complexity and
outpatient limitations of specific compartment preoperative surgical assessment and planning.
Some POP-Q anterior compartment and apical scoring (C+/–D; dependent on uterine presence) may have
related to observer error, though the majority of clinicians had participated in the previous RCT, PROSPECT,1
and were considered experienced in the scoring process.
Diurnal variation of the prolapse presentation and bowel/bladder distension may have also affected vaginal
compartments and the overall POP-Q scores.
The findings suggest that objective clinical assessment of prolapse by POP-Q is not necessarily the highest
priority for surgical decision-making given that women who had low POP-Q scores did not consistently
have reduced POP-SSs, and this has been reported elsewhere.85
Overall, this preoperative clinical process and subsequent randomisation of women in the VUE trial aligns
with the pragmatism of clinical day-to-day practice, enabling better insight into surgical practice for this
cohort of women.
Surgical procedures and their differences
The majority of women did receive their randomly allocated surgery, though a number did not (see
Chapters 4 and 7). It is possible that factors, such as lifestyle change, weight loss, oestrogen treatment and
physiotherapy, could have benefited some women, causing them to change their mind about the need
for surgery. It is also possible that the presence of a uterus may improve results from these conservative
approaches.86
Some women also received different surgery to that proposed preoperatively after examination under
anaesthetic, suggesting that a preoperative POP-Q assessment may be useful and cost-effective if symptoms
or significant lifestyle changes have occurred since surgical listing. This pre-emptive action may be useful for
women whose initial examination was by a less experienced clinician. It is also possible that assessment
under anaesthetic has allowed a more thorough evaluation of the vaginal compartments, but may also
overestimate the degree of prolapse as the pelvic floor is paralysed. This reaffirms the need for
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comprehensive preoperative counselling and consent (both verbal and written) in relation to the potential
change in surgical plans under anaesthesia.39
Although both the Uterine and the Vault trials were evaluating different approaches to apical repair,
associated factors, such as the use of different types of anaesthesia, are also likely to have influenced
final outcome measures or surgical decisions within theatre. Procedures undertaken by a vaginal approach
were more likely to involve a spinal or regional anaesthetic (see Chapters 4 and 7). Abdominal procedures
were more likely to require a general anaesthetic, particularly so in those receiving laparoscopic procedures
when respiratory and operating position requirements are important. Overall, abdominal procedures (open/
laparoscopic) for both trials were significantly longer than vaginal procedures (see Chapters 4 and 7), and
given that prolapse surgery affects the more elderly population, this approach may have exposed women
to an increased anaesthetic risk (particularly in those with associated morbidity). This was not identified
within the VUE trial, but the relatively healthy women in the trial and self-selected group of participating
surgeons may not be representative to provide reassurance for more widespread use.
Recently, robotic laparoscopic surgery has been considered for abdominal pelvic floor procedures, although
small RCTs to date have indicated that the operation is even longer and operating costs are higher.87
These early findings are unlikely to favour its general clinical use in the current NHS and further evaluation
is required.
As agreed in the VUE trial protocol,31 synthetic mesh was utilised in some of the transvaginal procedures,
whether for concomitant surgery or the apical compartment. Transvaginal mesh use changed during the
lifetime of the VUE trial, with a reduction in use for prolapse surgery and a consistent number (though
small) for incontinence. The ongoing debate on the use of mesh implants and disseminated publications
from national and professional organisations during the time of the trial was likely to be a causal factor
affecting women’s and surgeons’ choice of surgical approach.88 This trend is also in line with a recent UK
national prolapse survey, and at present the use of transvaginal mesh has been paused by NHS England
and NHS Northern Ireland.23,24,27–29,77,89–91
Mesh implants were required in all abdominal procedures (see Appendices 3 and 5), though information on
specific anatomical site mesh application was not requested/retrieved on the intraoperative CRF. As a result,
it is not possible to identify those surgeons who indirectly or specifically repaired the anterior compartment
either by an additional anterior leaf of mesh or by their individual technique during abdominal surgery. This
does, however, emphasise the pragmatic approach of the variability in surgical practice in relation to mesh
position for individual patients.
More concomitant anterior and posterior repairs were undertaken in the vaginal groups for both trials
(see Chapters 4 and 7). This may be related to the local surgical field given the good visibility of other
compartmental descent compared with abdominal procedures, and its outcome is discussed in The VUE
trial of the future.
Overall, intraoperative complications and subsequent SAE rates in the VUE trial, irrespective of surgical
approach, were lower than previously published rates for pelvic floor surgery.92 This finding may be because
of the surgical experience in the self-selected cohort of participating gynaecologists in the trial, as described
in Trial recruitment and treatment choice.
Women’s symptoms after operation
Prolapse symptoms outcomes at 6 months after surgery, at 12 months after randomisation, with a clinic
appointment for POP-Q assessment 12 months after surgery were collected (see Chapters 4 and 7).
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The use of this method of data collection may be considered by some clinical investigators as controversial,
but has robust statistical support and is commonly used in drug trials (Clinical Trials of an Investigational
Medicinal Product). By data retrieval at 6 months after surgery, the POP-SS is very specific and aligned to
time allocation for surgery. However, in routine clinical practice, women do undergo a waiting time before
surgery, hence the outcome data at 12 months after randomisation is equivalent to a patient’s normal
clinical pathway. This post-randomisation analysis at 12 months offers the expectations in improvement
12 months after treatment allocation occurred. The 12 months after surgery clinical assessment enables
the surgeon to assess objective changes after the procedure. This time differential (c. 60 days) will become
irrelevant for outcome measures over the longer term, which will be critical in informing health-care
commissioners, health-care professionals and consumers to provide estimates of treatment effects currently
not available in the literature.
Financial considerations for all
Women who were in paid employment and required time off work for surgery were found to require longer
convalescence in the uterine preservation group in the Uterine trial (see Chapter 5). This may affect future
generations in relation to surgery options given the increasing pensionable age and employment legislation,
particularly in relation to unpaid leave, and will undoubtedly become integral in decision-making for the
women themselves.
At 12 months, the randomised surgical approaches for each trial were found to be clinically effective in
the relief of symptoms and objective surgical outcome. However, in both trials the short-term cost-effective
impact and the health economic findings suggest that vaginal surgical approaches for apical prolapse may
be more beneficial (see Chapters 5 and 8). The differential was based on additional re-operation rates for
uterine preservation cohorts in the Uterine trial as well as longer operating times. The differential was more
evident in the Vault trial when direct comparison of abdominal and vaginal approaches were made. This
finding may suggest that current HRG classification for health-care costs in terms of pelvic floor surgery may
require more frequent revision and amendment to accurately reflect costs and the rate of change in surgical
techniques offered by clinicians. Regular long-term follow-up of women in both trials, particularly in relation
to health economics, will enable more accurate costings for the present apical surgical techniques. This will
identify if the predictions presented in this publication hold true for the long-term future.
The VUE trial of the future
Currently, the women participating in the VUE trial are being followed up for 6 years after randomisation,
though this time frame does not provide a thorough evaluation of long-term outcomes given the expected
increase in lifespan. A follow-up of up to 12 years is hoped to be achieved to enable longer-term evaluation
of outcomes. This would include women who did not receive any form of surgery for prolapse.
Women participating in the VUE trial were generally in their seventh decade, with a slightly older cohort in
the Vault trial (see Chapters 3 and 6). Longer-term follow-up may be more difficult because of age-related
diseases and/or death. Alternative methods for data collection and outcome measures require recognition
of abilities and cognitive function (i.e. age specific) over time.
Although there was no difference in POP-Q scores in the Uterine trial between the two groups, in the Vault trial
there was a statistical difference in relation to the anterior wall prolapse after a vaginal vault repair (although
the numbers were small). Anatomical correction does not guarantee functional improvement in neighbouring
systems, with the risk of deterioration, such as de novo urinary incontinence or faecal incontinence, as was
evident in both trials (see Chapters 4 and 7). Women participating in the VUE trial did experience bowel and
bladder symptoms that required hygiene measures after their operation despite improved POP-Q scores (see
Chapters 4 and 7). The cause of bowel and bladder dysfunction is a complex issue, but the resultant effects on
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QoL and finance for an elderly woman are substantial. This emphasises the need for assessment of potential
short-, medium- and long-term changes made by different surgical techniques given the expected overall
age-related hand–eye co-ordination, mobility changes and potential life expectancy of women in the future.
Preservation of the uterus is not without risk. Long-term information about additional investigations and
treatments required for those women who had uterine preservation will be particularly important and may
require analysis taking into account actual treatment received for accurate risk information. This would
also enable the additional personal, financial and health impact to be scrutinised rather than prolapse
symptomatology in isolation as an outcome measure. This is likely to be considered an important measure
for health-care providers, clinicians and women alike.
The majority of women within the VUE trial were postmenopausal and results are generalisable for this cohort
of women. It is somewhat difficult to extrapolate these outcomes for women under the age of 45 years who
may also present with an apical prolapse that remains unresponsive to conservative treatments. These women
are more likely to be fertile and require cervical screening, both of which may be unacceptable if uterine
removal is an option. Uterine preservation prolapse surgery is possible and used presently for those women
pursuing fertility preservation and future pregnancy (although excluded from the VUE trial). Although
comprehensive adequately powered long-term data will not become available from the VUE trial for this age
group, subanalysis of those women randomised to uterine preservation who were under 45 years of age may
assist in information on its benefits or otherwise for apical prolapse.
Limitations
Although few participating women were lost to follow-up overall in both the Uterine and the Vault trials,
the proportion of women who were successfully included was < 50% of those initially identified. Although
not all of these women would have been eligible for the VUE trial, it may have allowed for an increased
generalisability.
The surgeons who participated in the VUE trial chose the uterine preservation procedure they were most
familiar with, which, although allowed pragmatic practice, did allow for greater heterogeneity in the
uterine preservation arm of the Uterine trial. However, some highly skilled laparoscopic surgeons familiar
with the VUE trial surgical procedures did not take part and may have influenced the uterine preservation
cohort outcomes in relation to health economic and clinical outcomes. There were several reasons for this:
surgical bias to particular procedures, site difficulties with timing of ethics approval, and research and
development processes.
A small number of participating women did not undergo surgery and this cohort was not offered a 12-month
post-surgical examination for POP-Q evaluation. The women were, however, included in the POP-SS outcomes
at 12 months. The retrieval of POP-Q scores from these women who had no surgery may have impacted the
POP-Q outcomes and also provided some information on the natural progression or regression of prolapse in
women with apical prolapse.
The questionnaire response rate and that of clinic attendance have also identified a greater clinical attendance
than questionnaire return. This suggests that women may place greater importance on objective assessment of
prolapse by a health-care professional than their symptoms through questionnaire completion. However, it is
possible women do not understand the importance of their feedback through serial structured questionnaire
completion over time and this requires further evaluation.
Health-care costs were greater for abdominal procedures; however, the cost may still be artificially lower than
the actual costings given that surgical equipment costs within each trial were assumed to be equivalent, and
this may not be the case if disposable instruments were used. This information was not collected in the VUE
trial other than additional costings for mesh implantation and should be considered for any further trials in
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the future. In addition, there was a greater exposure to health-care professionals after an operation if women
had undergone uterine preservation; this may be artificially high at present given the limited experience of
primary care with these procedures and the requirement of more specialist advice. If this hypothesis is true,
then a trend to less health-care input will occur. Further investigation into primary health-care behaviours in
relation to new interventions may be useful to inform a health-care economic analysis.
The blinding of participants was particularly difficult given the different surgical approaches and the
required counselling before the operation. Blinding participants to their surgical procedure by performing
sham incisions to conceal the route of surgery was not considered necessary or ethical. This would have
caused falsely increased operating times, pain relief and recovery times in those having vaginal operations
and unlikely to have had an impact on women’s 12-month primary outcomes. However, it was more
useful to blind the POP-Q assessor at the 12-month examination, although this was sometimes difficult if
the assessor had also been the surgeon or if the patient divulged the procedure before examination.
Future generations
In conclusion, this publication reports primarily on a postmenopausal population of women with apical
prolapse who experienced different obstetric care from today (primarily in terms of fewer caesarean sections
and forceps deliveries). The change in obstetric practice, in addition to societal changes tending towards
smaller families, has a potential to reduce the pelvic floor insult associated with childbirth.93 Linkage to
increases in caesarean section rate and reduced instrumental vaginal delivery has demonstrated a reduction
in lifetime risk for prolapse surgery.67,71 In addition, the impact from reduced hysterectomy rates through
changes in gynaecological practice may also improve pelvic floor health.94–97 Over time it is therefore
possible that prolapse requiring surgical treatment may be significantly reduced or delayed for several years
in life. This may limit the opportunity for further large RCTs for both uterine and vault prolapse in the future
because of a potential reduction in the number of women requiring treatment. However, this hypothesis
does not take into account the increasing incidence of obesity worldwide, which may also affect prolapse98
and its related symptoms.99 Further trials for assessment of uterine preservation for prolapse may also not be
possible over time given the increased risk of gynaecological cancers related to obesity.
With the increasing information on the impact of mesh-related procedures worldwide, the use of synthetic
mesh implants must also be scrutinised in the long term. The use of mesh and its positioning is particularly
important in relation to all structures within the pelvis and abdomen. Subsequent abdominal or pelvic
surgery may become more difficult if adherent mesh from a prolapse repair is nearby to the operating field,
causing increased open procedures and increased lengths of hospital stay. This must also be considered and
reviewed in the long term given the increasing longevity of human life.
Although evidence to date has not been favourable for biological graft support in pelvic floor surgery, some
trials have shown promise.100–103 It is therefore possible that the present synthetic mesh may also be further
adapted or totally replaced by more advanced biological graft material for prolapse surgery to allow clinically
effective and potentially safer treatments. This research and development will undoubtedly take many years and
high resources and may await studies, such as the VUE trial, to identify their role, if any, before manufacture.
Conclusion
There was no evidence that an abdominal procedure was more clinically effective for either a uterine or
vault prolapse in terms of all measured outcomes in the short term, but the abdominal procedures were
slightly more expensive to perform. To identify if predictions described in this publication hold true (see
Chapter 9 for long-term predictions over the next 30 years in relation to any benefit difference), long-term
follow-up of the VUE trial participants will provide a unique opportunity to collect long-term information
on the most clinically effective, safe and cost-effective treatment for apical prolapse.
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of information from people’s patient records, to understand more about disease, develop new treatments,
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Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
106
References
1. Glazener C, Breeman S, Elders A, Hemming C, Cooper K, Freeman R, et al. Clinical effectiveness
and cost-effectiveness of surgical options for the management of anterior and/or posterior vaginal
wall prolapse: two randomised controlled trials within a comprehensive cohort study – results
from the PROSPECT Study. Health Technol Assess 2016;20(95). https://doi.org/10.3310/hta20950
2. Hunskaar S, Burgio KL, Clark A, Lapitan MC, Nelson R, Sillen U, et al. Epidemiology of Urinary (UI)
and Faecal (FI) Incontinence and Pelvic Organ Prolapse (POP). In Abrams P, Cardozo L, Khoury S
and Wein A, editors. Incontinence 3rd Edition. Bristol: International Continence Society; 2005.
pp. 255–312.
3. Olsen AL, Smith VJ, Bergstrom JO, Colling JC, Clark AL. Epidemiology of surgically managed
pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997;89:501–6. https://doi.org/
10.1016/S0029-7844(97)00058-6
4. Phillips CH, Anthony F, Benyon C, Monga AK. Collagen metabolism in the uterosacral ligaments
and vaginal skin of women with uterine prolapse. BJOG 2006;113:39–46. https://doi.org/10.1111/
j.1471-0528.2005.00773.x
5. Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, et al. Prevalence of symptomatic
pelvic floor disorders in US women. JAMA 2008;300:1311–16. https://doi.org/10.1001/jama.300.
11.1311
6. Samuelsson EC, Victor FTA, Tibblin G, Svardsudd KF. Signs of genital prolapse in a Swedish
population of women 20 to 59 years of age and possible related factors. Am J Obstet Gynecol
1999;180:299–305. https://doi.org/10.1016/S0002-9378(99)70203-6
7. Swift SE, Tate SB, Nicholas J. Correlation of symptoms with degree of pelvic organ support
in a general population of women: what is pelvic organ prolapse? Am J Obstet Gynecol
2003;189:372–7. https://doi.org/10.1067/S0002-9378(03)00698-7
8. Hendrix SL, Clark A, Nygaard I, Aragaki A, Barnabei V, McTiernan A. Pelvic organ prolapse in
the Women’s Health Initiative: gravity and gravidity. Am J Obstet Gynecol 2002;186:1160–6.
https://doi.org/10.1067/mob.2002.123819
9. Bugge C, Adams EJ, Gopinath D, Reid F. Pessaries (mechanical devices) for pelvic organ prolapse
in women. Cochrane Database Syst Rev 2013;2:CD004010. https://doi.org/10.1002/14651858.
CD004010.pub3
10. Oliver R, Thakar R, Sultan AH. The history and usage of the vaginal pessary: a review. Eur J Obstet
Gynecol Reprod Biol 2011;156:125–30. https://doi.org/10.1016/j.ejogrb.2010.12.039
11. Maher C, Baessler K, Barber M, Cheon C, Consten E, Cooper K. Pelvic Organ Prolapse Surgery
(Committee 15). International Continence Society, Florence, Italy, 12–15 September 2017.
12. Abrams P, Cardozo L, Wagg A, Wein A, eds. Incontinence. 6th ed. Bristol: International
Continence Society; 2017.
13. Hagen S, Stark D. Conservative prevention and management of pelvic organ prolapse in
women. Cochrane Database Syst Rev 2011;12:CD003882. https://doi.org/10.1002/14651858.
CD003882.pub4
14. Ismail SI, Bain C, Hagen S. Oestrogens for treatment or prevention of pelvic organ prolapse in
postmenopausal women. Cochrane Database Syst Rev 2010;9:CD007063. https://doi.org/
10.1002/14651858.CD007063.pub2
DOI: 10.3310/hta24130 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 13
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hemming et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
15. Weber MA, Kleijn MH, Langendam M, Limpens J, Heineman MJ, Roovers JP. Local oestrogen for
pelvic floor disorders: a systematic review. PLOS ONE 2015;10:e0136265. https://doi.org/10.1371/
journal.pone.0136265
16. Wu JM, Matthews CA, Conover MM, Pate V, Jonsson Funk M. Lifetime risk of stress urinary
incontinence or pelvic organ prolapse surgery. Obstet Gynecol 2014;123:1201–6. https://doi.org/
10.1097/AOG.0000000000000286
17. Smith FJ, Holman CD, Moorin RE, Tsokos N. Lifetime risk of undergoing surgery for pelvic organ
prolapse. Obstet Gynecol 2010;116:1096–100. https://doi.org/10.1097/AOG.0b013e3181f73729
18. NHS Digital. Hospital Admitted Patient Care Activity, 2016–17. Leeds: NHS Digital; 2017.
URL: https://digital.nhs.uk/catalogue/PUB30098 (accessed 24 January 2018).
19. Office for National Statistics. Z1 – Zipped Population Projections Data Files, UK. Newport:
Office for National Statistics; 2017. URL: www.ons.gov.uk/peoplepopulationandcommunity/
populationandmigration/populationprojections/datasets/z1zippedpopulationprojectionsdatafilesuk
(accessed 24 January 2018).
20. National Institute for Health and Care Excellence. Uterine Prolapse. Manchester: National Institute
for Health and Care Excellence. URL: www.nice.org.uk/guidance/conditions-and-diseases/
gynaecological-conditions/uterine-prolapse/products?Status=Published (accessed February 2019).
21. National Institute for Health and Care Excellence. Vault Prolapse. Manchester: National Institute
for Health and Care Excellence. URL: www.nice.org.uk/Search?q=vault+prolapse (accessed
24 January 2018).
22. Maher C, Feiner B, Baessler K, Christmann-Schmid C, Haya N, Brown J. Surgery for women with
apical vaginal prolapse. Cochrane Database Syst Rev 2016;10:CD012376. https://doi.org/10.1002/
14651858.CD012376
23. National Institute for Health and Care Excellence. Sacrocolpopexy with Hysterectomy Using Mesh
to Repair Uterine Prolapse. Interventional Procedures Guidance IPG577. Manchester: NICE; 2017.
URL: www.nice.org.uk/guidance/ipg577 (accessed 4 July 2017).
24. National Institute for Health and Care Excellence. Sacrocolpopexy Using Mesh to Repair Vaginal
Vault Prolapse. Interventional Procedures Guidance IPG583. Manchester: NICE; 2017. URL: www.
nice.org.uk/guidance/ipg583 (accessed 23 January 2018).
25. Wright JD, Herzog TJ, Tsui J, Ananth CV, Lewin SN. Nationwide trends in the performance of
inpatient hysterectomy in the United States. Obstet Gynecol 2013;122:233–41. https://doi.org/
10.1097/AOG.0b013e318299a6cf
26. Jia X, Glazener C, Mowatt G, MacLennan G, Bain C, Fraser C, Burr J. Efficacy and safety of using
mesh or grafts in surgery for anterior and/or posterior vaginal wall prolapse: systematic review
and meta-analysis. BJOG 2008;115:1350–61. https://doi.org/10.1111/j.1471–0528.2008.01845.x
27. National Institute for Health and Care Excellence. Uterine Suspension Using Mesh (Including
Sacrohysteropexy) to Repair Uterine Prolapse. Interventional Procedures Guidance IPG584.
Manchester: NICE; 2017. URL: www.nice.org.uk/guidance/ipg584 (accessed 23 January 2018).
28. National Institute for Health and Clinical Excellence. Infracoccygeal Sacropexy Using Mesh to
Repair Uterine Prolapse. Interventional Procedures Guidance IPG582. Manchester: NICE; 2017.
URL: www.nice.org.uk/guidance/ipg582 (accessed 23 January 2018).
29. National Institute for Health and Care Excellence. Infracoccygeal Sacropexy Using Mesh to Repair
Vaginal Vault Prolapse. Interventional Procedures Guidance IPG581. Manchester: NICE; 2017.
URL: www.nice.org.uk/guidance/ipg581 (accessed 23 January 2018).
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
108
30. Maher C, Feiner B, Baessler K, Schmid C. Surgical management of pelvic organ prolapse in
women. Cochrane Database Syst Rev 2013;4:CD004014. https://doi.org/10.1002/14651858.
CD004014.pub5
31. Glazener C, Constable L, Hemming C, Breeman S, Elders A, Cooper K, et al. Two parallel,
pragmatic, UK multicentre, randomised controlled trials comparing surgical options for upper
compartment (vault or uterine) pelvic organ prolapse (the VUE Study): study protocol for a
randomised controlled trial. Trials 2016;17:441. https://doi.org/10.1186/s13063–016–1576-x
32. Toozs-Hobson P, Freeman R, Barber M, Maher C, Haylen B, Athanasiou S, et al. An International
Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the
terminology for reporting outcomes of surgical procedures for pelvic organ prolapse. Int
Urogynecol J 2012;23:527–35. https://doi.org/10.1007/s00192–012–1726-y
33. Hagen S, Glazener C, Sinclair L, Stark D, Bugge C. Psychometric properties of the pelvic organ prolapse
symptom score. BJOG 2009;116:25–31. https://doi.org/10.1111/j.1471–0528.2008.01903.x
34. Hagen S, Glazener C, Cook J, Herbison P, Toozs-Hobson P. Further properties of the pelvic organ
prolapse symptom score: minimally important change and test-retest reliability. Neurourol Urodyn
2010;29:1055–6.
35. Dolan P. Modelling valuations for EuroQoL health states. Med Care 1997;35:1095–108.
https://doi.org/10.1097/00005650-199711000-00002
36. Abrams P, Avery K, Gardener N, Donovan J, on behalf of the ICIQ Advisory Board. The
international consultation on incontinence modular questionnaire. J Urol 2006;175:1063–6.
https://doi.org/10.1016/S0022-5347(05)00348-4
37. Bump RC, Mattiasson A, Bø K, Brubaker LP, DeLancey JO, Klarskov P, et al. The standardisation of
terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol
1996;175:10–17. https://doi.org/10.1016/S0002-9378(96)70243-0
38. Nygaard I, Brubaker L, Zyczynski HM, Cundiff G, Richter H, Gantz M, et al. Long-term outcomes
following abdominal sacrocolpopexy for pelvic organ prolapse. JAMA 2013;309:2016–24.
https://doi.org/10.1001/jama.2013.4919
39. Fayyad A, Hill S, Gurung V, Prashar S, Smith AR. How accurate is symptomatic and clinical
evaluation of prolapse prior to surgical repair? Int Urogynecol J Pelvic Floor Dysfunct
2007;18:1179–83. https://doi.org/10.1007/s00192–007–0306-z
40. Drossman DA, Dumitrascu DL. Rome III: new standard for functional gastrointestinal disorders.
J Gastrointestin Liver Dis 2006;15:237–41.
41. Scottish Government. Transvaginal Mesh Implants Independent Review: Final Report.
Edinburgh: Scottish Government; 2017. URL: www.gov.scot/Publications/2017/03/3336/0
(accessed 1 February 2018).
42. NHS England. Mesh Oversight Group Report. London: NHS England; 2017. URL: www.england.
nhs.uk/wp-content/uploads/2017/07/mesh-oversight-group-report.pdf (accessed 1 February 2018).
43. Joint Formulary Committee. British National Formulary. (online) London: BMJ Group and
Pharmaceutical Press. URL: www.medicinescomplete.com (accessed February 2019).
44. Information Services Division Scotland. Specialty Costs – Detailed Tables. Edinburgh: Information
Services Division Scotland. URL: www.isdscotland.org/Health-topics/Finance/Costs/Detailed-Tables/
Speciality-Costs/index.asp (accessed 6 February 2018).
45. Department of Health and Social Care. NHS Reference Costs 2015–16. London: Department of Health
and Social Care; 2016. URL: www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016
(accessed 3 May 2017).
DOI: 10.3310/hta24130 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 13
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hemming et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
109
46. Curtis L, Burns A. Unit Costs of Health and Social Care 2016. URL: www.pssru.ac.uk/project-
pages/unit-costs/2016/index.php (accessed 13 May 2017).
47. Information Services Division Scotland. ISD Scotland 63. Edinburgh: Information Services Division
Scotland. URL: www.isdscotland.org/Health-Topics/Finance/Costbook/Speciality-Costs/Overhead.asp
(accessed October 2012).
48. Information Services Division Scotland. R140X Theatre Services. Edinburgh: Information Services
Division Scotland. URL: www.isdscotland.org/Health-topics/Finance/Costs/Detailed-Tables/Theatres.asp
(accessed 1 February 2018).
49. NHS Business Services Authority. Electronic Drug Tariff. Newcastle upon Tyne: NHS Business
Services Authority. URL: www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/
drug-tariff (accessed 1 October 2018).
50. Information Services Division Scotland. Costs: File Listings. Edinburgh: Information Services
Division Scotland. URL: www.isdscotland.org/Health-Topics/Finance/Costs/File-Listings-2016.asp
(accessed 11 January 2017).
51. Warrington Clinical Commissioning Group. Continence and Catheter Care Formulary. Warrington:
Warrington Clinical Commissioning Group; 2014. URL: www.warringtonccg.nhs.uk/Page%
20Images/public-info/Catheter%20Care%20Formulary%20Revised%20February%202014%
20revised.pdf (accessed February 2019).
52. Office for National Statistics. Annual Survey of Hours and Earnings: 2016 Provisional Results.
Newport: Office for National Statistics; 2016. URL: www.ons.gov.uk/employmentandlabourmarket/
peopleinwork/earningsandworkinghours/bulletins/annualsurveyofhoursandearnings/
2016provisionalresults (accessed 11 January 2017).
53. EuroQoL Group. EuroQoL: a new facility for the measurement of health-related quality of life.
Health Policy 1990;16:199–208. https://doi.org/10.1016/0168-8510(90)90421-9
54. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness
analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487–96.
https://doi.org/10.1002/hec.944
55. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. 2nd edn. Oxford:
Oxford University Press; 2015.
56. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic
Evaluation of Health Care Programmes. 3rd edn. Oxford: Oxford University; 2005.
57. National Institute for Health and Care Excellence. Developing NICE Guidelines: The Manual.
Manchester: NICE; 2014. URL: www.nice.org.uk/guidance/pmg20/resources/developing-nice-
guidelines-the-manual-pdf-72286708700869 (accessed 18 May 2017).
58. Royston P. Multiple imputation of missing values: update of ice. Stata J 2005;5:527–36.
https://doi.org/10.1177/1536867X0500500404
59. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps:
a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327–40.
https://doi.org/10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W
60. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup
analysis for non-censored cost-effectiveness data. Health Econ 2004;13:461–75. https://doi.org/
10.1002/hec.843
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
61. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332. https://doi.org/
10.1136/bmj.c332
62. Office for National Statistics. Interim Life Tables 2007–2009. Newport: Office for National
Statistics. URL: www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/
lifeexpectancies#datasets (accessed February 2019).
63. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal
2013. Manchester: NICE; 2013. URL: www.nice.org.uk/process/pmg9/chapter/foreword (accessed
7 February 2018).
64. Latimer N. NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations
Alongside Clinical Trials – Extrapolation with Patient-level Data. Manchester: National Institute for
Health and Care Excellence. URL: http://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/
2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf (accessed 7 February 2018).
65. Latimer NR. Survival analysis for economic evaluations alongside clinical trials – extrapolation
with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making
2013;33:743–54. https://doi.org/10.1177/0272989X12472398
66. Ara R, Wailoo A. NICE DSU Technical Support Document 12: The Use of Health State Utility
Values in Decision Models. Manchester: National Institute for Health and Care Excellence.
URL: http://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2016/03/TSD12-Utilities-in-
modelling-FINAL.pdf (accessed 7 February 2018).
67. Løwenstein E, Ottesen B, Gimbel H. Incidence and lifetime risk of pelvic organ prolapse surgery
in Denmark from 1977 to 2009. Int Urogynecol J 2015;26:49–55. https://doi.org/10.1007/
s00192–014–2413-y
68. Haya N, Baessler K, Christmann-Schmid C, de Tayrac R, Dietz V, Guldberg R, et al. Prolapse and
continence surgery in countries of the Organisation for Economic Cooperation and Development in
2012. Am J Obstet Gynecol 2015;212:755.e1–755.e27. https://doi.org/10.1016/j.ajog.2015.02.017
69. Boyles SH, Weber AM, Meyn L. Procedures for pelvic organ prolapse in the United States,
1979–97. Am J Obstet Gynecol 2003;188:108–15. https://doi.org/10.1067/mob.2003.101
70. Shah AD, Kohli N, Rajan SS, Hoyte L. The age distribution, rates, and types of surgery for pelvic
organ prolapse in the USA. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:421–8. https://doi.org/
10.1007/s00192–007–0457-y
71. Lisonkova S, Lavery JA, Ananth CV, Chen I, Muraca G, Cundiff GW, Joseph KS. Temporal trends
in obstetric trauma and inpatient surgery for pelvic organ prolapse: an age-period-cohort analysis.
Am J Obstet Gynecol 2016;215:208.e1–208.e12. https://doi.org/10.1016/j.ajog.2016.02.027
72. Swift SE. The distribution of pelvic organ support in a population of female subjects seen for
routine gynecologic health care. Am J Obstet Gynecol 2000;183:277–85. https://doi.org/10.1067/
mob.2000.107583
73. Lukacz ES, Lawrence JM, Buckwalter JG, Burchette RJ, Nager CW, Luber KM. Epidemiology of
prolapse and incontinence questionnaire: validation of a new epidemiologic survey. Int Urogynecol
J Pelvic Floor Dysfunct 2005;16:272–84. https://doi.org/10.1007/s00192-005-1314-5
74. Ellerkmann RM, Cundiff GW, Melick CF, Nihira MA, Leffler K, Bent AE. Correlation of symptoms
with location and severity of pelvic organ prolapse. Am J Obstet Gynecol 2001;185:1332–7.
https://doi.org/10.1067/mob.2001.119078
DOI: 10.3310/hta24130 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 13
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hemming et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
111
75. Frick AC, Barber MD, Paraiso MF, Ridgeway B, Jelovsek JE, Walters MD. Attitudes towards
hysterectomy in women undergoing evaluation for uterovaginal prolapse. Female Pelvic Med
Reconstr Surg 2013;19:103–9. https://doi.org/10.1097/SPV.0b013e31827d8667
76. Korbly NB, Kassis NC, Good MM, Richardson ML, Book NM, Yip S, et al. Patient preferences for
uterine preservation and hysterectomy in women with pelvic organ prolapse. Am J Obstet
Gynecol 2013;209:470.e1–6. https://doi.org/10.1016/j.ajog.2013.08.003
77. National Institute for Health and Care Excellence. Transvaginal Mesh Repair of Anterior or
Posterior Vaginal Wall Prolapse. Manchester: NICE; 2017. URL: www.nice.org.uk/guidance/ipg599
(accessed 13 February 2018).
78. Lin TY, Su TH, Wang YL, Lee MY, Hsieh CH, Wang KG, Chen GD. Risk factors for failure of
transvaginal sacrospinous uterine suspension in the treatment of uterovaginal prolapse. J Formos
Med Assoc 2005;104:249–53.
79. Neuman M, Lavy Y. Conservation of the prolapsed uterus is a valid option: medium term results
of a prospective comparative study with the posterior intravaginal slingoplasty operation. Int
Urogynecol J Pelvic Floor Dysfunct 2007;18:889–93. https://doi.org/10.1007/s00192-006-0262-z
80. Romanzi LJ, Tyagi R. Hysteropexy compared to hysterectomy for uterine prolapse surgery: does
durability differ? Int Urogynecol J 2012;23:625–31. https://doi.org/10.1007/s00192-011-1635-5
81. Pan K, Cao L, Ryan NA, Wang Y, Xu H. Laparoscopic sacral hysteropexy versus laparoscopic
sacrocolpopexy with hysterectomy for pelvic organ prolapse. Int Urogynecol J 2016;27:93–101.
https://doi.org/10.1007/s00192-015-2775-9
82. Haylen BT, Maher CF, Barber MD, Camargo S, Dandolu V, Digesu A, et al. An International
Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on
the terminology for female pelvic organ prolapse (POP). Int Urogynecol J 2016;27:165–94.
https://doi.org/10.1007/s00192-015-2932-1
83. Rooney K, Kenton K, Mueller ER, FitzGerald MP, Brubaker L. Advanced anterior vaginal wall
prolapse is highly correlated with apical prolapse. Am J Obstet Gynecol 2006;195:1837–40.
https://doi.org/10.1016/j.ajog.2006.06.065
84. Hsu Y, Chen L, Summers A, Ashton-Miller JA, DeLancey JO, DeLancey JO. Anterior vaginal wall
length and degree of anterior compartment prolapse seen on dynamic MRI. Int Urogynecol J
Pelvic Floor Dysfunct 2008;19:137–42. https://doi.org/10.1007/s00192-007-0405-x
85. Barber MD, Brubaker L, Nygaard I, Wheeler TL, Schaffer J, Chen Z, Spino C, Pelvic Floor Disorders
Network. Defining success after surgery for pelvic organ prolapse. Obstet Gynecol 2009;114:600–9.
https://doi.org/10.1097/AOG.0b013e3181b2b1ae
86. Hagen S, Stark D, Glazener C, Dickson S, Barry S, Elders A, et al. Individualised pelvic floor muscle
training in women with pelvic organ prolapse (POPPY): a multicentre randomised controlled trial.
Lancet 2014;383:796–806. https://doi.org/10.1016/S0140-6736(13)61977-7
87. Paraiso MF, Jelovsek JE, Frick A, Chen CC, Barber MD. Laparoscopic compared with robotic
sacrocolpopexy for vaginal prolapse: a randomised controlled trial. Obstet Gynecol
2011;118:1005–13. https://doi.org/10.1097/AOG.0b013e318231537c
88. King AB, Goldman HB. Stress incontinence surgery at the time of prolapse surgery: mandatory or
forbidden? World J Urol 2015;33:1257–62. https://doi.org/10.1007/s00345-015-1591-7
89. Jha S, Cutner A, Moran P. The UK National Prolapse Survey: 10 years on. Int Urogynecol J
2018;29:795–801. https://doi.org/10.1007/s00192–017–3476–3
90. BBC News. Immediate Stop to NHS Mesh Operations. URL: www.bbc.co.uk/news/health-44763673
(accessed 7 July 2018).
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
112
91. Smyth C. Pause in Surgical Mesh Use to be Extended to Northern Ireland. URL: www.bbc.co.uk/
news/uk-northern-ireland-44772354 (accessed 10 July 2018).
92. Diwadkar GB, Barber MD, Feiner B, Maher C, Jelovsek JE. Complication and reoperation rates after
apical vaginal prolapse surgical repair: A systematic review. Obstet Gynecol 2009;113:367–73.
https://doi.org/10.1097/AOG.0b013e318195888d
93. Glazener C, Elders A, MacArthur C, Lancashire RJ, Herbison P, Hagen S, et al. Childbirth and
prolapse: long-term associations with the symptoms and objective measurement of pelvic organ
prolapse. BJOG 2013;120:161–8. https://doi.org/10.1111/1471-0528.12075
94. Aigmueller T, Dungl A, Hinterholzer S, Geiss I, Riss P. An estimation of the frequency of surgery
for posthysterectomy vault prolapse. Int Urogynecol J 2010;21:299–302. https://doi.org/10.1007/
s00192–009–1033–4
95. Marchionni M, Bracco GL, Checcucci V, Carabaneanu A, Coccia EM, Mecacci F, Scarselli G. True
incidence of vaginal vault prolapse. Thirteen years of experience. J Reprod Med 1999;44:679–84.
96. Morley GW, DeLancey JO. Sacrospinous ligament fixation for eversion of the vagina. Am J Obstet
Gynecol 1988;158:872–81. https://doi.org/10.1016/0002-9378(88)90088-9
97. Cooper K, Lee A, Chien P, Raja E, Timmaraju V, Bhattacharya S. Outcomes following
hysterectomy or endometrial ablation for heavy menstrual bleeding: retrospective analysis of
hospital episode statistics in Scotland. BJOG 2011;118:1171–9. https://doi.org/10.1111/
j.1471-0528.2011.03011.x
98. Bradley CS, Nygaard IE, Brown MB, Gutman RE, Kenton KS, Whitehead WE, et al. Bowel
symptoms in women 1 year after sacrocolpopexy. Am J Obstet Gynecol 2007;197:642.e1–8.
https://doi.org/10.1016/j.ajog.2007.08.023
99. Luber KM, Boero S, Choe JY. The demographics of pelvic floor disorders: current observations
and future projections. Am J Obstet Gynecol 2001;184:1496–501. https://doi.org/10.1067/
mob.2001.114868
100. Culligan PJ, Salamon C, Priestley JL, Shariati A. Porcine dermis compared with polypropylene
mesh for laparoscopic sacrocolpopexy: a randomised controlled trial. Obstet Gynecol
2013;121:143–51. https://doi.org/10.1097/AOG.0b013e31827558dc
101. Claerhout F, De Ridder D, Van Beckevoort D, Coremans G, Veldman J, Lewi P, Deprest J.
Sacrocolpopexy using xenogenic acellular collagen in patients at increased risk for graft-related
complications. Neurourol Urodyn 2010;29:563–7. https://doi.org/10.1002/nau.20805
102. Quiroz LH, Gutman RE, Shippey S, Cundiff GW, Sanses T, Blomquist JL, Handa VL. Abdominal
sacrocolpopexy: anatomic outcomes and complications with Pelvicol, autologous and synthetic graft
materials. Am J Obstet Gynecol 2008;198:557.e1–5. https://doi.org/10.1016/j.ajog.2008.01.050
103. Deprest J, De Ridder D, Roovers JP, Werbrouck E, Coremans G, Claerhout F. Medium term
outcome of laparoscopic sacrocolpopexy with xenografts compared to synthetic grafts. J Urol
2009;182:2362–8. https://doi.org/10.1016/j.juro.2009.07.043
104. PROACT Medical Ltd. Our Products. 2018. URL: www.proactmedical.co.uk/our-products
(last accessed 20 June 2019).
105. Roovers JP, van der Vaart CH, van der Bom JG, van Leeuwen JH, Scholten PC, Heintz AP.
A randomised controlled trial comparing abdominal and vaginal prolapse surgery: effects on
urogenital function. BJOG 2004;111:50–6. https://doi.org/10.1111/j.1471-0528.2004.00001.x
DOI: 10.3310/hta24130 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 13
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hemming et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
113
106. Malandri M, Iordanidou E, Takou M, Moraitis B, Balaxis D. A Randomised Comparison of Two
Vaginal Procedures for the Treatment of Stage Two, or Higher Uterine Prolapse: Hysterectomy
With Mesh Versus Only Mesh Implantation. International Continence Society, October 2012,
Beijing, China, abstract no. 101.
107. Detollenaere RJ, Kreuwel IA, Dijkstra JR, Kluivers KB, van Eijndhoven HW. The impact of sacrospinous
hysteropexy and vaginal hysterectomy with suspension of the uterosacral ligaments on sexual
function in women with uterine prolapse: a secondary analysis of a randomised comparative study.
J Sex Med 2016;13:213–19. https://doi.org/10.1016/j.jsxm.2015.12.006
108. Carramao S, Auge APF, Pacetta AM. A randomised comparison of two vaginal procedures for the
treatment of uterine prolapse using polypropylene mesh: histateroxy versus hysterectomy. Rev Col
Bras Cir 2009;36:65–72.
109. Juneja M, Munday D, Kopetz V, Barry C. Hysterectomy vs No Hysterectomy for Uterine Prolapse in
Conjunction with Posterior Infracococcygeal Colpopexy – A Randomised Pilot Study 12 Months
Review. International Continence Society and International Urogynaecological Association,
23–7 August 2010, Toronto, ON, Canada, abstract no. 692.
110. Dietz V, van der Vaart CH, van der Graaf Y, Heintz P, Schraffordt Koops SE. One-year follow-up
after sacrospinous hysteropexy and vaginal hysterectomy for uterine descent: a randomised study.
Int Urogynecol J 2010;21:209–16. https://doi.org/10.1007/s00192-009-1014-7
111. Rahmanou P, Price N, Jackson SR. Laparoscopic hysteropexy versus vaginal hysterectomy for the
treatment of uterovaginal prolapse: a prospective randomised pilot study. Int Urogynecol J
2015;26:1687–94. https://doi.org/10.1007/s00192-015-2761-2
112. Jeng CJ, Yang YC, Tzeng CR, Shen J, Wang LR. Sexual functioning after vaginal hysterectomy or
transvaginal sacrospinous uterine suspension for uterine prolapse: a comparison. J Reprod Med
2005;50:669–74.
113. Maher CF, Qatawneh AM, Dwyer PL, Carey MP, Cornish A, Schluter PJ. Abdominal sacral
colpopexy or vaginal sacrospinous colpopexy for vaginal vault prolapse: a prospective randomised
study. Am J Obstet Gynecol 2004;190:20–6. https://doi.org/10.1016/j.ajog.2003.08.031
114. Maher CF, Feiner B, Decuyper EM, Nichlos CJ, Hickey KV, O’Rourke P. Laparoscopic sacral
colpopexy versus total vaginal mesh for vaginal vault prolapse: a randomized trial. Am J Obstet
Gynecol 2011;204:360.e1–7. https://doi.org/10.1016/j.ajog.2010.11.016
115. Lim YN, Rosamilia A, Dwyer PL, Alvarez J, Chao F, Murray C, et al. Randomised controlled trial
of post-hysterectomy vaginal vault prolapse treatment with extraperitoneal vaginal uterosacral
ligament suspension with anterior mesh reinforcement vs sacrocolpopexy (open/laparoscopic).
Int Urogynecol J 2012;23:S48–9.
116. Ritchie J, Spencer L. Qualitative Data Analysis for Applied Policy Research. In Bryman A, Burgess RG,
editors. Analysing Qualitative Data. London: Routledge; 1994. pp. 173–94. https://doi.org/10.4324/
9780203413081_chapter_9
117. Snowdon C, Garcia J, Elbourne D. Making sense of randomization; responses of parents of critically
ill babies to random allocation of treatment in a clinical trial. Social Sci Med 1997;45:1337–55.
https://doi.org/10.1016/S0277-9536(97)00063-4
118. Wade J, Donovan JL, Lane JA, Neal DE, Hamdy FC. It’s not just what you say, it’s also how you
say it: opening the ‘black box’ of informed consent appointments in randomised controlled trials.
Soc Sci Med 2009;68:2018–28. https://doi.org/10.1016/j.socscimed.2009.02.023
119. Fung EK, Loré JM. Randomised controlled trials for evaluating surgical questions. Arch Otolaryngol
Head Neck Surg 2002;128:631–4. https://doi.org/10.1001/archotol.128.6.631
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
114
120. McCann S, Campbell M, Entwistle V. Recruitment to clinical trials: a meta-ethnographic synthesis
of studies of reasons for participation. J Health Serv Res Policy 2013;18:233–41. https://doi.org/
10.1177/1355819613483126
121. Jackson CJ, Dixon-Woods M, Eborall H, Kenyon S, Toozs-Hobson P, Tincello DG. Women’s views
and experiences of a patient preference trial in surgery: a qualitative study of the CARPET1 trial.
Clin Trials 2010;7:696–704. https://doi.org/10.1177/1740774510381286
122. Jenkins V, Farewell V, Farewell D, Darmanin J, Wagstaff J, Langridge C, Fallowfield L, TTT Steering
committee. Drivers and barriers to patient participation in RCTs. Br J Cancer 2013;108:1402–7.
https://doi.org/10.1038/bjc.2013.113
DOI: 10.3310/hta24130 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 13
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hemming et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
115

Appendix 1 Additional information for Chapter 2
Final model (Uterine and Vault trials)
The Uterine and Vault trials had the same primary outcome and were analysed using the same statistical
model. The notation followed by the model, used in both trials, is presented in Table 40.
TABLE 39 Comparison between ROME criteria and equivalent questions for the VUE trial questionnaires for
diagnosis of constipation
ROME criteria: any two of Equivalent VUE trial questions
< 3 bowel movements per
week
Stool passing once a week or less
Straining Straining most or all of the time
Lumpy or hard stools Hard stools
Sensation of incomplete
defecation
Feeling that the bowel has not completely emptied most or all of the time
Manual manoeuvring required
to defecate
Manual manoeuvre to empty bowel most or all of the time (splinting of perineum or
vagina, or digital evacuation of the bowel)
Sensation of anorectal
obstruction
No equivalent VUE trial question
TABLE 40 Description of notation for final model for Uterine and Vault trials
Yij Continuous outcome (POP-SS at 12 months) in the j-th subject in the i-th surgeon
β0 Average response in the control group
β1 Treatment effect from the addition of uterine preservation/abdominal vault procedure (treatment effect)
β2 Explanatory variable for baseline POP-SS
β3 Explanatory variable for previous prolapse planned surgery (minimisation)
β4 Explanatory variable for previous incontinence planned surgery (minimisation)
β5 Explanatory variable for age category (minimisation)
Aij Indicator variable equal to 1, if participant has been exposed to uterine preservation/abdominal vault procedure
Bij Coefficient variable for baseline POP-SS
Cij Indicator variable equal to 1, if participant has had previous prolapse planned surgery
Dij Indicator variable equal to 1, if participant has had previous incontinence planned surgery
Eij Indicator variable equal to 1, if participant is 60 years old or over
bi Surgeon-level random effect
εij Residual error term
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The final model is the following:
Yij = β0 + β1Aij + β2Bij + β3Cij + β4Dij + β5Eij + bi + εij (4)
The surgeon-level random effects bi is assumed to be normally distributed with mean 0 and variance σ2A,
i.e. bi ∼ N(0, σ2A). The error term was assumed to be:
εij ∼ N(0, σ2w ). (5)
Unit costs for trial-based economic evaluation
TABLE 41 Anaesthesia costs
Anaesthesia
type Drug
Unit
price (£) Price per
Resource
use
Cost per
average
case (£) Comments Sources
General 1% injection
of propofol
15.36 20-ml
ampoule
1 ampoule 3.07 Based on information
used in PROSPECT
BNF;43 and
Glazener et al.1
100 µg of
fentanyl
6.53 2-ml
ampoule
(50 µg/ml)
1 ampoule 1.31 Based on information
used in PROSPECT
BNF;43 and
Glazener et al.1
Morphine 9.36 1-ml vial 1 vial 0.94 Based on information
used in PROSPECT
BNF;43 and
Glazener et al.1
Sevoflurane
(volatile agent)
125.00 250-ml
bottle
25 ml 12.50 Based on information
used in PROSPECT
BNF;43 and
Glazener et al.1
Laryngeal
mask
29.50 Box of
10 masks
1 mask 2.95 PROACT Medical Ltd,
Corby, UK; disposable
laryngeal airway
PRO-breathe104
Price list from the
manufacturer’s
website
Total general 20.76 Based on cost of
consumables per case
0.5% injection
of anhydrous
bupivacaine
hydrochloride
injection
9.25 4-ml
ampoule
1 ampoule 1.85 Based on information
used in PROSPECT
BNF;43 and
Glazener et al.1
Lidocaine 0.40 10-ml
ampoule
1 ampoule 0.40 Based on information
used in PROSPECT
BNF;43 and
Glazener et al.1
Total cost spinal 2.25 Based on cost of
consumables per case
Cost local Lidocaine 0.40 10-ml
ampoule
1 ampoule 0.40 Based on information
used in PROSPECT
BNF;43 and
Glazener et al.1
Total general and local 21.16 Based on cost of both
general and local
anaesthesia
BNF;43 and
Glazener et al.1
Total general and spinal 23.01 Based on cost of both
general and spinal
anaesthesia
BNF;43 and
Glazener et al.1
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TABLE 42 Cost of further surgery
OPCS HRG Average
unit cost
(£)
Quartile (£)
Code Description Code Description Lower Upper
Anterior or posterior prolapse
P221/
P222/
P223
Anterior and posterior
colporrhaphy and
amputation of cervix uteri
MA03C Major open lower genital tract
procedures, with a CC score of
≥ 3
3204 2599 3690
P228/
P229/
P231
Anterior colporrhaphy and
amputation of cervix uteri
NEC
MA03D Major open lower genital tract
procedures, with a CC score of
0–2
2787 2378 3156
P232 Anterior colporrhaphy –
NEC
MA04C Intermediate open lower genital
tract procedures, with a CC score
of ≥ 3
2599 2040 3062
P233 Posterior colporrhaphy –
NEC
MA04D Intermediate open lower genital
tract procedures, with a CC score
of 0–2
2231 1913 2579
Cost used in analysis: anterior procedures only 2693 2209 3109
Cost used in analysis: posterior procedures only 2231 1913 2579
Cost used in analysis: both anterior and posterior procedures 3204 2599 3690
Apical repair/hysterectomy, vault or uterine suspension
P24.3 Repair of vault of vagina
using abdominal approach
– NEC
MA02A Very major open, upper or lower
genital tract procedures, with a
CC score of ≥ 4
2738 2366 3119
P24.4 Repair of vault of vagina
using vaginal approach –
NEC
MA02B Very major open, upper or lower
genital tract procedures, with a
CC score of 2 or 3
4133 3300 4691
P24.5 Repair of vault of vagina
with mesh using abdominal
approach
MA02C Very major open, upper or lower
genital tract procedures, with a
CC score of 0 or 1
4133 3300 4691
P24.6 Repair of vault of vagina
with mesh using vaginal
approach
MA03C Major open lower genital tract
procedures, with a CC score of
≥ 3
2738 2366 3119
P24.7 Sacrospinous fixation of
vagina
MA03D Major open lower genital tract
procedures, with a CC score of
0–2
4133 3300 4691
P24.2 Sacrocolpopexy MA03C&D Major open lower genital tract
procedures, with a CC score of
0–2 and ≥ 3
Same as above two rows
Q08.2 Vaginal hysterectomy and
excision of periuterine
tissue – NEC
MA07E Major open upper genital tract
procedures, with a CC score of
≥ 5
6289 4308 7000
Q54.4 Suspension of uterus using
mesh – NEC open
MA07F Major open upper genital tract
procedures, with a CC score of
3 or 4
4572 3669 5069
MA07G Major open upper genital tract
procedures, with a CC score of
0–2
3745 3084 4295
Q54.1 Suspension of uterus – NEC MA11 Intermediate open upper genital
tract procedures
3008 2429 3393
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TABLE 42 Cost of further surgery (continued )
OPCS HRG Average
unit cost
(£)
Quartile (£)
Code Description Code Description Lower Upper
Q54.4 Suspension of uterus using
mesh – NEC laparoscopy
MA08A Major, laparoscopic or endoscopic,
upper genital tract procedures,
with a CC score of ≥ 2
3719 3024 4173
Q54.4 Suspension of uterus using
mesh – NEC laparoscopy
MA08B Major, laparoscopic or
endoscopic, upper genital tract
procedures, with a CC score of
0–1
3228 2678 3685
Average cost of apical procedures 4162 3335 4692
P241 Repair of vault of vagina
using combined abdominal
and vaginal approach
MA01Z Complex open, upper or lower
genital tract procedures
5813 4067 7961
MA02A Very major open, upper or lower
genital tract procedures, with a
CC score of ≥ 4a
6165 4842 7183
MA02B Very major open, upper or lower
genital tract procedures, with a
CC score of 2 or 3
4875 4153 5238
MA02C Very major open, upper or lower
genital tract procedures, with a
CC score of 0 or 1
4189 3519 4732
Average cost of two or more of the apical procedures (included hysterectomy, uterine
preservation and vault procedures)b
5261 4145 6279
Urinary incontinence procedures
M522/
M523
Retropubic suspension of
neck of bladder
LB59Z Major, open or laparoscopic,
bladder neck procedures (female)
4037 2942 4601
Urinary incontinence sling procedures
M533 Introduction of tension-free
vaginal tape
LB51A Vaginal tape operations for
urinary incontinence, with a CC
score of ≥ 2
2220 1732 2713
M536 Introduction of
transobturator tape
LB51B Vaginal tape operations for
urinary incontinence, with a CC
score of 0 or 1
1972 1660 2188
Average cost of sling incontinence surgery 2096 1696 2451
WF01A-
WF02B
Consultant-led or
non-consultant-led visit
502 Gynaecology 130 96 145
CC, complications and comorbidities; N/A, not applicable; NEC, not elsewhere classifiable.
a If three procedures, this cost was used.
b Average of the four identified HRG codes.
Source for all procedures is NHS Reference Costs 2015–16 spell tariffs.45
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TABLE 43 Cost of permanent catheters
Resource Product Manufacturer
Pack
size
Packs for
1 year
Unit cost
(2017) (£)
Total
cost (£) Source
Sterile catheterisation
insertion pack
Cath-It (one pack) Richardson
Healthcare Ltd,
Borehamwood, UK
1 4 1.98 7.92 NHS EDT
June 201749
Sterile lubricant for
instillation
OptiLube sterile
lubricating jelly
(1 × 11-ml syringe)
Optimum Medical
Ltd, Leeds, UK
1 4 0.96 3.84 NHS EDT
June 201749
Indwelling catheter Folysil X-tra (size 14),
pack size 1
Coloplast A/S,
Humlebaek,
Denmark
1 6 (4+ 2
spares)
6.37 38.22 NHS EDT
June 201749
Leg bags (assumes
patients have
continuous drainage)
Simpla® Profile,
500ml, 25-cm tube
Coloplast 10 6 25.66 153.96 NHS EDT
June 201749
Catheter stabilisation
device
Leg bag holder –
aqua-sleeve, size
standard
Coloplast 4 2 8.50 17.00 NHS EDT
June 201749
Night drainage bags Single use, Prosys®
(2)
Clinisupplies Ltd,
Harrow, UK
10 37 3.06 113.22 NHS EDT
June 201749
Total Average annual cost 334.16
Cost per week 6.43
EDT, electronic drug tariff.
TABLE 44 Cost of disposable catheters
Product Manufacturer
Pack
size
Packs for
1 yeara
Unit cost
(2017) (£)
Total
cost (£) Source
hi-slip® Plus Bullen Healthcare, Liverpool,
UK
30 37 32.86 1215.82 NHS EDT
201749
Advance
catheter
Hollister Ltd, Wokingham, UK 25 44 36.40 1601.60 NHS EDT
201749
SpeediCath®
Compact
Coloplast 30 37 46.77 1730.49 NHS EDT
201749
SpeediCath Coloplast 30 37 46.17 1708.29 NHS EDT
201749
HYDROSIL® Rochester Medical,
Stewartville, MN, USA
30 37 44.06 1630.22 NHS EDT
201749
LoFric® Sense™ Wellspect Healthcare,
Mölndal, Sweden
30 37 44.60 1650.20 NHS EDT
201749
Average cost for 12 months 1589.44
Cost for 1 week 30.56
EDT, electronic drug tariff.
a Assumes average usage of three per day.
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TABLE 45 Antibiotic costs
Name Dose
Cost (NHS
indicative price, £) Number Cost per tablet (£)a
Nitrofurantoin, 100-mg tablets 100 mg 16.80 28 tablets 0.60
Amoxicillin, 500-mg capsules 500 mg 0.91 15 capsules 0.06
Cefalexin, 500-mg capsules 500 mg 1.43 21 capsules 0.07
Ciprofloxacin, 250-mg tablets 250 mg 1.50 20 tablets 0.08
Clindamycin, 150-mg capsules 150 mg 9.00 24 capsules 0.38
Darifenacin (as darifenacin hydrobromide),
7.5-mg tablets
7.5 mg 25.48 28 tablets 0.91
Flucloxacillin, 250-mg capsules 250 mg 1.31 28 tablets 0.05
Trimethoprim, 100-mg tablets 200 mg 1.15 14 tablets 0.08
Phenoxymethylpenicillin, 250-mg tablets 250 mg 1.06 28 tablets 0.04
Duloxetine, 20-mg gastroresistant capsules 20 mg 2.94 28 tablets 0.11
Average cost per tablet 0.24
a The source for all drug costs was the British National Formulary, 2017 edition.43
TABLE 46 Costs for pessariesa
Type of pessary Price (£) for onea
Ring pessary
Bioteque America (San Jose, CA, USA) 20.00
GBUK Healthcare (Selby, UK) 19.00
Milex (CooperSurgical, Inc., Trumball, CT, USA) 21.28
Average 20.09
Shelf/Gelhorn pessary
Bioteque America 21.40
GBUK 20.49
Milex 22.92
Average 21.54
a Pessary costs were obtained from Glazener et al.;1 the British National Formulary, 2017 edition;43 the Electronic Drug
Tariff, 2017;49 and manufacturers’ price lists.
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Appendix 2 Additional information for Chapter 3
TABLE 47 Centres, surgeons and recruitment
Centres Surgeons
Treatment (n)
Uterine
preservation
(N= 282)
Vaginal
hysterectomy
(N= 283)
James Cook University Paul Ballard and Aethele Khunda 34 36
Aberdeen Christine Hemming and Kevin Cooper 29 28
Manchester Anthony Smith, Fiona Reid, Karen Ward, Carolyn North,
Melissa Bradbury and Rohna Kearney
13 13
University Hospital North Tees Santhosh Puthuraya and Elaine Gouk 14 11
Torbay Subramanian Narayanan 10 12
Calderdale Royal Hospital Yi Ling Chan, Anu Bondili and Maged Shendy 10 11
Hinchingbrooke Hospital Ashish Pradhan, Helen Johnson and Umar Hussain 10 11
Croydon University Ranee Thakar, Madhu Naidu and Abdul Sultan 9 12
Queen Alexandra Hospital,
Portsmouth
Claire Burton, Christopher Guyer, Rebecca Hardcastle
and Ali Ahmed
11 10
South Tees Paul Ballard and Aethele Khunda 11 10
Basingstoke Christian Phillips and Tim Sayer 10 11
Derriford Hospital, Plymouth Robert Freeman, Luigi Bombieri and A Dua 10 7
Crosshouse Wael Agur, Ashraf Habib, Inna Sokolova,
Mohamed Riad and David Rae
7 10
Birmingham Philip Toozs-Hobson, Pallavi Latthe and
Supriya Bulchandani
8 8
Royal Preston Brice Rodriguez and Sanjeev Prashar 8 8
Musgrove Park Adel Naguib 7 7
Leicester General Douglas Tincello 9 5
Gloucester Mark James 6 7
Addenbrooke Mark Slack, Rohna Kearney, Vladimir Revicky and
Alexandros Derpapas
8 4
Royal Derby Jaydip Dasgupta and Victor Chilaka 6 5
Arrowe Park Tom Aust, Patrick Doyle and Jeremy Weetch 6 5
Bradford Carmel Ramage and Sue Calvert 4 5
Harrogate and District Tracy Jackson and Adrian Barnett 4 4
Liverpool Ruben Trochez, Gillian Fowler and E Adams 5 3
New Cross Hospital,
Wolverhampton
Khaled Afifi, Ayman Elnaqa and Charles Cox 2 6
Jessop Wing, Sheffield Stephen Radley and Swati Jha 4 3
Heart of England Gurminder Matharu and Afshan Khaja 3 3
Royal Victoria Infirmary Karen Brown, Karen Rose and Paul Hilton 3 3
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TABLE 47 Centres, surgeons and recruitment (continued )
Centres Surgeons
Treatment (n)
Uterine
preservation
(N= 282)
Vaginal
hysterectomy
(N= 283)
Southport and Ormskirk Shaireen Aleem 2 3
Fife Chu Lim and Carolyn McKinley 3 2
North Cumbria Mohamed Matar 2 3
Kettering General Sunil Doshi 2 2
Countess of Chester Mofid Ibraheim and Lorraine Dinardo 2 2
Barnsley Meenakshi Dass and Khaled Farag 1 2
UH North Staffordshire Jason Cooper 2 1
Hull and East Yorkshire Jagdish Gandhi 2 0
Worcester Acute Deepali Sinha and Angus Thomson 0 2
Cornwall Hospitals Farah Lone and Rob Holmes 0 2
Southmead Hospital Chendrimada Madhu 1 1
Royal Bolton Philip Chia and Abimbola Williams 1 1
Pinderfields Kathryn Fishwick 1 1
Sunderland Royal Jonathan Chamberlain 1 0
Medway Maritime Hospital Maya Basu and Hasib Ahmed 1 0
Dartford and Gravesham Rob MacDermott, Angeli Thallon, Andreas Lesseps
and Abhisheck Gupta
0 1
UH North Durham Fiona Lloyd, Velur Sindhu, Seema Sen and Robert Wood 0 1
Luton and Dunstable
University
Abdalla Fayyad 0 1
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TABLE 48 Approached participants
Participants n (%)
Approached 1544 (100.0)
Randomised 565 (36.6)
Not included 979 (63.4)
Ineligible 177 (11.5)
Declined 774 (50.1)
Other reasons/missed appointment 28 (1.8)
TABLE 49 Reasons for non-inclusion in the trial
Reason n (%)
Ineligible 177 (100)
A specific operation is necessary 77 (43.5)
No prolapse 38 (21.5)
Unsuitable owing to medical history 28 (15.8)
Not suitable for surgery 13 (7.3)
Uterine pathology 11 (6.2)
Change of prolapse type from original diagnosis 10 (5.6)
Unable to give informed consent 9 (5.1)
Unable to complete study questionnaires 9 (5.1)
Operation cancelled 6 (3.4)
Declined 774 (100)
Wanted a hysterectomy 324 (41.9)
Declined/refused surgery 219 (28.3)
Did not want to participate in the study 154 (19.9)
Did not want to be randomised 149 (19.3)
Wanted a uterine preservation 107 (13.8)
Wanted to try a pessary 34 (4.4)
Wished to go with surgeon’s choice 25 (3.2)
Wanted a vaginal procedure 21 (2.7)
Did not want mesh 21 (2.7)
Wanted an abdominal procedure 16 (2.1)
Wanted to complete questionnaires 9 (1.2)
Changed mind after initially consenting 7 (0.9)
Other reasons/missed appointment 28 (3.6)
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TABLE 50 Baseline characteristics, by randomised allocation
Characteristics
Treatment, mean (SD); N
Uterine preservation (N= 280) Vaginal hysterectomy (N= 283)
Number of
Normal vaginal deliveries 2.3 (1.3); 271 2.3 (1.1); 277
Caesareans before labour 0.1 (0.3); 188 0.1 (0.3); 191
Breech vaginal deliveries 0.0 (0.2); 188 0.0 (0.2); 188
Forceps deliveries 0.4 (0.6); 208 0.3 (0.5); 206
Caesareans during labour 0.0 (0.2); 186 0.1 (0.3); 197
Vacuum deliveries 0.0 (0.2); 185 0.0 (0.2); 187
Previous anterior surgery
Mesh used 1 (0.4) 3 (1.1)
TABLE 51 Preoperative objective measurements (POP-Q continuous) at baseline
Measurement
Treatment
Uterine preservation (N= 280) Vaginal hysterectomy (N= 283)
POP-Q measurement (cm), mean (SD); N [range]
Ba 1.7 (1.8); 265 [–2.0 to 6.0] 2.0 (1.9); 267 [–3.0 to 6.0]
C –0.4 (2.6); 265 [–6.0 to 6.0] 0.4 (2.7); 267 [–6.0 to 6.0]
Bp –1.4 (1.7); 258 [–7.0 to 6.0] –1.1 (2.3); 265 [–8.0 to 6.0]
Total vaginal length 8.6 (1.4); 251 [3.0 to 13.0] 8.5 (1.4); 250 [2.0 to 12.0]
Overall POP-Q stage, n (%)
1 2 (0.7) 1 (0.4)
2a 11 (3.9) 12 (4.2)
2b 115 (41.1) 116 (41.0)
3 141 (50.4) 137 (48.4)
4 5 (1.8) 16 (5.7)
Missing 6 (2.1) 1 (0.4)
Stage 2b or more 261 (93.2) 269 (95.1)
Ba, leading anterior edge; Bp, leading posterior edge; C, cervix/vault.
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TABLE 52 Urinary symptoms
Symptom
Treatment, n (%)
Uterine preservation (N= 280) Vaginal hysterectomy (N= 283)
UI
None 24 (8.6) 21 (7.4)
Slight 109 (38.9) 115 (40.6)
Moderate 80 (28.6) 84 (29.7)
Severe 18 (6.4) 10 (3.5)
Very severe 2 (0.7) 2 (0.7)
Missing 47 (16.8) 51 (18.0)
Stress UI 37 (13.2) 29 (10.2)
Missing 43 (15.4) 48 (17.0)
Urge UI missing 9 (3.2) 11 (3.9)
Mixed UI 22 (7.9) 10 (3.5)
Missing 7 (2.5) 13 (4.6)
UI for no reason 9 (3.2) 6 (2.1)
Missing 8 (2.9) 16 (5.7)
UI when asleep 4 (1.4) 5 (1.8)
Missing 37 (13.2) 46 (16.3)
UI with sex 12 (4.3) 5 (1.8)
Missing 115 (41.1) 118 (41.7)
UI, urinary incontinence.
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Appendix 3 Additional information for Chapter 4
TABLE 53 Mesh use (for those that had surgery)
Type of surgery
Treatment, n (%); N
Uterine preservation (N= 280) Vaginal hysterectomy (N= 283)
Apical surgery
No mesh 157 (63.0); 249 242 (92.7); 261
Synthetic non-absorbable 81 (32.5); 249 6 (2.3); 261
Biological 5 (2.0); 249 2 (0.8); 261
Mesh kit 0 (0); 249 1 (0.4); 261
Missing 6 (2.4); 249 10 (3.8); 261
Concomitant surgery
Anterior repair only
No mesh 106 (93.8); 113 139 (97.9); 142
Synthetic non-absorbable 2 (1.8); 113 0 (0); 142
Biological 2 (1.8); 113 2 (1.4); 142
Missing 3 (2.7); 113 1 (0.7); 142
Posterior repair only
No mesh 17 (81.0); 21 21 (95.5); 22
Synthetic non-absorbable 3 (14.3); 21 1 (4.5); 22
Biological 1 (4.8); 21 0 (0); 22
Both anterior and posterior repair
Anterior compartment only
No mesh 78 (95.1); 82 84 (98.8); 85
Synthetic non-absorbable 1 (1.2); 82 1 (1.2); 85
Biological 1 (1.2); 82 0 (0); 85
Missing 2 (2.4); 82 0 (0); 85
Posterior compartment only
No mesh 75 (91.5); 82 84 (98.8); 85
Synthetic non-absorbable 4 (4.9); 82 1 (1.2); 85
Biological 2 (2.4); 82 0 (0); 85
Missing 1 (1.2); 82 0 (0); 85
Continence procedure
No mesh 1 (14.3); 7 2 (22.2); 9
Synthetic non-absorbable 6 (85.7); 7 7 (77.8); 9
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TABLE 54 Surgical characteristics
Characteristic
Treatment, n (%)
Uterine preservation (N= 280) Vaginal hysterectomy (N= 283)
Grade of operating gynaecologist
Consultant 225 (80.4) 189 (66.8)
Trainee doctor 24 (8.6) 53 (18.7)
Speciality doctor 15 (5.4) 28 (9.9)
Missing 16 (5.7) 13 (4.6)
Grade of anaesthetist
Consultant 195 (69.6) 202 (71.4)
Specialty doctor 47 (16.8) 43 (15.2)
Trainee doctor 19 (6.8) 23 (8.1)
Missing 19 (6.8) 15 (5.3)
Anaesthetica
General 225 (80.4) 227 (80.2)
Spinal/epidural 48 (17.1) 48 (17.0)
Local 19 (6.8) 34 (12.0)
Other 1 (0.4) 4 (1.4)
Prophylatic antibiotic used 253 (90.4) 265 (93.6)
Catheter inserted in theatre 252 (90.0) 255 (90.1)
Vaginal pack 185 (66.1) 214 (75.6)
Urinary catheter
Urethral 250 (89.3) 255 (90.1)
None 4 (1.4) 4 (1.4)
Suprapubic 1 (0.4) 1 (0.4)
Missing 25 (8.9) 23 (8.1)
a More than one type of anaesthetic could be used.
TABLE 55 Intervention details
Details
Treatment
Effect size
(95% CI); p-value
Uterine preservation (N= 280) Vaginal hysterectomy (N= 283)
Mean (SD); N
Median
(P25–75)a Mean (SD); N
Median
(P25–75)a
Duration of operation
(minutes)
113.7 (50.3);
253
102.0
(80.0–135.0)
103.0 (33.1);
259
98.0
(80.0–125.0)
9.79 (3.50 to 16.07);
0.002b
Length of stay (days) 1.9 (1.2); 262 2.0 (1.0–2.0) 1.9 (1.1); 269 2.0 (1.0–2.0) 0.99 (0.87 to 1.12);
0.8912c
Blood loss (ml) 125.0 (110.7);
246
100.0
(50.0–150.0)
166.3 (147.3);
261
125.0
(100.0–200.0)
–42.20 (–62.68 to
–21.73); < 0.001a
Time to surgery (days) 61.2 (70.8);
269
39.0
(10.0–85.0)
56.7 (61.6);
261
40.0 (8.0–89.0)
a P25–75 is the 25th to the 75th percentile range.
b Effect size is a MD adjusted for the minimisation variables and fitting surgeon as a random effect.
c Effect size is an incidence rate ratio adjusted for the minimisation variables and fitting surgeon as a random effect.
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FIGURE 20 Distribution of individual POP-SSs at (a) baseline and at follow-up, that is, (b) at 6 months after surgery
and (c) at 12 months after randomisation. (continued )
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TABLE 56 Individual prolapse symptoms at 6 months after surgery
6 months after surgery outcomes
Treatment
Uterine preservation
(N= 280)
Vaginal hysterectomy
(N= 283)
Symptomatic, n (%); N
Number of women with symptoms 192 (81.0); 238 194 (79.0); 246
Number of women without symptoms 46 (19.0); 238 52 (21.0); 246
Individual prolapse symptoms, n (%); N
Bowel not empty (any) 137 (100.0); 137 150 (100.0); 150
Bowel not empty (most/all of the time) 30 (13.0); 240 26 (11.0); 246
Bladder not empty (any) 127 (100.0); 127 117 (100.0); 117
Bladder not empty (most/all of the time) 29 (12.0); 237 19 (8.0); 246
Strain to empty bladder (any) 84 (100.0); 84 77 (100.0); 77
Strain to empty bladder (most/all of the time) 19 (8.0); 237 10 (4.0); 246
Dragging in back (any) 80 (100.0); 80 66 (100.0); 66
Dragging in back (most/all of the time) 15 (6.0); 238 8 (3.0); 243
Dragging in abdomen (any) 73 (100.0); 73 62 (100.0); 62
Dragging in abdomen (most/all of the time) 15 (6.0); 237 8 (3.0); 245
Something coming down (any) 72 (100.0); 72 61 (100.0); 61
Something coming down (most/all of the time) 26 (11.0); 236 16 (7.0); 245
Uncomfortable feeling or pain when standing (any) 50 (100.0); 50 53 (100.0); 53
Uncomfortable feeling or pain when standing
(most/all of the time)
16 (7.0); 236 11 (4.0); 245
Most bothersome symptom, n (%); N
Bowel not empty 59 (43.0); 137 49 (40.0); 122
Bladder not empty 26 (19.0); 137 24 (20.0); 122
Something coming down 21 (15.0); 137 19 (16.0); 122
Dragging in back 15 (11.0); 137 15 (12.0); 122
Strain to empty bladder 8 (6.0); 137 8 (7.0); 122
Dragging in abdomen 5 (4.0); 137 2 (2.0); 122
Uncomfortable feeling or pain when standing 3 (2.0); 137 5 (4.0); 122
Which symptom causes most bother not applicable 92 (40.0); 229 113 (48.0); 235
EQ-5D
Mean (SD); N 0.844 (0.229); 228 0.878 (0.192); 244
Visual Scale, mean (SD); N 80.2 (17.0); 239 82.1 (16.2); 247
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TABLE 57 POP-Q continuous outcomes at 12 months after surgery
Outcome
Treatment
Uterine preservation (N= 280) Vaginal hysterectomy (N= 283)
POP-Q measurement (cm), mean (SD); N [range]
Ba –1.3 (1.7); 232 [–6.0 to 6.0] –1.3 (2.0); 225 [–3.0 to 6.0]
C –6.1 (2.5); 230 [–10.0 to 4.0] –6.2 (2.9); 225 [–10.0 to 6.0]
Bp –2.5 (1.1); 229 [–9.0 to 4.0] –2.1 (1.5); 226 [–8.0 to 6.0]
Total vaginal length 8.3 (1.3); 222 [4.0 to 12.0] 7.9 (1.2); 221 [4.0 to 11.0]
Change in D –3.6 (2.8); 192 [–15.0 to 3.0]
Overall POP-Q individual stage, n (%); N
Stage 0 50 (21.5); 233 45 (19.7); 229
Stage 1 68 (29.2); 233 59 (25.8); 229
Stage 2a 41 (17.6); 233 47 (20.5); 229
Stage 2b 61 (26.2); 233 54 (23.6); 229
Stage 3 12 (5.2); 233 16 (7.0); 229
Stage 4 1 (0.4); 233 8 (3.5); 229
Ba, leading anterior edge; Bp, leading posterior edge; C, cervix/vault; D, posterior fornix.
TABLE 58 Urinary symptoms at 12 months after randomisation
Symptom
Treatment, n (%); N
Uterine preservation vs. vaginal hysterectomy,
effect size (95% CI); p-value
Uterine
preservation
(N= 280)
Vaginal
hysterectomy
(N= 283)
SUI 11 (5.8); 189 6 (3.2); 190 2.04 (0.72 to 5.81); 0.18
Mixed UI 9 (3.9); 232 1 (0.4); 238
UI for no reason 0 (0) 2 (0.9); 232
UI when asleep 3 (1.5); 194 2 (1.0); 199
UI with sex 3 (2.2); 137 1 (0.7); 137
SUI, stress urinary incontinence; UI, urinary incontinence.
TABLE 59 Time to further surgery
Time to further
surgery
Treatment
Effect size
(95% CI);
p-value
Uterine preservation (N= 280) Vaginal hysterectomy (N= 283)
Mean (SD); N Median (P25–75)a Mean (SD); N Median (P25–75)a
Number of days 290.1 (149.6); 16 259.0
(183.5–363.5)
263.2 (91.7); 10 306.5
(231.0–325.0)
1.66 (0.80 to
3.44); 0.177b
a P25–75 is the 25th to the 75th percentile range.
b Effect size is a hazard ratio, adjusted for minimisation variables and fitting surgeon as a random effect.
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TABLE 60 Subgroup analyses of POP-SSs at 12 months after randomisation
Subgroup
Treatment, mean (SD); N
Effect sizea (95% CI); p-value
Uterine preservation
(N= 280)
Vaginal hysterectomy
(N= 283)
Age group (years)
< 60 years 5.7 (6.1); 68 4.0 (4.9); 62 1.46 (–0.17 to 3.09); 0.08
≥ 60 years 3.6 (4.1); 162 4.3 (5.4); 176
Previous incontinence surgery
Yes 3.3 (2.6); 7 2.9 (4.1); 8 0.53 (–4.31 to 5.37); 0.83
No 4.2 (4.9); 223 4.2 (5.3); 230
Previous anterior/posterior surgery
Yes 4.3 (4.9); 196 4.2 (5.3); 205 –0.02 (–0.95 to 0.91); 0.97
No 3.8 (4.7); 34 3.9 (5.0); 33
a The effect size is presented as a MD for continuous variables and an OR for binary variables (uterine preservation vs.
vaginal hysterectomy), adjusted for baseline when available and minimisation variables.
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Appendix 4 Additional information for Chapter 5
TABLE 61 Intervention resource use and costs for the Uterine trial
Intervention
Resource usage, n (%); N
Costs (£)
Mean cost (SD); N Uterine preservation
vs. vaginal
hysterectomyUterine
preservation
(N= 280)
Vaginal
hysterectomy
(N= 283)
Uterine
preservation
(N= 280)
Vaginal
hysterectomy
(N= 283) MD 95% CI
Number entering
surgery
264 (94); 280 270 (95); 283
Anaesthesia 264 (100); 264 270 (100); 270 18.10 (6.71);
264
17.85 (6.93);
270
Theatre overheads 264 (100); 264 270 (100); 270 420.19 (0.00);
264
420.19 (0.00);
270
Mesh for apical
prolapse
86 (33); 264 9 (3); 270
Mesh for concomitant
anterior
6 (2); 264 3 (1); 270
Mesh for concomitant
posterior
11 (4); 264 2 (1); 270
Mesh for prolapse cost 52.17 (99.13);
264
10.50 (69.61);
270
Incontinence mesh 6 (2); 264 7 (3); 270 2.52 (16.59);
264
2.88 (17.69);
270
Return to theatre 1 (0); 264 2 (1); 270 3.50 (56.81);
264
6.84 (79.29);
270
Catheterisation 252 (95); 264 256 (95); 270 6.08 (1.33); 264 6.04 (1.42); 270
Pain relief 264 (100); 264 270 (100); 270 1.79 (1.96); 264 1.67 (1.87); 270
Laxatives 167 (63); 264 162 (60); 270 1.24 (0.95); 264 1.18 (0.96); 270
Antibiotics 253 (96); 264 264 (98); 269 1.02 (0.21); 264 1.04 (0.13); 269
Vaginal pack 189 (72); 264 217 (80); 270 3.34 (2.11); 264 3.75 (1.86); 270
Resource
usage, mean
(SD); N
Resource
usage, mean
(SD); N
Gynaecologist time
(minutes)
113.05 (49.40);
265
103.20 (32.46);
270
267.49
(123.61); 264
251.69 (98.65);
270
Anaesthetist time
(minutes)
113.05 (49.40);
265
103.20 (32.46);
270
229.98
(117.74); 264
214.16 (87.89);
270
Nurse time (minutes) 113.05 (49.40);
265
103.20 (32.46);
270
304.17
(132.92); 265
277.66 (87.34);
270
Length of stay (days) 1.90 (1.23); 264 1.89 (1.14); 270 339.69
(220.27); 264
338.77
(204.15); 270
Total intervention costsa 1213.04
(472.08); 264
1116.18
(371.28); 270
91.59 –5.16 to
178.01
a The effect size was based on GLM regression with log-link and gamma family.
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TABLE 62 Hospital resource use and costs for the Uterine trial (postcode verified)
Hospital resource use
(postcode verified)
Resource usage, n (%); N
Costs (£)
Mean costs (SD); N Uterine
preservation vs.
vaginal
hysterectomyUterine
preservation
(N= 280)
Vaginal
hysterectomy
(N= 283)
Uterine
preservation
(N= 280)
Vaginal
hysterectomy
(N= 283) MD 95% CI
New prolapse
procedure
16 (6); 265 8 (3); 269 237.74 (971.53);
265
93.69 (570.16);
269
179.27 38.47 to
320.07
Anterior only 4 (2); 265 1 (0); 269
Posterior only 1 (0); 265 4 (1); 269
Apical only 7 (3); 265 2 (1); 269
Anterior and posterior 1 (0); 265 0 (0); 269
Anterior and apical 2 (1); 265 0 (0); 269
Posterior and apical 0 (0); 265 1 (0); 269
Anterior and posterior
and apical
1 (0); 265 0 (0); 269
New UI procedure 3 (1); 265 3 (1); 269 23.73 (222.17);
265
23.38 (220.52);
269
–6.00 –56.73 to
44.72
Sling 3 (1); 265 3 (1); 269
Abdominal 0 (0); 265 0 (0); 269
Botox 0 (0); 265 0 (0); 269
Injectable 0 (0); 265 0 (0); 269
Hospital admission
other (including SAE)
10 (4); 282 9 (3); 283 55.30 (437.13);
279
58.60 (554.81);
283
–7.45 –113.11
to 98.21
Total hospital
admission costsa
319.69
(1073.49); 265
178.71
(839.97); 269
165.72 –39.00 to
370.45
OLS, ordinary least squares; UI, urinary incontinence.
a The effect size was based on OLS linear regression as the gamma family, log-link does not converge.
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TABLE 63 Resource use and costs for consultations with health professionals for the Uterine trial (patient reported)
Other consultations
(participant reported
number of consultations)
Resource usage, mean (SD); na
Costs (£)
Mean costs (SD); nb Uterine
preservation
vs. vaginal
hysterectomyUterine
preservation
(N= 280)
Vaginal
hysterectomy
(N= 283)
Uterine
preservation
(N= 280)
Vaginal
hysterectomy
(N= 283) MD 95% CI
Outpatient consultations 1.67 (1.04); 69 1.74 (1.22); 54 88.23 (140.33);
183
60.38 (133.69);
192
GP 1.73 (1.65); 55 2.06 (1.55); 51 18.59 (43.07);
184
17.91 (40.59);
199
Practice nurse 2.17 (1.70); 12 1.67 (0.87); 9 2.51 (10.83);
150
1.32 (6.15);
165
District or incontinence
nurse
1.71 (1.11); 7 1.75 (0.96); 4 3.14 (16.46);
145
1.67 (11.59);
159
Physiotherapy (practice) 2.50 (0.71); 2 2.00 (N/A); 1 1.21 (10.33);
140
0.43 (5.41);
158
Physiotherapy (hospital) 2.21 (1.63); 14 3.17 (1.64); 12 7.12 (27.55);
148
7.98 (31.83);
162
Other consultations
(participant reported)
24.10 (76.25);
126
16.67 (86.26);
149
Total cost professional
consultationsc
112.59 (179.45);
219
85.83 (169.92);
227
21.74 –17.96
to 61.45
OLS, ordinary least squares.
a For resource use, n refers to the number of women reporting seeing the health professional.
b For costs, n refers to the number of women for whom data were available. See assumptions in Chapter 2 for
more details.
c The effect size was based on OLS linear regression as the gamma family, log-link does not converge.
DOI: 10.3310/hta24130 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 13
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hemming et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
139
TABLE 64 Treatment and medication costs
Other treatments and
medications (participant
reported)
Resource usage, n (%); Na Costs (£)
Uterine
preservation
(N= 280)
Vaginal
hysterectomy
(N= 283)
Mean costs (SD); nb Uterine
preservation vs.
vaginal
hysterectomyUterine
preservation
(N= 280)
Vaginal
hysterectomy
(N= 283) MD 95% CI
Oestrogens 31 (16); 191 31 (15); 203 13.02 (71.08);
176
25.57 (112.49);
189
Antibiotics 29 (15); 191 38 (19); 198 0.24 (0.73);
182
1.35 (8.33);
183
Bladder medications 11 (6); 178 15 (8); 188 0.21 (1.89);
173
0.21 (1.89);
177
Reusable/intermittent
catheter
5 (3); 180 4 (2); 204 0.22 (1.65);
179
0.06 (0.64);
202
Ring pessary 14 (8); 185 9 (4); 205 1.52 (5.33);
185
0.88 (4.13);
205
Shelf pessary 8 (4); 181 4 (2); 205 0.95 (4.44);
181
0.42 (2.99);
205
Permanent catheter 1 (1); 177 2 (1); 201 0.52 (3.95);
177
0.15 (1.52);
201
Total other treatmentsc 13.74 (64.71);
215
24.22 (108.51);
224
–11.66 –28.92
to 5.60
a N refers to the number of women for whom it was possible to calculate and/or assume a resource use for.
See description in Chapter 2, Methods for assumptions made.
b N refers to the number of women for whom it was possible to calculate and/or assume a resource use for. See
description in Chapter 2, Methods for assumptions made. Note that in most cases N (costs) < N (resource use). This is
because, although it may be known whether or not women received treatment (e.g. oestrogen), it may not be known
how long they were treated for. Therefore, the sample for costs is less than the sample for resource use.
c The effect size is based on GLM regression, with log-link and gamma family.
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TABLE 65 Wider-perspective costs
Participant-incurred
costs
Resource usage, n (%); N Costs (£)
Uterine
preservation
(N= 280)
Vaginal
hysterectomy
(N= 283)
Mean costs (SD); N Uterine
preservation
vs. vaginal
hysterectomyaUterine
preservation
(N= 280)
Vaginal
hysterectomy
(N= 283) MD 95% CI
Opportunity cost of time and travel
Inpatient stays 91 (26); 262 88 (23); 266
Outpatient
consultations
33 (52); 185 23 (51); 194
Primary care
consultations
12 (25); 202 11 (22); 212
Subtotal 127 (80); 164 112 (72); 174 18 5 to 31
Purchase of over-the-
counter medication
17 (9); 197 12 (6); 209 2 (12); 190 1 (6); 207
Private medical care 3 (2); 189 2 (1); 200 43 (515); 188 2 (19); 200
Other expenses 7 (4); 190 2 (1); 200 2 (14); 188 2 (28); 200
Absence from paid employment
Currently in
employment
74 (33); 224 72 (31); 234
Reported needing
time off workb
64 (86); 74 66 (91); 72
Days of sick leaveb,c 35.23 (65.25);
64
22.36 (40.43);
66
1163 (4267);
207
707 (2591);
225
856 –975 to 2688
Total participant
perspective costs
1266 (4127);
129
460 (1505);
152
609 47 to 1172
Total NHS perspective
costs (Table 18)
1643 (1302);
207
1345 (754);
217
292 68 to 517
Wider-perspective
costs (NHS and
personal)
2852 (4629);
129
1774 (1726);
151
911 359 to 1463
OLS, ordinary least squares.
a All models report effect sizes based on gamma distribution, log-link unless otherwise stated for issues of convergence,
in which case OLS is used.
b This row should be interpreted as the proportion of women who reported being in paid employment, who also reported
the need to take time off from work for prolapse-related symptoms at completion of their 12-month follow-up
questionnaire.
c Days of sick leave reports the mean (SD) number of days sick leave required among those women who reported needing
to take time off work.
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FIGURE 22 Scatterplot (a) and CEAC (b) for a seemingly unrelated regression (imputed data set).
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FIGURE 23 Scatterplot (a) and CEAC (b) for a wider-perspective analysis of costs (imputed data set).
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FIGURE 24 Scatterplot (a) and CEAC (b) using HRG tariffs instead of component costing for index interventions
(imputed data set).
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FIGURE 25 Scatterplot (a) and CEAC QALY calculation (b) sensitivity analysis 1 (imputed data set).
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FIGURE 26 Scatterplot (a) and CEAC QALY calculation (b) sensitivity analysis 2 (imputed data set).
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FIGURE 27 Scatterplot (a) and CEAC QALY calculation (b) sensitivity analysis 3 (imputed data set).
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FIGURE 28 Scatterplot (a) and CEAC (b) complete-case analysis of cost and QALY pairs.
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FIGURE 29 Scatterplot (a) and CEAC (b) for a seemingly unrelated regression on complete-case analysis of cost and
QALY pairs.
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Appendix 5 Additional information for Chapter 6
TABLE 66 Recruitment, by centre and randomised allocation
Centres recruiting Staff
Treatment (n)
Abdominal
vault (N= 105)a
Vaginal vault
(N= 104)
Basingstoke Christian Phillips and Tim Sayer 12 13
Queen Alexandra
Hospital, Portsmouth
Claire Burton, Christopher Guyer, Rebecca Hardcastle
and Ali Ahmed
9 9
Manchester Anthony Smith, Fiona Reid, Karen Ward, Carolyn North,
Melissa Bradbury and Rohna Kearney
9 7
Aberdeen Christine Hemming and Kevin Cooper 8 7
Birmingham Philip Toozs-Hobson, Pallavi Latthe and Supriya
Bulchandani
8 7
Hinchingbrooke
Hospital
Ashish Pradhan, Helen Johnson and Umar Hussain 4 7
Bradford Carmel Ramage and Sue Calvert 4 6
Southport and
Ormskirk
Shaireen Aleem 6 4
Leicester General Douglas Tincello 4 5
Musgrove Park Adel Naguib 3 5
James Cook University Paul Ballard and Aethele Khunda 2 4
Harrogate and District Tracy Jackson and Adrian Barnett 3 3
Torbay Subramanian Narayanan 3 2
Arrowe Park Tom Aust, Patrick Doyle and Jeremy Weetch 1 4
Liverpool Ruben Trochez, Gillian Fowler and E Adams 2 3
Pinderfields Kathryn Fishwick 3 2
Derriford Hospital,
Plymouth
Robert Freeman, Luigi Bombieri and A Dua 3 1
Addenbrooke’s Mark Slack, Rohna Kearney, Vladimir Revicky and
Alexandros Derpapas
2 2
UH North Staffordshire Jason Cooper 1 2
UH North Tees Santhosh Puthuraya and Elaine Gouk 3 0
Royal Preston Brice Rodriguez and Sanjeev Prashar 2 1
Sunderland Royal Jonathan Chamberlain 2 1
Royal Victoria Infirmary Karen Brown, Karen Rose and Paul Hilton 2 1
Worcester Acute Deepali Sinha and Angus Thomson 2 1
Dartford and
Gravesham
Rob MacDermott, Angeli Thallon, Andreas Lesseps and
Abhisheck Gupta
1 1
Crosshouse Wael Agur, Ashraf Habib, Inna Sokolova, Mohamed Riad
and David Rae
1 1
Cornwall Hospitals Farah Lone and Rob Holmes 1 0
continued
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TABLE 66 Recruitment, by centre and randomised allocation (continued )
Centres recruiting Staff
Treatment (n)
Abdominal
vault (N= 105)a
Vaginal vault
(N= 104)
New Cross Hospital,
Wolverhampton
Khaled Afifi, Ayman Elnaqa and Charles Cox 1 0
Heart of England Gurminder Matharu and Afshan Khaja 1 0
Royal Bolton Philip Chia and Abimbola Williams 0 1
Calderdale Royal
Hospital
Yi Ling Chan, Anu Bondili and Maged Shendy 0 1
Southmead Hospital Chendrimada Madhu 1 0
Hull and East Yorkshire Jagdish Gandhi 0 1
Barnsley Meenakshi Dass and Khaled Farag 0 1
Gloucester Mark James 1 0
Jessop Wing, Sheffield Stephen Radley and Swati Jha 0 1
a One patient was excluded after recruitment because they did not meet the inclusion criteria.
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TABLE 68 Reasons for non-inclusion
Participants n (%)
Ineligible 115 (100.0)
A specific operation is necessary 73 (63.5)
Unsuitable owing to medical history 21 (18.3)
No prolapse 10 (8.7)
Change of prolapse type from original diagnosis 4 (3.5)
Not suitable for surgery 3 (2.6)
Operation cancelled 2 (1.7)
Unable to complete study questionnaires 1 (0.9)
Declined 211 (100.0)
Declined/refused surgery 58 (27.5)
Did not want to participate in the study 54 (25.6)
Wanted an abdominal procedure 53 (25.1)
Did not want to be randomised 38 (18.0)
Wanted a vaginal procedure 32 (15.2)
Wished to go with surgeon’s choice 13 (6.2)
Wanted to try a pessary 11 (5.2)
Did not want mesh 8 (3.8)
Did not want to complete questionnaires 4 (1.9)
Wanted a hysterectomy 2 (0.9)
Changed mind after initially consenting 1 (0.5)
TABLE 67 Approached participants
Participants n (%)
Approached 544 (100.0)
Randomised 209 (38.4)
Not included 335 (61.6)
Ineligible 115 (21.1)
Declined 211 (38.8)
Other reasons/missed appointment 9 (1.7)
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TABLE 70 Preoperative objective measurements (POP-Q continuous) at baseline
Measurement
Treatment
Abdominal vault (N= 104) Vaginal vault (N= 104)
POP-Q measurement (cm), mean (SD); N [range]
Ba 0.0 (2.3); 100 [–3.0 to 6.0] –0.1 (2.6); 99 [–3.0 to 6.0]
C –0.4 (2.5); 99 [–3.0 to 6.0] –0.3 (2.7); 99 [–3.0 to 6.0]
Bp –0.5 (2.0); 99 [–3.0 to 4.0] 0.0 (2.1); 96 [–3.0 to 6.0]
Total vaginal length 8.1 (1.5); 91 [2.0 to 12.0] 8.1 (1.6); 88 [4.0 to 12.0]
Overall prolapse stage, n (%)
0 0 (0.0) 0 (0.0)
1 0 (0.0) 0 (0.0)
2a 10 (9.6) 3 (2.9)
2b 41 (39.4) 37 (35.6)
3 50 (48.1) 56 (53.8)
4 1 (1.0) 5 (4.8)
Missing 2 (1.9) 3 (2.9)
Ba, leading anterior edge; Bp, leading posterior edge; C, cervix/vault.
TABLE 69 Additional baseline characteristics, by randomised allocation
Characteristic
Treatment
Abdominal vault (N= 104) Vaginal vault (N= 104)
Number of, mean (SD); N
Normal vaginal deliveries 2.4 (1.2); 100 2.5 (1.2); 101
Caesarean sections before labour 0.1 (0.2); 61 0.0 (0.2); 66
Breech vaginal deliveries 0.0 (0.2); 60 0.1 (0.4); 64
Forceps deliveries 0.3 (0.5); 66 0.2 (0.5); 69
Caesarean sections during labour 0.0 (0.0); 59 0.0 (0.2); 64
Vacuum deliveries 0.0 (0.1); 55 0.0 (0.0); 63
Previous anterior surgery mesh use, n (%) 3 (2.9) 1 (1.0)
Previous posterior surgery mesh use, n (%) 0 (0) 0 (0)
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TABLE 71 Urinary symptoms
Symptom
Treatment, n (%)
Abdominal vault (N= 104) Vaginal vault (N= 104)
Any incontinence missing 5 (4.8) 4 (3.8)
UI
None 4 (3.8) 8 (7.7)
Slight 46 (44.2) 45 (43.3)
Moderate 35 (33.7) 39 (37.5)
Severe 2 (1.9) 1 (1.0)
Missing 17 (16.3) 11 (10.6)
Stress UI 14 (13.5) 16 (15.4)
Missing 14 (13.5) 8 (7.7)
Urge UI, missing 2 (1.9) 1 (1.0)
Mixed UI 7 (6.7) 5 (4.8)
Missing 3 (2.9) 2 (1.9)
UI for no reason
Missing 4 (3.8) 4 (3.8)
UI when asleep
Missing 13 (12.5) 9 (8.7)
UI with sex 2 (1.9) 2 (1.9)
Missing 40 (38.5) 39 (37.5)
UI, urinary incontinence.
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Appendix 6 Additional information for Chapter 7
TABLE 72 Mesh use
Surgery
Treatment, n (%); N
Abdominal vault (N= 104) Vaginal vault (N= 104)
Apical surgery
No mesh 10 (10.9); 92 86 (91.5); 94
Synthetic non-absorbable 71 (77.2); 92 4 (4.3); 94
Biological 4 (4.3); 92 2 (2.1); 94
Mesh kit 6 (6.5); 92 0 (0); 94
Missing 1 (1.1); 92 2 (2.1); 94
Concomitant surgery
Anterior repair only
No mesh 9 (81.8); 11 24 (88.9); 27
Synthetic non-absorbable 2 (18.2); 11 1 (3.7); 27
Biological 0 (0); 11 0 (0); 27
Missing 0 (0); 11 2 (7.4); 27
Posterior repair only
No mesh 15 (93.8); 16 21 (87.5); 24
Synthetic non-absorbable 1 (6.3); 16 2 (8.3); 24
Biological 0 (0); 16 0 (0); 24
Missing 0 (0); 16 1 (4.2); 24
Both anterior and posterior repair
Anterior compartment only
No mesh 5 (55.6); 9 27 (96.4); 28
Synthetic non-absorbable 4 (44.4); 9 0 (0); 28
Biological 0 (0); 9 1 (3.6); 28
Posterior compartment only
No mesh 5 (55.6); 9 27 (96.4); 28
Synthetic non-absorbable 4 (44.4); 9 0 (0); 28
Biological 0 (0); 9 1 (3.6); 28
Continence procedure
No mesh 1 (33.3); 3 1 (50.0); 2
Synthetic non-absorbable 2 (66.7); 3 1 (50.0); 2
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TABLE 73 Surgical characteristics
Characteristics
Treatment, n (%)
Abdominal vault (N= 104) Vaginal vault (N= 104)
Grade of operating gynaecologist
Consultant 90 (86.5) 92 (88.5)
Trainee doctor 8 (7.7) 4 (3.8)
Specialty doctor 4 (3.8) 4 (3.8)
Missing 2 (1.9) 4 (3.8)
Grade of anaesthetist
Consultant 72 (69.2) 60 (57.7)
Specialty doctor 18 (17.3) 27 (26.0)
Trainee doctor 11 (10.6) 8 (7.7)
Missing 3 (2.9) 9 (8.7)
Anaesthetic
General 98 (94.2) 90 (86.5)
Spinal/epidural 8 (7.7) 11 (10.6)
Local 4 (3.8) 7 (6.7)
Other 0 (0) 1 (1.0)
Prophylactic antibiotic used 95 (91.3) 96 (92.3)
Catheter inserted in theatre 98 (94.2) 87 (83.7)
Vaginal pack 21 (20.2) 81 (77.9)
Urinary catheter
Urethral 96 (92.3) 88 (84.6)
Suprapubic 0 (0) 1 (1.0)
Both 1 (1.0) 0 (0)
None 1 (1.0) 0 (0)
Do not know 1 (1.0) 0 (0)
Missing 5 (4.8) 15 (14.4)
TABLE 74 Intervention details
Details
Treatment
Effect size
(95% CI);
p-value
Abdominal vault (N= 104) Vaginal vault (N= 104)
Mean (SD); N Median (P25–75)a Mean (SD); N Median (P25–75)a
Duration of operation
(minutes)
145.5 (53.9); 94 145.0 (108.0–175.0) 82.0 (34.1); 94 75.0 (61.0–93.0) 60.48 (49.80 to
71.16); < 0.001b
Length of stay (days) 2.1 (1.6); 101 2.0 (1.0–3.0) 1.8 (1.2); 100 2.0 (1.0–2.0) 1.21 (0.99 to
1.49); 0.059c
Blood loss (ml) 97.7 (78.1); 90 100.0 (50.0–100.0) 107.8 (74.8); 86 100.0 (50.0–150.0) –15.25 (–35.21
to 4.71); 0.134c
Time to surgery (days) 75.8 (94.4); 102 44.0 (14.0–105.0) 64.3 (97.8); 100 36.0 (11.5–81.5)
a P25–75 is the 25th to the 75th percentile range.
b Effect size is a MD, adjusted for minimisation variables.
c Effect size is an incidence rate ratio, adjusted for minimisation variables.
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FIGURE 31 Distribution of POP-SSs (a) at baseline and at follow-up, that is, (b) at 6 months after surgery and (c) at
12 months after randomisation. (continued )
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TABLE 75 Prolapse symptoms at 6 months after surgery
Symptoms
Treatment
Abdominal vault (N= 104) Vaginal vault (N= 104)
Symptomatic, n (%) N
Number of women with symptoms 78 (89); 88 75 (87); 86
Number of women without symptoms 10 (11); 88 11 (13); 86
Prolapse-related QoL score, mean (SD); count 2.3 (3.0); 87 2.6 (2.8); 87
Individual prolapse symptoms, n (%) N
Bowel not empty (any) 62 (100); 62 56 (100); 56
Bowel not empty (most/all of the time) 13 (15); 89 8 (9); 87
Bladder not empty (any) 54 (100); 54 54 (100); 54
Bladder not empty (most/all of the time) 11 (12); 89 8 (9); 87
Strain to empty bladder (any) 38 (100); 38 37 (100); 100
Strain to empty bladder (most/all of the time) 7 (8); 87 6 (7); 87
Dragging in back (any) 36 (100); 36 39 (100); 39
Dragging in back (most/all of the time) 6 (7); 87 7 (8); 86
Something coming down (any) 31 (100); 31 41 (100); 41
Something coming down (most/all of the time) 13 (15); 89 15 (17); 87
Dragging in abdomen (any) 29 (100); 29 32 (100); 32
Dragging in abdomen (most/all of the time) 2 (2); 87 7 (8); 87
Uncomfortable feeling or pain when standing (any) 28 (100); 28 32 (100); 32
Uncomfortable feeling or pain when standing
(most/all of the time)
7 (8); 87 7 (8); 86
Most bothersome symptom, n (%) N
Bowel not empty 27 (46); 59 18 (32); 56
Bladder not empty 14 (24); 59 6 (11); 56
Something coming down 6 (10); 59 19 (34); 56
Strain to empty bladder 4 (7); 59 3 (5); 56
Dragging in back 4 (7); 59 2 (4); 56
Uncomfortable feeling or pain when standing 3 (5); 59 4 (7); 56
Dragging in abdomen 1 (2); 59 4 (7); 56
Which symptom causes most bother not applicable 24 (29); 83 23 (29); 79
EQ-5D
Mean (SD); count 0.826 (0.217); 82 0.823 (0.175); 86
Visual Scale, mean (SD); count 78.2 (16.9); 83 77.5 (17.0); 85
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TABLE 76 POP-Q continuous outcomes at 12 months after surgery
Outcome
Treatment
Vaginal vault (N= 104)Abdominal vault (N= 104)
POP-Q measurement (cm), mean (SD); N [range]
Ba –0.9 (1.9); 80 [–3.0 to 4.0] –1.5 (1.7); 84 [–3.0 to 4.0]
C –5.8 (2.9); 80 [–10.0 to 4.0] –6.8 (2.7); 84 [–10.0 to 4.0]
Bp –2.0 (1.4); 80 [–6.0 to 3.0] –2.1 (1.4); 85 [–8.0 to 4.0]
Total vaginal length 7.7 (1.6); 77 [2.0 to 10.0] 8.4 (1.5); 83 [4.0 to 12.0]
Overall POP-Q stage, n (%); N
Stage 0 19 (22.1); 86 14 (17.3); 81
Stage 1 25 (29.1); 86 16 (19.8); 81
Stage 2a 14 (16.3); 86 13 (16.0); 81
Stage 2b 22 (25.6); 86 25 (30.9); 81
Stage 3 5 (5.8); 86 10 (12.3); 81
Stage 4 1 (1.2); 86 3 (3.7); 81
Ba, leading anterior edge; Bp, leading posterior edge; C, cervix/vault.
TABLE 77 Urinary symptoms at 12 months after randomisation
Symptom
Treatment, n (%) N
Effect sizea (95% CI); p-valueAbdominal vault (N= 104) Vaginal vault (N= 104)
SUI 6 (8.1); 74 5 (6.3); 79 1.42 (0.40 to 5.10); 0.59
Mixed UI 1 (1.2); 86 1 (1.2); 87
UI for no reason 3 (3.5); 85 2 (2.3); 86
UI when asleep 1 (1.4); 74 1 (1.2); 81
UI with sex 0 (0) 1 (1.9); 54
SUI, stress urinary incontinence; UI, urinary incontinence
TABLE 78 Time to further surgery
Time to further
surgery
Treatment
Effect sizea
(95% CI); p-value
Abdominal vault (N= 104) Vaginal vault (N= 104)
Mean (SD); N Median (P25–75)b Mean (SD); N Median (P25–75)b
Number of days 337.7 (206.3); 7 243.0 (219.0–395.0) 310.0 (190.8); 7 350.0 (152.0–367.0) 0.94 (0.31, 2.87);
0.921
a Effect size is presented as a hazard ratio, adjusted for minimisation variables and with surgeon fitted as a random effect.
b P25–75 is the 25th to the 75th percentile range.
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TABLE 79 Subgroup analyses of POP-SSs at 12 months after randomisation
Subgroup
Treatment, mean (SD); n
Effect sizea (99% CI); p-valueAbdominal vault (N= 104) Vaginal vault (N= 104)
Age group (years)
< 60 4.1 (4.2); 19 5.5 (5.1); 15 –0.34 (–3.84 to 3.16); 0.85
≥ 60 6.1 (5.6); 69 6.0 (5.5); 71
Previous incontinence surgery
Yes 3.0 (0); 1 11.0 (0); 1 –1.61 (–16.29 to 13.08); 0.83
No 5.7 (5.4); 87 5.9 (5.4); 85
Previous anterior/posterior surgery
Yes 5.3 (5.3); 58 6.2 (5.8); 59 –1.07 (–2.88 to 0.73); 0.24
No 6.2 (5.6); 30 5.4 (4.5); 27
a Effect size is presented as a MD for continuous variables and an OR for binary variables (abdominal vs. vaginal), adjusted
for baseline when available and minimisation variables.
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Appendix 7 Additional information for Chapter 8
TABLE 80 Intervention resource use and costs for the Vault trial
Intervention cost
Resource usage, n (%); N Costs (£)
Abdominal vault
(N= 104)
Vaginal vault
(N= 104)
Mean costs (SD); N
Abdominal vault
vs. vaginal vault
Abdominal
vault (N= 104)
Vaginal vault
(N= 104) MD 95% CI
Anaesthesia 102 (100); 102 100 (100);
100
20.12 (3.75); 102 18.96 (5.60);
100
Theatre overheads 102 (100); 102 100 (100);
100
420.19 (0.00);
102
420.19 (0.00);
100
Mesh for apical
prolapse
82 (80); 102 6 (6); 100
Mesh for concomitant
anterior
6 (6); 102 2 (2); 100
Mesh for concomitant
posterior
5 (5); 102 3 (3); 100
Mesh for prolapse 143.44 (150.83);
102
19.99 (79.82);
100
Incontinence mesh 2 (2); 102 1 (1); 100 2.18 (15.48); 102 1.11 (11.11); 100
Return to theatre 0 (0); 102 0 (0); 100 0.00 (0.00); 102 0.00 (0.00); 100
Catheterisation 98 (96); 102 88 (88); 100 6.12 (1.24); 102 5.61 (2.08); 100
Pain relief 102 (100); 102 100 (100);
100
2.25 (2.25); 102 1.73 (1.91); 100
Laxatives 57 (56); 102 62 (62); 100 1.10 (0.98); 102 1.22 (0.96); 100
Antibiotics 95 (93); 102 96 (97); 99 0.99 (0.27); 102 1.03 (0.18); 99
Vaginal pack 25 (25); 102 81 (81); 100 1.14 (2.02); 102 3.78 (1.84); 100
Gynaecologist’s time
(minutes), mean (SD); n
142.71 (52.24);
103
83.90 (33.90);
100
335.49 (123.91);
102
197.40 (79.92);
100
Anaesthetist’s time
(minutes), mean (SD); N
142.71 (52.24);
103
83.90 (33.90);
100
279.80 (138.14);
102
162.59 (92.23);
100
Nurse time (minutes),
mean (SD); N
142.71 (52.24);
103
83.90 (33.90);
100
383.96 (140.54);
103
225.73 (91.22);
100
Length of stay (days);
mean (SD); N
2.15 (1.63); 102 1.76 (1.16);
100
384.32 (292.01);
102
315.04 (206.88);
100
Total intervention costs 1541.55 (500.02);
102
935.22 (351.74);
100
582.31 472.32 to
692.30
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TABLE 81 Hospital resource use and costs for the Vault trial (postcode verified)
Hospital resource use
(postcode verified)
Resource usage, n (%); N Costs (£)
Abdominal vault
(N= 104)
Vaginal vault
(N= 104)
Mean costs (SD); N
Abdominal vault
vs. vaginal vault
Abdominal vault
(N= 104)
Vaginal vault
(N= 104) MD 95% CI
New prolapse procedure 6 (6); 103 5 (5); 97 167.13 (694.31);
103
199.39 (870.13);
97
–22.99 –270.95 to
224.96
Anterior 2 (2); 103 1 (1); 97
Posterior 2 (2); 100 0 (0); 97
Apical 1 (1); 103 4 (4); 97
Anterior and posterior 1 (1); 103 0 (0); 97
Anterior and apical 0 (0); 103 0 (0); 97
Posterior and apical 0 (0); 103 0 (0); 97
Anterior and posterior
and apical
0 (0); 103 0 (0); 97
New UI procedure 3 (3); 103 1 (1); 97 61.05 (354.19);
103
21.61 (212.82);
97
44.70 –53.81 to
143.21
Sling 3 (3); 103 1 (1); 97
Abdominal 0 (0); 103 0 (0); 97
Botox 0 (0); 103 0 (0); 97
Injectable 0 (0); 103 0 (0); 97
Hospital admission other
(including SAE)
3 (3); 104 4 (4); 104 12.71 (74.49);
104
61.45 (312.51);
104
–39.52 –125.40 to
46.37
Total hospital admission
costs
241.14 (777.74);
103
286.89 (932.08);
97
–19.69 –251.73 to
212.35
UI, urinary incontinence.
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TABLE 82 Resource use and costs for consultations with health professionals for the Vault trial (patient reported)
Other consultations
(participant reported
number of consultations)
Resource usage, mean (SD) Na Costs (£)
Abdominal
vault (N= 104)
Vaginal vault
(N= 104)
Mean costs (SD); Nb
Abdominal vault
vs. vaginal vault
Abdominal
vault (N= 104)
Vaginal vault
(N= 104) MD 95% CI
Outpatient consultations 1.60 (0.82); 25 1.59 (1.01); 37 77.51 (121.67);
73
111.17 (138.27);
72
GP 2.95 (3.14); 19 2.36 (2.14); 25 28.80 (74.71);
70
31.70 (62.20);
67
Practice nurse 2.17 (2.04); 6 1.00 (0.00); 3 3.48 (13.46); 54 0.89 (3.50); 49
District or incontinence
nurse
2.00 (1.41); 2 2.50 (2.00); 3 2.67 (15.83); 57 7.76 (27.95); 49
Physiotherapy
Practice 1.00 (N/A); 1 2.00 (N/A); 1 0.60 (4.50); 57 1.48 (10.03); 46
Hospital 3.00 (2.45); 7 1.63 (0.74); 8 12.10 (42.71);
59
8.67 (22.39); 51
Other consultations
(participant reported)
14.38 (81.71);
48
20.70 (49.90);
40
Total cost of professional
consultations
116.69 (183.22);
81
141.54 (154.69);
84
–43.21 –94.87
to 8.44
a For resource use, N refers to the number of women reporting seeing the health professional.
b For costs, N refers to the number of women for whom data were available. See Chapter 2 for more details.
TABLE 83 Costs of medications/devices in the Vault trial
Other treatments and
medications (participant
reported)
Resource usage, n (%); Na Costs (£)
Abdominal
vault (N= 104)
Vaginal vault
(N= 104)
Mean costs (SD); Nb
Abdominal vault
vs. vaginal vault
Abdominal
vault (N= 104)
Vaginal vault
(N= 104) MD 95% CI
Oestrogens 17 (25); 69 13 (19); 69 66.32 (207.90);
60
31.90 (124.20);
65
Antibiotics 13 (20); 66 19 (26); 72 1.03 (6.04); 61 1.11 (3.58); 67
Bladder medications 9 (13); 67 6 (10); 62 0.94 (4.17); 62 0.42 (3.14); 58
Reusable/intermittent catheter 3 (4); 74 4 (6); 67 0.53 (3.82); 73 0.20 (1.12); 65
Ring pessary 3 (4); 75 3 (4); 68 0.80 (3.96); 75 0.89 (4.16); 68
Shelf pessary 0 (0); 73 3 (4); 69 0.00 (0.00); 73 0.94 (4.42); 69
Permanent catheter 0 (0); 71 2 (3); 64 1.27 (9.15); 72 0.48 (2.68); 64
Total other treatments 56.46 (190.41);
76
27.86 (109.60);
84
61.19 –8.25 to
130.63
a N refers to the number of women for whom it was possible to calculate and/or assume a resource use. See Chapter 2
for assumptions made.
b N refers to the number of women for whom it was possible to calculate and/or assume a resource use. See Chapter 2
for assumptions made. Note that in most cases N (costs) < N (resource use). This is because, although it may be known
whether or not women received treatment (e.g. oestrogen), it may not be known how long for. Therefore, the sample
for costs is less than the sample for resource use.
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TABLE 84 Wider-perspective costs
Participant-incurred
costs
Resource usage, n (%); N Costs (£)
Abdominal vault
(N= 104)
Vaginal vault
(N= 104)
Mean costs (SD); N
Abdominal vs.
vaginala (£)
Abdominal
vault (N= 104)
Vaginal vault
(N= 104) MD 95% CI
Opportunity cost of
time and travel
Inpatient stays 91.31 (28.84);
102
90.12 (24.97);
97
Outpatient
consultations
28.54 (44.81);
73
43.16 (54.02);
73
Primary care
consultations
18.40 (39.44);
74
17.82 (26.13);
71
Subtotal 134.22 (90.91);
65
138.49 (77.17);
60
Purchase of over-the-
counter medication
4 (6); 68 6 (8); 71 0.43 (2.66); 66 4.70 (21.03); 71
Private medical care 0 (0); 64 0 (0); 66 0.00 (0.00); 64 0.00 (0.00); 66
Other expenses 2 (3); 63 3 (4); 68 1.27 (9.46); 63 9.60 (56.81); 68
Absence from paid
employment
672.56 (2729.50);
78
578.50 (2658.55);
81
Currently in
employment
22 (27); 83 19 (23); 82
Reported needing
time off workb
19 (86); 22 19 (100); 19
Days of sick leaveb,c 25.63 (47.14); 19 21.75 (46.79);
19
Total participant
perspective costs
864 (3141); 51 645 (2887); 47 –53 –400 to 294
Total NHS perspective
costs (Table 35)
1542 (500); 102 935 (352); 100 582 472 to 692
Wider-perspective
costs (NHS and
personal)
2758 (3507); 51 2032 (3061); 47 825 208 to 1443
a All models report effect sizes based on gamma distribution, log link unless otherwise stated for issues of convergence,
in which case OLS is used.
b This row should be interpreted as the proportion of women who reported being in paid employment and who also
reported needing to take time off from work for prolapse-related symptoms at completion of their 12-month follow-up
questionnaire.
c Days of sick leave reports the mean (SD) number of days of sick leave required among those women who reported
needing to take time off work.
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FIGURE 33 Scatterplot (a) and CEAC (b) for seemingly unrelated regression (imputed data set).
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FIGURE 34 Scatterplot (a) and CEAC (b) for wider-perspective analysis of costs (imputed data set).
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FIGURE 35 Scatterplot (a) and CEAC (b) using HRG tariffs instead of component costing for index interventions
(imputed data set).
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FIGURE 36 Scatterplot (a) and CEAC QALY calculation (b) sensitivity analysis 1 (imputed data set).
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FIGURE 37 Scatterplot (a) and CEAC QALY calculation (b) sensitivity analysis 2 (imputed data set).
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FIGURE 38 Scatterplot (a) and CEAC QALY calculation (b) sensitivity analysis 3 (imputed data set).
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FIGURE 39 Scatterplot (a) and CEAC (b) complete-case analysis of cost and QALY pairs.
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Appendix 8 Additional information for Chapter 9
TABLE 85 Parametric survival model results: Uterine trial failures
Variables
Survival function (SE)
Coxa Gamma Log-logistic Exponential Gompertz Weibull
Adjusted models
Uterine preservation 1.566 (0.575) –0.428 (0.357) –0.405 (0.342) 1.556 (0.571) 1.556 (0.572) 1.553 (0.571)
Baseline EQ-5D 0.202 (0.131) 1.774 (0.771) 1.631 (0.662) 0.190 (0.124) 0.191 (0.125) 0.184 (0.120)
Age 0.520 (0.185) 0.637 (0.361) 0.631 (0.338) 0.504 (0.179) 0.505 (0.180) 0.496 (0.177)
Planned anterior
surgery
2.287 (0.966) –0.832 (0.428) –0.794 (0.404) 2.308 (0.976) 2.305 (0.975) 2.332 (0.989)
Planned posterior
surgery
0.585 (0.220) 0.454 (0.372) 0.494 (0.352) 0.578 (0.218) 0.578 (0.218) 0.574 (0.217)
Planned incontinence
surgery
0.735 (0.551) 0.142 (0.843) 0.244 (0.706) 0.735 (0.549) 0.735 (0.549) 0.731 (0.545)
Constant – 4.214 (2.085) 3.452 (1.685) 0.027 (0.047) 0.027 (0.048) 0.021 (0.038)
Scale – 1.742 0.877 – –0.0019 1.104
Kappa – 0.193 – – – –
Log-likelihood –193.108 –143.775 –144.019 –144.350 –144.350 –144.174
AIC 398.217 305.550 304.039 302.699 304.694 304.348
BIC 343.61 337.867 332.299 338.522 338.176
Unadjusted models
Uterine preservation 1.615 (0.552) –0.430 (0.363) –0.445 (0.328) 1.610 (0.550) 1.610 (0.551) 1.610 (0.550)
Constant – 6.850 (0.820) 6.057 (0.720) 0.002 (0.001) 0.002 (0.001) 0.001 (0.001)
Scale – 2.763 0.906 – –0.0095 1.078
Kappa – –0.580 – – – –
Log-likelihood –220.136 –162.163 –162.882 –163.096 –163.022 –162.988
AIC 442.273 332.327 331.765 330.192 332.045 331.975
BIC – 349.448 344.606 338.753 344.886 344.816
BIC, Bayesian information criterion.
a Cox proportional hazards assumption rejected, so this model was not considered further.
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FIGURE 41 Uterine trial failure: long-term extrapolation of different survival functions. H, hysterectomy;
P, preservation.
TABLE 86 Parametric survival model results: Vault trial failures
Variables
Survival function (SE)
Coxa
Generalised
gamma Log-logistic Exponential Gompertz Weibull
Adjusted models
Abdominal vault 0.827 (0.409) 0.174 (0.339) 0.111 (0.343) 0.833 (0.411) 0.826 (0.409) 0.819 (0.406)
Baseline EQ-5D 1.415 (1.831) –0.211 (0.815) –0.251 (0.906) 1.418 (1.842) 1.429 (1.835) 1.434 (1.830)
Age 2.324 (1.766) –0.603 (0.537) –0.554 (0.525) 2.344 (1.780) 2.354 (1.789) 2.360 (1.794)
Planned anterior
surgery
1.021 (0.503) –0.007 (0.334) 0.007 (0.341) 1.017 (0.500) 0.994 (0.489) 0.989 (0.487)
Planned posterior
surgery
0.296 (0.155) 0.841 (0.403) 0.827 (0.397) 0.294 (0.154) 0.292 (0.153) 0.291 (0.152)
Planned incontinence
Surgery
0.058 (0.065) 2.145 (0.763) 2.030 (0.860) 0.064 (0.071) 0.052 (0.059) 0.045 (0.051)
Constant – 0.104 0.262 (2.153) 1.397 (4.240) 1.508 (4.580) 0.687 (2.112)
Scale – 0.262 0.645 – 0.034 1.481
Kappa – 2.716 – – – –
Log-likelihood –81.077 –62.333 –62.567 –63.730 –63.286 –62.442
AIC 174.153 142.666 141.132 141.459 142.572 140.884
BIC 193.508 171.698 166.938 164.040 168.378 166.690
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TABLE 86 Parametric survival model results: Vault trial failures (continued )
Variables
Survival function (SE)
Coxa
Generalised
gamma Log-logistic Exponential Gompertz Weibull
Unadjusted models
Abdominal vault 0.885 (0.430) –0.024 0.087 (0.349) 0.885 (0.430) 0.885 (0.430) 0.885 (0.430)
Constant – 4.992 4.508 (0.637) 0.005 (0.004) 0.004 (0.003) 0.001 (0.002)
Scale – 1.425 0.683 – 0.028 1.420
Kappa – 2.535 – – – –
Log-likelihood –86.789 –67.692 –68.288 –69.431 –69.124 –68.381
AIC 175.577 143.385 142.577 142.862 144.248 142.762
BIC 178.881 156.598 152.487 149.468 154.158 152.671
BIC, Bayesian information criterion.
a Cox proportional hazards assumption rejected, so this model was not considered further.
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FIGURE 42 Vault trial failure: long-term extrapolation of different survival functions. A, abdominal; V, vaginal.
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TABLE 87 Parametric survival model results: Uterine trial complications
Variablesa
Survival function (SE)
Coxb Log-logistic Exponential Gompertz Weibull
Adjusted models
Uterine preservation 1.071 (0.472) –0.120 (0.756) 1.077 (0.476) 1.070 (0.471) 1.075 (0.474)
Baseline EQ-5D 0.691 (0.689) 0.886 (1.743) 0.541 (0.550) 0.666 (0.667) 0.607 (0.611)
Age 0.783 (0.363) 0.522 (0.802) 0.707 (0.328) 0.771 (0.358) 0.741 (0.344)
Planned anterior surgery 0.221 (0.228) 2.575 (1.821) 0.219 (0.226) 0.220 ((0.227) 0.220 (0.227)
Planned posterior surgery 1.063 (0.474) –0.086 (0.765) 1.019 (0.454) 1.058 (0.472) 1.038 (0.463)
Planned incontinence
surgery
0.821 (0.848) 0.301 (1.784) 0.878 (0.906) 0.826 (0.853) 0.854 (0.881)
Constant – 3.452 (4.567) 0.039 (0.104) 0.092 (0.244) 0.115 (0.309)
Scale – 1.672 – –0.141 0.588
Kappa – – – – –
Log-likelihood –127.103 –116.539 –120.405 –113.9881 –116.624
AIC 266.207 249.077 254.809 243.9761 249.248
BIC 291.324 282.567 284.113 277.466 282.737
Unadjusted models
Uterine preservation 1.118 (0.489) –0.197 (0.754) 1.132 (0.495) 1.132 (0.495) 1.126 (0.492)
Constant – 8.552 (1.693) 0.002 (0.001) 0.002 (0.001) 0.006 (0.005)
Scale – 1.688 – –0.142 0.585
Kappa – – – – –
Log-likelihood –130.155 –116.539 –123.627 –117.066 –119.750
AIC 262.311 245.374 251.254 240.131 245.500
BIC 266.551 258.095 259.735 252.852 258.221
BIC, Bayesian information criterion.
a A generalised gamma model was considered, but did not converge on the available data.
b Cox proportional hazards assumption rejected, so this model was not considered further.
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FIGURE 43 Uterine trial complications: long-term extrapolation of different survival functions. H, hysterectomy;
P, preservation.
TABLE 88 Parametric survival model results: Vault trial complications
Variablesa
Survival function (SE)
Coxb Log-logistic Exponential Gompertz Weibull
Adjusted models
Abdominal vault
suspension
0.763 (0.591) 0.373 (1.032) 0.750 (0.582) 0.763 (0.591) 0.757 (0.586)
Baseline EQ-5D 4.154 (10.704) –1.868 (3.480) 3.985 (10.204) 4.320 (11.202) 4.140 (10.663)
Age 1.804 (1.953) –0.775 (1.455) 1.781 (1.928) 1.822 (1.972) 1.801 (1.949)
Planned anterior surgery 0.803 (0.615) 0.307 (1.015) 0.769 (0.588) 0.815 (0.624) 0.790 (0.605)
Planned posterior surgery 0.705 (0.544) 0.472 (1.042) 0.720 (0.556) 0.699 (0.540) 0.711 (0.549)
Constant – 8.129 (5.227) 0.001 (0.003) 0.002 (0.006) 0.002 (0.007)
Scale – 1.293 – –0.073 0.762
Kappa – – – – –
Log-likelihood –34.598 –37.480 –37.802 –37.047 –37.500
AIC 79.195 88.960 87.603 88.095 89.000
BIC 94.962 111.033 106.523 110.168 111.073
continued
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TABLE 88 Parametric survival model results: Vault trial complications (continued )
Variablesa
Survival function (SE)
Coxb Log-logistic Exponential Gompertz Weibull
Unadjusted models
Abdominal vault
suspension
0.693 (0.530) 0.489 (1.006) 0.684 (0.522) 0.694 (0.530) 0.689 (0.526)
Constant – 6.385 (1.967) 0.003 (0.004) 0.006 (0.008) 0.007 (0.009)
Scale – 1.275 – –0.070 0.774
Kappa – – – – –
Log-likelihood –35.518 –38.397 –38.682 –38.006 –38.414
AIC 73.037 82.793 81.364 82.012 82.828
BIC 76.268 92.487 87.826 91.706 92.522
BIC, Bayesian information criterion.
a A generalised gamma model was considered, but did not converge on the available data.
b Cox proportional hazards assumption rejected, so this model was not considered further.
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FIGURE 44 Vault trial complications: long-term extrapolation of different survival functions. A, abdominal;
V, vaginal.
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Detailed results from the economic model sensitivity analyses
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FIGURE 45 Cost-effectiveness acceptability curve: 0% discounting.
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FIGURE 46 Scatterplot of incremental cost-effectiveness: 0% discounting.
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FIGURE 47 Cost-effectiveness acceptability curve: 6% discounting.
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FIGURE 48 Scatterplot of incremental cost-effectiveness: 6% discounting.
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FIGURE 49 Cost-effectiveness acceptability curve: age 53 years.
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FIGURE 50 Scatterplot of incremental cost-effectiveness: age 53 years.
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FIGURE 51 Cost-effectiveness acceptability curve: age 73 years.
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FIGURE 52 Scatterplot of incremental cost-effectiveness: age 73 years.
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FIGURE 53 Cost-effectiveness acceptability curve: HRG-based intervention costing.
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FIGURE 54 Scatterplot of incremental cost-effectiveness: HRG-based intervention costing.
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FIGURE 55 Cost-effectiveness acceptability curve: time horizon – 5 years.
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FIGURE 56 Scatterplot of incremental cost-effectiveness: time horizon – 5 years.
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FIGURE 57 Cost-effectiveness acceptability curve: time horizon – 10 years.
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FIGURE 58 Scatterplot of incremental cost-effectiveness: time horizon – 10 years.
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FIGURE 59 Cost-effectiveness acceptability curve: time horizon – 20 years.
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FIGURE 60 Scatterplot of incremental cost-effectiveness: time horizon – 20 years.
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
190
0
0 20 40 60
Willingness to pay (£000)
Pe
rc
en
ta
g
e 
o
f 
it
er
at
io
n
s 
co
st
-e
ff
ec
ti
ve
80 100
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Vaginal hysterectomy
Uterine preservation
Treatment
FIGURE 61 Cost-effectiveness acceptability curve: removing general population age adjustment for utilities.
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FIGURE 62 Scatterplot of incremental cost-effectiveness: removing general population age adjustment for utilities.
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FIGURE 63 Cost-effectiveness acceptability curve: health-state costs based on trial-level rather than treatment-level
data.
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FIGURE 64 Scatterplot of incremental cost-effectiveness: health-state costs based on trial-level rather than
treatment-level data.
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FIGURE 65 Cost-effectiveness acceptability curve: health-state utility values based on trial-level rather than
treatment-level data.
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FIGURE 66 Scatterplot of incremental cost-effectiveness: health-state utility values based on trial-level rather than
treatment-level data.
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FIGURE 67 Cost-effectiveness acceptability curve: baseline utility set equal for both uterine preservation and
vaginal hysterectomy.
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FIGURE 68 Scatterplot of incremental cost-effectiveness: baseline utility set equal for both uterine preservation and
vaginal hysterectomy.
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Appendix 9 Evidence synthesis
Uterine trial
Meta-analyses: uterine preservation versus vaginal hysterectomy
This appendix contains the results of meta-analyses of eight RCTs comparing uterine preservation with vaginal
hysterectomy, including new RCTs published since, or excluded from, the most recent Cochrane review22 and
with the new data from the VUE Uterine trial. The eight pre-existing trials used a variety of surgical techniques
and have therefore been presented separately as subgroups but combined in meta-analysis.
Meta-analyses have been undertaken for outcomes measured up to 12 months after surgery.
Prolapse symptoms: up to the 12-month follow-up
Within 12 months of surgery, and based on data from three pre-existing trials, the difference in the number
of women with persistent prolapse symptoms was not statistically significant (RR 1.43, 95% CI 0.87 to 2.35),
and the heterogeneity was high (I2 = 80%). The addition of the data from the VUE trial added substantially
to the previous findings, increasing the proportion of participants by nearly 60%. In total, 103 out of 404
(25.5%) women had residual prolapse symptoms at up to 12 months after uterine preservation versus
91 out of 411 (22.1%) after hysterectomy (RR 1.16, 95% CI 0.91 to 1.48) (Figure 69). The difference was
not statistically significant, the CI was wide, and the heterogeneity was high (I2 = 71%). The VUE trial has
contributed a weighting of 75% to this meta-analysis.
Any prolapse (objective failure): up to the 12-month follow-up
Within the first postoperative year, and based on data from three pre-existing trials, the difference in the risk
of objective failure was not statistically significant (RR 1.40, 95% CI 0.56 to 3.53), and the heterogeneity
was high (I2 = 61%). The addition of the data from the VUE trial added substantially to the previous result,
increasing the proportion of participants by around 60%. In total, 83 out of 381 (21.8%) of women had
residual prolapse after uterine preservation versus 84 out of 375 (22.4%) after hysterectomy (RR 0.97,
95% CI 0.76 to 1.25) (Figure 70), albeit with a CI compatible with 24% better after preservation to 25%
worse. The VUE trial has contributed a weighting of 92% to this meta-analysis.
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Uterine preservation
Study or subgroup Events Events Weight (%)Total Total
Vaginal hysterectomy RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Abdominal sacrohysteropexy vs. vaginal hysterectomy + anterior and/or posterior colporrhaphy at 1 year
Uterine preservation + vaginal mesh repair vs. vaginal hysterectomy + mesh repair
Roovers 2004 Uterine105
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.52 (p = 0.01)
16
16
41
41
41
41
5.5
5.5
0.5
0.5
100.0
3.20 (1.29 to 7.92)
3.20 (1.29 to 7.92)
11.35 (0.66 to 196.81)
11.35 (0.66 to 196.81)
1.16 (0.91 to 1.48)
5
5
103
404
30
30
31
31
411
0
0
91
5
5
Malandri 2012 Uterine106
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.67 (p = 0.10)
Vaginal hysteropexy + sutures vs. vaginal hysterectomy
19.0
19.0
0.63 (0.31 to 1.29)
0.63 (0.31 to 1.29)
11
11
102
102
100
100
17
17
Detollenaere 2016 Uterine107
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.26 (p = 0.21)
Uterine preservation vs. vaginal hysterectomy (VUE trial data)
75.0
75.0
1.06 (0.81 to 1.41)
1.06 (0.81 to 1.41)
71
71
231
231
239
239
69
69
VUE Uterine 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.44 (p = 0.66)
Total (95% CI)
Total events
Heterogeneity: χ2 = 10.43, df = 3 (p = 0.02); I2 = 71%
Test for overall effect: z = 1.18 (p = 0.24)
Test for subgroup differences: χ2 = 10.29, df = 3 (p = 0.02); I2 = 70.9%
0.005 0.001 1 100 200
Favours preservation Favours hysterectomy
Treatment
FIGURE 69 Number of women with prolapse symptoms: up to the 12-month follow-up. M–H, Mantel–Haenszel.
A
PPEN
D
IX
9
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
196
Uterine preservation
Study or subgroup Events Events Weight (%)Total Total
Vaginal hysterectomy RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Uterine preservation + vaginal mesh repair vs. vaginal hysterectomy + mesh repair
Vaginal hysteropexy + sutures vs. vaginal hysterectomy
Malandri 2012 Uterine106
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.67 (p = 0.10)
5
5
30
30
31
31
0.6
0.6
5.3
5.3
100.0
11.35 (0.66 to 196.81)
11.35 (0.66 to 196.81)
0.11 (0.01 to 2.00)
0.11 (0.01 to 2.00)
0.97 (0.76 to 1.25)
0
0
83
381
102
102
100
100
375
4
4
84
0
0
Detollenaere 2016 Uterine107
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.49 (p = 0.14)
Hysteropexy + mesh for SSF vs. hysterectomy + SSF + mesh
2.4
2.4
1.88 (0.40 to 8.78)
1.88 (0.40 to 8.78)
4
4
16
16
15
15
2
2
Carramao 2009 Uterine108
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.80 (p = 0.42)
Uterine preservation vs. vaginal hysterectomy (VUE trial data)
91.7
91.7
0.93 (0.72 to 1.21)
0.93 (0.72 to 1.21)
74
74
233
233
229
229
78
78
VUE Uterine 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.53 (p = 0.60)
Total (95% CI)
Total events
Heterogeneity: χ2 = 5.82, df = 3 (p = 0.12); I2 = 48%
Test for overall effect: z = 0.23 (p = 0.82)
Test for subgroup differences: χ2 = 5.80, df = 3 (p = 0.12); I2 = 48.3%
0.005 0.001 1 10 200
Favours preservation Favours hysterectomy
Treatment
FIGURE 70 Number of women with any prolapse (objective failure): up to the 12-month follow-up. M–H, Mantel–Haenszel.
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Further prolapse surgery
Uterine preservation
Study or subgroup
Abdominal sacrohysteropexy with GORE-TEX vs. vaginal hysterectomy, vaginal repair, uterosacral ligament plication
Events
9
9
0.001 0.1 1 10 1000
Favours preservation Favours hysterectomy
41
41
41
41
1
1
3.8
3.8
9.00 (1.19 to 67.85)
9.00 (1.19 to 67.85)
Roovers 2004 Uterine105
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.13 (p = 0.03)
Events Weight (%)Total Total
Vaginal hysterectomy RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Vaginal uterine conservation + posterior coccygeal colpopexy vs. vaginal hysterectomy + posterior coccygeal colpopexy
2
2
7
7
9
9
0
0
1.7
1.7
6.25 (0.35 to 112.52)
6.25 (0.35 to 112.52)
Juneja 2010 Uterine109
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.24 (p = 0.21)
Sacrospinous hysteropexy vs. vaginal hysterectomy
4
4
34
34
31
31
2
2
8.0
8.0
1.82 (0.36 to 9.27)
1.82 (0.36 to 9.27)
Dietz 2010 Uterine110
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.72 (p = 0.47)
Uterine preservation + vaginal mesh repair vs. vaginal hysterectomy + mesh repair
5
5
30
30
31
31
0
0
1.9
1.9
11.35 (0.66 to 196.81)
11.35 (0.66 to 196.81)
Malandri 2012 Uterine106
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.67 (p = 0.10)
Vaginal hysteropexy + sutures vs. vaginal hysterectomy
1
1
102
102
102
102
7
7
26.9
26.9
0.14 (0.02 to 1.14)
0.14 (0.02 to 1.14)
Detollenaere 2016 Uterine107
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.84 (p = 0.07)
Laparoscopic hysteropexy vs. vaginal hysterectomy
7
7
50
50
50
50
7
7
26.9
26.9
1.00 (0.38 to 2.64)
1.00 (0.38 to 2.64)
Rahmanou 2015 Uterine111
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.00 (p = 1.00)
Uterine preservation vs. vaginal hysterectomy (VUE trial data)
15
15
244
244
242
242
8
8
30.8
30.8
1.86 (0.80 to 4.31)
1.86 (0.80 to 4.31)
VUE Uterine 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.45 (p = 0.15)
43
508 506
25
100.0 1.69 (1.06 to 2.70)Total (95% CI)
Total events
Heterogeneity: χ2 = 11.75, df = 6 (p = 0.07); I2 = 49%
Test for overall effect: z = 2.21 (p = 0.03)
Test for subgroup differences: χ2 = 11.75, df = 6 (p = 0.07); I2 = 48.8%
Treatment
FIGURE 71 Women having further prolapse surgery: up to the 12-month follow-up. M–H, Mantel–Haenszel.
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Any urinary incontinence: up to the 12-month follow up
Uterine preservation
Study or subgroup Events Events Weight (%)Total Total
Vaginal hysterectomy RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Uterine preservation + vaginal mesh repair vs. vaginal hysterectomy + mesh repair
Uterine preservation vs. vaginal hysterectomy (VUE trial data)
Malandri 2012 Uterine106
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.70 (p = 0.48)
1
1
30
30
31
31
0.6
0.6
99.4
99.4
100.0
3.10 (0.13 to 73.16)
3.10 (0.13 to 73.16)
1.05 (0.83 to 1.34)
1.05 (0.83 to 1.34)
1.07 (0.84 to 1.35)
87
87
88
267
237
237
241
241
272
84
84
84
0
0
VUE Uterine 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.42 (p = 0.67)
Total (95% CI)
Total events
Heterogeneity: χ2 = 0.45, df = 1 (p = 0.50); I2 = 0%
Test for overall effect: z = 0.52 (p = 0.61)
Test for subgroup differences: χ2 = 0.44, df = 1 (p = 0.51); I2 = 0%
0.02 0.01 1 10 50
Favours preservation Favours hysterectomy
Treatment
FIGURE 72 Number of women with any urinary incontinence: up to the 12-month follow-up. M–H, Mantel–Haenszel.
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Continence surgery
Uterine preservation
Study or subgroup Events Events Weight (%)Total Total
Vaginal hysterectomy RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Vaginal hysteropexy + sutures vs. vaginal hysterectomy
Uterine preservation vs. vaginal hysterectomy (VUE trial data)
Detollenaere 2016 uterine107
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.25 (p = 0.21)
1
1
102
102
102
102
50.0
50.0
50.0
50.0
100.0
0.25 (0.03 to 2.20)
0.25 (0.03 to 2.20)
0.75 (0.17 to 3.32)
0.75 (0.17 to 3.32)
0.50 (0.15 to 1.65)
3
3
4
344
242
242
242
242
344
4
4
8
4
4
VUE Uterine 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.38 (p = 0.70)
Total (95% CI)
Total events
Heterogeneity: χ2 = 0.68, df = 1 (p = 0.41); I2 = 0%
Test for overall effect: z = 1.14 (p = 0.25)
Test for subgroup differences: χ2 = 0.67, df = 1 (p = 0.41); I2 = 0%
0.002 0.001 1 10 500
Favours preservation Favours hysterectomy
Treatment
FIGURE 73 Number of women having continence surgery. M–H, Mantel–Haenszel.
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Adverse events
Six pre-existing trials reported the number of women who had AEs after surgery. These included urinary tract
infections, urinary retentions, buttock or sacral pain, stroke, pneumonia, ileus, atrial fibrillation and death.
Although the AEs were more common in the uterine preservation group [24/320 (8%) vs. 14/320 (4%) in
the hysterectomy group; RR 1.68, 95% CI 0.90 to 3.15] (Figure 74), this did not reach statistical significance.
The addition of the data from the VUE trial added substantially to the previous result, increasing the proportion
of participants by around 45%. In total, 38 out of 582 (6.5%) of women had AEs after uterine preservation
versus 30 out of 589 (5.1%) after hysterectomy (RR 1.27, 95% CI 0.80 to 2.01) (Figure 74). Although the
result was not statistically significant, the CI was compatible with 20% fewer women having AEs after uterine
preservation to 101% more. The trial VUE trial has contributed a weighting of 53% to this meta-analysis.
Dyspareunia
Two pre-existing trials reported that around 4% of women reported dyspareunia, but there was no
statistically significant difference between the groups (RR 0.81, 95% CI 0.24 to 2.73) (Figure 75). The
addition of the data from the VUE trial (for sexually active women only) nearly doubled the number of
participants. In total, 4 out of 208 (1.9%) of women had dyspareunia after uterine preservation versus
7 out of 202 (3.5%) after hysterectomy (RR 0.61, 95% CI 0.20 to 1.83) (Figure 75). The data were too
sparse to be reliable. The VUE trial has contributed a weighting of 32% to this meta-analysis.
Mesh exposure/erosion
Three small pre-existing trials found that around 10% of women reported mesh exposure, but there was
no statistically significant difference between the groups (RR 0.89, 95% CI 0.32 to 2.42) (Figure 76). None
of these trials reported whether or not the women required surgery for their mesh exposures. In the VUE
trial, only one woman (out of 262 in the uterine preservation group, of whom 97 received non-absorbable
mesh as part of their apical or concomitant prolapse surgery, or continence surgery) required surgery for
mesh exposure, compared with none in the hysterectomy group (in 269 women of whom 16 received
non-absorbable mesh). The mesh in this woman was used as part of the VUE suspension procedure (rather
than for a concomitant procedure). There was no statistically significant difference between the groups
(RR 1.03, 95% CI 0.40 to 2.65).
Summary (the Uterine trial)
In summary, after the addition of the VUE trial data to the pre-existing trials, when comparing uterine
suspension with hysterectomy, there was little difference between the groups in terms of prolapse symptoms
or objective prolapse recurrence, but with wide CIs indicating some uncertainty. However, women were
more likely to require further prolapse surgery after uterine preservation than after hysterectomy in the first
12 months after surgery. In the first 12 months after surgery, there was not enough evidence to reliably
compare data for urinary incontinence or continence surgery, or SAEs, dyspareunia or mesh exposure, as few
women experienced these complications.
Vault trial
Appendix 9 contains the results of meta-analyses of three pre-existing RCTs comparing abdominal vault
with vaginal vault repair and with the new data from the VUE trial. There was one other new trial115
published since the last Cochrane review in 2016.22 The four RCTs used different surgical techniques and
have therefore been presented separately as subgroups, but combined in a meta-analysis.
Meta-analyses have been undertaken for outcomes measured up to 12 months after surgery.
Prolapse symptoms: up to the 12-month follow-up
The two pre-existing trials were too small to provide conclusive evidence: there was no statistically significant
difference between the abdominal and vaginal approaches (RR 0.49, 95% CI 0.15 to 1.57) (Figure 77).
The addition of the data from the VUE trial nearly doubled the number of participants. In total, fewer women
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Uterine preservation
Study or subgroup
Abdominal sacrohysteropexy with GORE-TEX vs. vaginal hysterectomy, vaginal repair, uterosacral ligament plication
Events
6
6
0.005 0.001 1 10 200
Favours preservation Favours hysterectomy
41
41
41
41
5
5
16.7
16.7
1.20 (0.40 to 3.62)
1.20 (0.40 to 3.62)
Roovers 2004 Uterine105
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.32 (p = 0.75)
Events Weight (%)Total Total
Vaginal hysterectomy RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Vaginal sacrospinous uterine suspension vs. vaginal hysterectomy
13
13
80
80
78
78
3
3
10.1
10.1
4.22 (1.25 to 14.25)
4.22 (1.25 to 14.25)
Jeng 2005 Uterine112
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.32 (p = 0.02)
Uterine preservation + vaginal mesh repair vs. vaginal hysterectomy + mesh repair
0
0
30
30
31
31
0
0
Not estimable
Not estimable
Malandri 2012 Uterine106
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: not applicable
Vaginal hysteropexy + sutures vs. vaginal hysterectomy
3
3
103
103
105
105
2
2
6.6
6.6
1.53 (0.26 to 8.96)
1.53 (0.26 to 8.96)
Detollenaere 2016 Uterine107
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.47 (p = 0.64)
Laparoscopic hysteropexy vs. vaginal hysterectomy
0
0
50
50
50
50
0
0
Not estimable
Not estimable
Rahmanou 2015 Uterine111
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: not applicable
Hysteropexy + mesh for SSF vs. hysterectomy + SSF + mesh
2
2
16
16
15
15
4
4
13.8
13.8
0.47 (0.10 to 2.20)
0.47 (0.10 to 2.20)
Carramao 2009 Uterine108
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.96 (p = 0.34)
Uterine preservation vs. vaginal hysterectomy (VUE trial data)
14
14
262
262
269
269
16
16
52.7
52.7
0.90 (0.45 to 1.80)
0.90 (0.45 to 1.80)
VUE Uterine 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.30 (p = 0.76)
38
582 589
30
100.0 1.27 (0.80 to 2.01)Total (95% CI)
Total events
Heterogeneity: χ2 = 6.35, df = 4 (p = 0.17); I2 = 37%
Test for overall effect: z = 1.01 (p = 0.31)
Test for subgroup differences: χ2 = 6.27, df = 4 (p = 0.18); I2 = 36.2%
Treatment
FIGURE 74 Number of women with AEs. M–H, Mantel–Haenszel.
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Uterine preservation
Study or subgroup Events Events Weight (%)Total Total
Vaginal hysterectomy RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Vaginal sacrospinous uterine suspension vs. vaginal hysterectomy
Uterine preservation + vaginal mesh repair vs. vaginal hysterectomy + mesh repair
Jeng 2005 Uterine112
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.04 (p = 0.97)
4
4
80
80
78
78
50.1
50.1
18.2
18.2
100.0
0.97 (0.25 to 3.76)
0.97 (0.25 to 3.76)
0.34 (0.01 to 8.13)
0.34 (0.01 to 8.13)
0.61 (0.20 to 1.83)
0
0
4
208
30
30
31
31
202
1
1
7
4
4
Malandri 2012 Uterine106
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.66 (p = 0.51)
Uterine preservation vs. vaginal hysterectomy (VUE trial data)
31.7
31.7
0.19 (0.01 to 3.90)
0.19 (0.01 to 3.90)
0
0
98
98
93
93
2
2
VUE Uterine 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.08 (p = 0.28)
Total (95% CI)
Total events
Heterogeneity: χ2 = 1.16, df = 2 (p = 0.56); I2 = 0%
Test for overall effect: z = 0.88 (p = 0.38)
Test for subgroup differences: χ2 = 1.14, df = 2 (p = 0.57); I2 = 0%
0.001 0.1 1 10 1000
Favours preservation Favours hysterectomy
Treatment
FIGURE 75 Number of women with dyspareunia. M–H, Mantel–Haenszel.
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Uterine preservation
Study or subgroup Events Events Weight (%)Total Total
Vaginal hysterectomy RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Uterine preservation + vaginal mesh repair vs. vaginal hysterectomy + mesh repair
Vaginal uterine conservation + posterior coccygeal colpopexy vs. vaginal hysterectomy + posterior coccygeal colpopexy
Malandri 2012 Uterine106
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.28 (p = 0.20)
0
0
30
30
31
31
46.1
46.1
5.9
5.9
100.0
0.15 (0.01 to 2.74)
0.15 (0.01 to 2.74)
6.25 (0.35 to 112.52)
6.25 (0.35 to 112.52)
1.03 (0.40 to 2.65)
2
2
6
315
7
7
9
9
324
0
0
6
3
3
Juneja 2010 Uterine109
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.24 (p = 0.21)
Hysteropexy + mesh for SSF vs. hysterectomy + SSF + mesh
41.4
41.4
0.94 (0.22 to 3.94)
0.94 (0.22 to 3.94)
3
3
16
16
15
15
3
3
Carramao 2009 Uterine108
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.09 (p = 0.93)
Uterine preservation vs. vaginal hysterectomy (VUE trial data)
6.6
6.6
3.08 (0.13 to 75.26)
3.08 (0.13 to 75.26)
1
1
262
262
269
269
0
0
VUE Uterine 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.69 (p = 0.49)
Total (95% CI)
Total events
Heterogeneity: χ2 = 3.66, df = 3 (p = 0.30); I2 = 18%
Test for overall effect: z = 0.06 (p = 0.95)
Test for subgroup differences: χ2 = 3.65, df = 3 (p = 0.30); I2 = 17.8%
0.001 0.1 1 10 1000
Favours preservation Favours hysterectomy
Treatment
FIGURE 76 Number of women with mesh exposure/erosion. M–H, Mantel–Haenszel.
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Abdominal repair
Study or subgroup Events Events Weight (%)Total Total
Vaginal repair RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Abdominal sacral colpopexy vs. vaginal sacrospinous colpopexy
Laparoscopic sacral colpopexy vs. total vaginal polypropylene mesh kit
Maher 2004 Vault113
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.48 (p = 0.63)
3
3
46
46
43
43
8.3
8.3
7.9
7.9
100.0
0.70 (0.17 to 2.95)
0.70 (0.17 to 2.95)
0.26 (0.03 to 2.25)
0.26 (0.03 to 2.25)
0.70 (0.49 to 0.99)
1
1
35
188
53
53
55
55
185
4
4
49
4
4
Maher 2011 Vault114
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.23 (p = 0.22)
Abdominal vs. vaginal vault repair (VUE trial data)
83.7
83.7
0.74 (0.52 to 1.06)
0.74 (0.52 to 1.06)
31
31
89
89
87
87
41
41
VUE Vault 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.64 (p = 0.10)
Total (95% CI)
Total events
Heterogeneity: χ2 = 0.90, df = 2 (p = 0.64); I2 = 0%
Test for overall effect: z = 2.02 (p = 0.04)
Test for subgroup differences: χ2 = 0.88, df = 2 (p = 0.64); I2 = 0%
0.002 0.001 1 10 500
Favours abdominal Favours vaginal
Treatment
FIGURE 77 Number of women with prolapse symptoms: up to the 12-month follow-up. M–H, Mantel–Haenszel.
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(35/188, 18.6%) had residual prolapse symptoms after an abdominal vault suspension than after a vaginal
vault suspension (49/185, 26.5%; RR 0.70, 95% CI 0.49 to 0.99) (Figure 77). This statistically significant result
favours the abdominal vault approach. The VUE trial contributed a weighting of 84% to this meta-analysis.
Any prolapse (objective failure): up to the 12-month follow-up
On combining data from three pre-existing trials, nearly twice as many women had residual measurable
prolapse after the vaginal approach (32/137, 23%, after the abdominal route vs. 55/129, 43% after the
vaginal repair; RR 0.55, 95% CI 0.38 to 0.80) (Figure 78). The addition of the data from the VUE trial
increased the proportion of participants by around 40%. In total, fewer women (60/223, 26.9%) had
residual objective prolapse protrusion in the 12 months after an abdominal vault suspension than after a
vaginal vault suspension procedure (93/210, 44.3%; RR 0.61, 95% CI 0.47 to 0.80) (Figure 78). This
statistically significant result favours the abdominal vault approach. The VUE trial contributed a weighting
of 41% to this meta-analysis.
Further prolapse surgery: up to the 12-month follow-up
Too few women required further prolapse surgery to provide conclusive evidence from the two small
pre-existing trials (RR 0.23, 95% CI 0.04 to 1.31) (Figure 79). The addition of the data from the VUE trial
doubled the number of participants, but in total only 18 women required further prolapse surgery in
the first 12 months. Although fewer women (6/201, 3%) had further surgery after an abdominal vault
suspension than after a vaginal vault suspension (12/198, 6%; RR 0.51, 95% CI 0.20 to 1.29), this did
not reach statistical significance (Figure 79). This result was compatible with 80% favouring the abdominal
vault approach versus 29% being worse off. The VUE trial contributed a weighting of 48% to this
meta-analysis.
Any urinary incontinence: up to the 12-month follow-up
In two pre-existing trials, fewer women reported urinary incontinence after abdominal (12/89, 13%) than
after vaginal surgery ((24/94, 26%; RR 0.53, 95% CI 0.28 to 0.99). The addition of the data from the
VUE trial almost doubled the number of participants. In total, the proportion of women with urinary
incontinence after an abdominal vault suspension (44/174, 25.3%) versus after a vaginal vault suspension
(49/180, 27.2%) was no longer statistically different (RR 0.92, 95% CI 0.65 to 1.31) (Figure 80). The VUE
trial contributed a weighting of 52% to this meta-analysis.
Continence surgery
In the two pre-existing trials, there was insufficient evidence to reliably identify a difference in the number of
women requiring subsequent continence surgery between the two groups (RR 0.49, 95% CI 0.13 to 1.91)
(Figure 81). The addition of the data from the VUE trial doubled the number of participants, but in total only
13 women required continence surgery in the first 12 months. Few women (6/201, 3%) had continence
surgery after an abdominal or after a vaginal vault suspension (7/198, 3.5%; RR 0.84, 95% CI 0.29 to 2.46),
and the difference did not reach statistical significance (Figure 81). The data are still too few to be reliable.
The VUE trial contributed a weighting of 14% to this meta-analysis.
Adverse events
Only two out of the three pre-existing trials reported AEs. The AEs included cystotomy, haematoma,
wound infection, voiding dysfunction (existing preoperatively), mesh infection requiring removal and
incisional hernia. More women had AEs in the abdominal groups (18/84, 21%) than in the vaginal groups
(7/75, 9%; RR 2.25, 95% CI 1 to 5.04) (Figure 82). The addition of the data from the VUE trial added
> 50% extra participants. Although more women (24/186, 12.9%) had further surgery after an abdominal
vault suspension than after a vaginal vault suspension (13/175, 7.4%; RR 1.68, 95% CI 0.89 to 3.18),
this did not reach statistical significance (Figure 82). This result was compatible with 11% having fewer
AEs with the abdominal approach versus 218% having more. The VUE trial contributed a weighting of
45% to this meta-analysis.
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Abdominal repair
Study or subgroup Events Events Weight (%)Total Total
Vaginal repair RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Abdominal sacral colpopexy vs. vaginal sacrospinous colpopexy
Laparoscopic sacral colpopexy vs. total vaginal polypropylene mesh kit
Maher 2004 Vault113
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.74 (p = 0.46)
11
11
46
46
42
42
14.3
14.3
33.1
33.1
100.0
0.77 (0.39 to 1.53)
0.77 (0.39 to 1.53)
0.39 (0.23 to 0.67)
0.39 (0.23 to 0.67)
0.61 (0.47 to 0.80)
12
12
60
223
53
53
55
55
210
32
32
93
13
13
Maher 2011 Vault114
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 3.39 (p = 0.0007)
Abdominal or laparoscopic sacral colpopexy vs. vaginal sacrospinous colpopexy
11.4
11.4
0.76 (0.35 to 1.63)
0.76 (0.35 to 1.63)
9
9
38
38
32
32
10
10
Lim 2012 Vault115
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.71 (p = 0.48)
Abdominal vs. vaginal vault repair (VUE trial data)
41.2
41.2
0.69 (0.47 to 1.02)
0.69 (0.47 to 1.02)
28
28
86
86
81
81
38
38
VUE Vault 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.87 (p = 0.06)
Total (95% CI)
Total events
Heterogeneity: χ2 = 3.80, df = 3 (p = 0.28); I2 = 21%
Test for overall effect: z = 3.63 (p = 0.0003)
Test for subgroup differences: χ2 = 3.79, df = 3 (p = 0.29); I2 = 20.9%
0.05 0.02 1 5 20
Favours abdominal Favours vaginal
Treatment
FIGURE 78 Number of women with any prolapse (objective failure): up to the 12-month follow-up. M–H, Mantel–Haenszel.
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Abdominal repair
Study or subgroup Events Events Weight (%)Total Total
Vaginal repair RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Abdominal sacral colpopexy vs. vaginal sacrospinous colpopexy
Laparoscopic sacral colpopexy vs. total vaginal polypropylene mesh kit
Maher 2004 Vault113
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.03 (p = 0.30)
1
1
46
46
43
43
24.6
24.6
27.3
27.3
100.0
0.31 (0.03 to 2.88)
0.31 (0.03 to 2.88)
0.15 (0.01 to 2.80)
0.15 (0.01 to 2.80)
0.51 (0.20 to 1.29)
0
0
6
201
53
53
55
55
198
3
3
12
3
3
Maher 2011 Vault114
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.27 (p = 0.20)
Abdominal vs. vaginal vault repair (VUE trial data)
48.1
48.1
0.82 (0.26 to 2.59)
0.82 (0.26 to 2.59)
5
5
102
102
100
100
6
6
VUE Vault 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.34 (p = 0.73)
Total (95% CI)
Total events
Heterogeneity: χ2 = 1.51, df = 2 (p = 0.47); I2 = 0%
Test for overall effect: z = 1.42 (p = 0.16)
Test for subgroup differences: χ2 = 1.46, df = 2 (p = 0.48); I2 = 0%
0.001 0.1 1 10 1000
Favours abdominal Favours vaginal
Treatment
FIGURE 79 Number of women having further prolapse surgery: up to the 12-month follow-up. M–H, Mantel–Haenszel.
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Abdominal repair
Study or subgroup Events Events Weight (%)Total Total
Vaginal repair RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Abdominal sacral colpopexy vs. vaginal sacrospinous colpopexy
Laparoscopic sacral colpopexy vs. total vaginal polypropylene mesh kit
Maher 2004 Vault113
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.23 (p = 0.22)
5
5
36
36
39
39
19.9
19.9
28.5
28.5
100.0
0.54 (0.20 to 1.43)
0.54 (0.20 to 1.43)
0.52 (0.23 to 1.18)
0.52 (0.23 to 1.18)
0.92 (0.65 to 1.31)
7
7
44
174
53
53
55
55
180
14
14
49
10
10
Maher 2011 Vault114
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.53 (p = 0.12)
Abdominal vs. vaginal vault repair (VUE trial data)
51.6
51.6
1.30 (0.84 to 1.99)
1.30 (0.84 to 1.99)
32
32
85
85
86
86
25
25
VUE Vault 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.18 (p = 0.24)
Total (95% CI)
Total events
Heterogeneity: χ2 = 5.42, df = 2 (p = 0.07); I2 = 63%
Test for overall effect: z = 0.45 (p = 0.66)
Test for subgroup differences: χ2 = 5.33, df = 2 (p = 0.07); I2 = 62.5%
0.05 0.02 1 5 20
Favours abdominal Favours vaginal
Treatment
FIGURE 80 Number of women with any urinary incontinence: up to the 12-month follow-up. M–H, Mantel–Haenszel.
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Abdominal repair
Study or subgroup Events Events Weight (%)Total Total
Vaginal repair RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Abdominal sacral colpopexy vs. vaginal sacrospinous colpopexy
Laparoscopic sacral colpopexy vs. total vaginal polypropylene mesh kit
Maher 2004 Vault113
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.53 (p = 0.59)
2
2
46
46
43
43
44.0
44.0
41.7
41.7
100.0
0.62 (0.11 to 3.55)
0.62 (0.11 to 3.55)
0.35 (0.04 to 3.22)
0.35 (0.04 to 3.22)
0.84 (0.29 to 2.46)
1
1
6
201
53
53
55
55
198
3
3
7
3
3
Maher 2011 Vault114
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.93 (p = 0.35)
Abdominal vs. vaginal vault repair (VUE trial data)
14.3
14.3
2.94 (0.31 to 27.80)
2.94 (0.31 to 27.80)
3
3
102
102
100
100
1
1
VUE Vault 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.94 (p = 0.35)
Total (95% CI)
Total events
Heterogeneity: χ2 = 1.92, df = 2 (p = 0.38); I2 = 0%
Test for overall effect: z = 0.32 (p = 0.75)
Test for subgroup differences: χ2 = 1.91, df = 2 (p = 0.38); I2 = 0%
0.005 0.001 1 10 200
Favours abdominal Favours vaginal
Treatment
FIGURE 81 Number of women having continence surgery. M–H, Mantel–Haenszel.
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Abdominal repair
Study or subgroup Events Events Weight (%)Total Total
Vaginal repair RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Abdominal sacral colpopexy vs. vaginal sacrospinous colpopexy
Abdominal or laparoscopic sacral colpopexy vs. vaginal sacrospinous colpopexy
Maher 2004 Vault113
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.63 (p = 0.53) 
5
5
46
46
43
43
23.0
23.0
32.2
32.2
100.0
1.56 (0.40 to 6.13)
1.56 (0.40 to 6.13)
2.74 (0.99 to 7.57)
2.74 (0.99 to 7.57)
1.68 (0.89 to 3.18)
13
13
24
186
38
38
32
32
175
4
4
13
3
3
Lim 2012 Vault115
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.94 (p = 0.05)
Abdominal vs. vaginal vault repair (VUE trial data)
44.9
44.9
0.98 (0.33 to 2.94)
0.98 (0.33 to 2.94)
6
6
102
102
100
100
6
6
VUE Vault 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.04 (p = 0.97)
Total (95% CI)
Total events
Heterogeneity: χ2 = 1.82, df = 2 (p = 0.40); I2 = 0%
Test for overall effect: z = 1.59 (p = 0.11)
Test for subgroup differences: χ2 = 1.82, df = 2 (p = 0.40); I2 = 0%
0.01 0.1 1 10 100
Favours abdominal Favours vaginal
Treatment
FIGURE 82 Number of women experiencing AEs. M–H, Mantel–Haenszel.
D
O
I:10.3310/hta24130
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2020
VO
L.24
N
O
.13
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2020.
This
w
ork
w
as
produced
by
H
em
m
ing
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
211
Dyspareunia
Only one of the three pre-existing trials reported dyspareunia. The trial was too small and the number of
sexually active women with dyspareunia too few to provide conclusive evidence (RR 0.77, 95% CI 0.32
to 1.83) (Figure 83). The addition of the data from the VUE trial (also restricted to sexually active women)
more than doubled the number of participants. In total, 7 out of 50 (14%) of the women had dyspareunia
after abdominal repair versus 7 out of 42 (17%) after vaginal repair (RR 0.88, 95% CI 0.38 to 2.04)
(Figure 83). The data were too sparse to be reliable. The VUE trial contributed a weighting of 7% to
this meta-analysis.
Mesh exposure/erosion
Two of the pre-existing trials reported mesh complications.114,115 Although there were more women with
mesh exposure in the vaginal group (four in the abdominal group vs. nine in the vaginal group), this did
not reach statistical significance (RR 0.42, 95% CI 0.13 to 1.36) (data not shown). Only one of these
trials114 reported how many women required surgery for their mesh exposure. In the VUE trial, none of the
abdominal group and only one woman in the vaginal group had surgery for her mesh exposure, and that
was for a concomitant mesh used for a continence procedure (Figure 84). There was no statistically
significant difference between the groups (RR 0.24, 95% CI 0.04 to 1.36) (Figure 84).
Summary (the Vault trial)
In summary, after the addition of the VUE trial data to the pre-existing trials, when comparing abdominal
versus vaginal vault suspension, significantly fewer women had prolapse symptoms or objective prolapse
recurrence. However, in the first 12 months there was not enough evidence to reliably compare the
consequences for further prolapse surgery, urinary incontinence or continence surgery, or SAEs,
dyspareunia or mesh exposure, as few women experienced these complications.
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Abdominal repair
Study or subgroup Events Events Weight (%)Total Total
Vaginal repair RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Abdominal sacral colpopexy vs. vaginal sacrospinous colpopexy
Abdominal vs. vaginal vault repair (VUE trial data)
Maher 2004 Vault113
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.60 (p = 0.55)
6
6
19
19
17
17
93.1
93.1
6.9
6.9
100.0
0.77 (0.32 to 1.83)
0.77 (0.32 to 1.83)
2.44 (0.10 to 57.37)
2.44 (0.10 to 57.37)
0.88 (0.38 to 2.04)
1
1
7
50
31
31
25
25
42
0
0
7
7
7
VUE Vault 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.55 (p = 0.58)
Total (95% CI)
Total events
Heterogeneity: χ2 = 0.50, df = 1 (p = 0.48); I2 = 0%
Test for overall effect: z = 0.29 (p = 0.77)
Test for subgroup differences: χ2 = 0.48, df = 1 (p = 0.49); I2 = 0%
0.001 0.1 1 10 1000
Favours abdominal Favours vaginal
Treatment
FIGURE 83 Number of women with dyspareunia. M–H, Mantel–Haenszel.
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Abdominal repair
Study or subgroup Events Events Weight (%)Total Total
Vaginal repair RR
M–H, fixed, 95% Cl
RR
M–H, fixed, 95% Cl
Laparoscopic sacral colpopexy vs. total vaginal polypropylene mesh kit
Abdominal versus vaginal vault repair (VUE trial data)
Maher 2011 Vault114
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.46 (p = 0.14)
1
1
53
53
55
55
76.4
76.4
23.6
23.6
100.0
0.21 (0.03 to 1.72)
0.21 (0.03 to 1.72)
0.33 (0.01 to 7.93)
0.33 (0.01 to 7.93)
0.24 (0.04 to 1.36)
0
0
1
155
102
102
100
100
155
1
1
6
5
5
VUE Vault 2018
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.69 (p = 0.49)
Total (95% CI)
Total events
Heterogeneity: χ2 = 0.05, df = 1 (p = 0.82); I2 = 0%
Test for overall effect: z = 1.61 (p = 0.11)
Test for subgroup differences: χ2 = 0.05, df = 1 (p = 0.82); I2 = 0%
0.002 0.001 1 10 50
Favours abdominal Favours vaginal
Treatment
FIGURE 84 Number of women requiring surgery for mesh exposure/erosion. M–H, Mantel–Haenszel.
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Appendix 10 VUE-Qual
Background
Recruitment to the VUE trial proved more difficult than anticipated, mainly because of patient preference
for a particular treatment. A qualitative evaluation (know as VUE-Qual) was proposed to provide a better
understanding of the issues impacting on the decision-making process.
Methods
Recruitment
Eligible patients were given an information sheet and consent form for VUE-Qual to allow the recruitment
consultation to be audio-recorded. The patients’ decision to take part (or not) in VUE-Qual did not have an
impact on their invitation to participate in the VUE trial. If the consent form had not been returned to the
trial office prior to the recruitment consultation, the recruiter asked potential participants if they were happy
to give verbal consent with the understanding that the consent form must be returned as soon as possible.
Audio files of the recruitment consultations could not be transferred to the qualitative researchers until
written consent had been received. To ensure confidentiality the files were anonymised, only identifiable by
the VUE trial number, transferred and stored securely.
Data analysis
The information exchange between the recruiter and potential participant was systematically evaluated
with the a priori aim of improving the informed consent process. Summary notes were made for each
recording. However, owing to time restrictions transcription was not possible. A modified framework
approach was used to thematically analyse the recordings to explore themes occurring throughout.116
Results
Participants
Eight potential VUE trial participants were approached regarding participation in VUE-Qual, seven of
whom were eligible for the Uterine trial and one who was eligible for the Vault trial. Of those participants
approached, six provided consent and two patients refused. The one patient that was eligible for the Vault
trial refused to participate in VUE-Qual.
During the recruitment consultations it became apparent that one participant was identified as having
a clear preference for one of the surgical interventions, thereby making her ineligible for the VUE trial.
The five other potential participants agreed to take part in the VUE trial following the recruitment
consultation (giving a VUE acceptance rate of 83%).
Recruitment consultations
There were many similarities throughout the recruitment consultations in terms of how they were structured:
initial introductions, establishing understanding of the VUE trial and trial processes (including completion of
trial paperwork) and postoperative care. The recruiter did not spend much time discussing surgical procedures,
as this would have been discussed previously in the gynaecology clinic.
Each consultation was recruiter led, although the recruiter gave participants time to talk and listened to
them intently. A script was not used; however, the recruiter did have a copy of the clinical assessments of
their prolapse symptoms. The recruiter established that participants had time for the consultation at the
beginning of the call, with the average duration being < 22 minutes.
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Randomisation
Prior to the recruitment consultation there seemed to be some uncertainty over the randomisation process.
It is not clear what information potential VUE trial participants were given in the gynaecology clinic,
specifically in relation to the random allocation process. However, when discussing with participants the
recruiter consistently used the term ‘equally happy’ to describe how they should feel regarding the random
allocation of surgical treatment. On only one occasion did the recruiter use the term ‘equipoise’ (equal
uncertainty) and proceeded to explain the term. The randomisation aspect of the VUE trial was discussed
with all participants. The exact method for allocation, use of a computer program, to make the selection
was mentioned only twice.
The randomisation aspect of the VUE trial appeared to cause some apprehension:
Participant 3: That was my only concern.
Patient preferences
The participant who was identified as having a clear preference for a hysterectomy (therefore ineligible
for the VUE trial) had discussed her preference with her family and they had agreed that her preferred
treatment was the best option for her. The recruiter did not challenge or explore this expressed preference.
One further participant was asked if she had a treatment preference after stating the procedure she wanted.
Some statements made, and issues raised, by the participants may have indicated a treatment preference
but were not pursued:
Participant 1: If I could I would prefer to get everything, cysts can change, for safety, just want to get
rid of it, will see what they want to do.
Participant 6: Do you mean the operation I’m away to have?
Two participants highlighted that they would want their doctor to do what they thought would be best
for them.
Clinical follow-up appointment
The trial patient information leaflet clearly stated that there were no additional benefits for participating
in the trial. The 12-month follow-up appointment was discussed with all participants and mentioned to
half that this was not a standard NHS appointment (i.e. research appointment):
Recruiter: Women like the 12 months clinic appointment, not usually followed up on NHS, physically
see the extent of any symptoms that are still remaining, peace of mind, opportunity to ask questions,
pros and cons.
Participation in the VUE trial
All six participants expressed a willingness to participate in the VUE trial, although provided no reason
for this. There was no indication, as relevant literature would suggest, that willingness to participate was
owing to altruism, the desire to help others. One participant did acknowledge the benefit of the trial for
women in the future, but did not pursue this as a reason for consenting to participate in the VUE trial:
Participant 3: Trying to find out what would be best in the long term, not for self necessarily.
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Although the women were eligible for participation in the VUE trial, the recruiter clearly recognised the
uncertainty of one of the participants and was very quick to put her at ease:
Recruiter: Don’t have to have surgery just because on study, if you’re unsure can have another
discussion with Dr B.
This highlights the importance of the recruiter in the decision-making process. In addition, throughout
the consultation the recruiter was able to build up a rapport with participants, making them feel more
comfortable about raising their concerns. This allowed the recruiter to offer reassurance and advice to help
them make their decision about whether or not to participate in the trial. A consistent example of how the
recruiter attempted to reassure the participants about trial participation was how she emphasised that their
personal needs would always come before the needs of the trial. This may have reassured participants that
if in the operating theatre the randomised allocation was no longer deemed necessary, it would not be
performed just because they were taking part in a trial.
Discussion
Qualitative methods were used to explore audio-recorded recruitment consultations within the VUE trial
between potential participants and the recruiter.
Importantly, the six participants that participated in VUE-Qual were all eligible for only the Uterine trial.
The trial population therefore did not give a true representation of the potential participants suitable for
both RCTs within the VUE trial. It is possible that the decision-making process may be different for potential
Vault trial participants, as they would have already undergone surgical treatment to remove the uterus.
In addition, the lower than expected acceptance rate for the trial was not reflected in the VUE-Qual
population, as there was an 83% acceptance rate in VUE-Qual versus a 33% overall rate when VUQ-Qual
was conducted in 2014. Furthermore, only one of the six participants declined randomisation because of a
preference for one of the surgical procedures. However, the reasons behind this patient preference was
not explored further by the recruiter.
VUE-Qual did highlight key findings of importance during the recruitment process, most importantly the
overarching theme relating to the recruiter relationship and rapport-building with potential participants.
This may be because the recruiter had previous experience of conducting recruitment consultations for
RCTs and provided information beyond the standard requirements of the recruitment process.
There was some confusion over the randomisation process, with one participant believing the recruiter
wanted to talk about the operation she was going to have. This would indicate that the participant had
already agreed to a surgical treatment and had not understood the randomisation element of the trial.
This has been evidenced in several other studies across a range of clinical conditions and populations in
which participants consent to randomisation even though it becomes apparent during follow-up that they
have not understood the process.117 It has been established that this willingness to participate may be a
way to avoid admitting to a lack of understanding.118
A considerable amount of time during the recruitment consultation was spent discussing how to complete
the paperwork. The recruiter took the time to address participants’ concerns and misunderstandings about
the trial paperwork, specifically the consent form and baseline questionnaire. There was also mention of the
follow-up questionnaires at 6 and 12 months for participants to self-evaluate their progress. This follow-up
aspect is important, as it can help with retention of participants so they do not just feel like a number in
a study.119 Knowing what is expected of them should they participate in the trial may help participants’
decision-making process, as they will not be asked to do anything they have not already been informed of.
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The importance of the relationship between recruiter and potential VUE trial participants became particularly
evident when the participants were describing their prolapse symptoms. The recruiter demonstrated empathy,
reassurance, advice and support when listening to their narratives. The participants were not asked for such
information, but the recruiter allowed them time to express their experiences. This could have made them
feel at ease and also impact on their decision to participate in the VUE trial. It has been reported previously
that the relationship potential participants have with the recruiter is a contributing factor to consent to trial
participation.120
The recruiter was very supportive of the participants’ decisions to take time to consider seeking surgical
treatment and did not pursue them to participate. This may have allowed the recruiter to gain the trust of
the participants, which is known to be beneficial for recruitment.121
For less experienced recruiters it may be beneficial to have a checklist for undertaking recruitment
consultations. This may take away the personal aspect of the recruitment consultation, but this would be
dependent on the personality of the recruiter. Having a competent and confident recruiter can reduce
anxiety among potential participants (which may lead them to decline participation).122
Strengths
The key strength of this study was the ability to examine in depth how trial information was presented
to potential VUE trial participants and to understand better how to improve aspects of the recruitment
process. The use of a digital audio-recorder allowed an accurate representation of the recruitment
consultations and is less intrusive than having an observer present during the recruitment consultation.
Another strength was that there were no additional requirements for the potential VUE trial participants if
they chose to participate in the VUE-Qual study, that is, it involved audio-recording a consultation they
would be having irrespective of the qualitative investigation.
Limitations
The main limitation of this study was the low number of potential participants available to be approached
regarding VUE-Qual; therefore, the themes identified may not represent the group of women eligible
to participate in the VUE trial as a whole. The VUE trial was a large multicentre surgical RCT; however,
VUE-Qual was conducted within only one trial centre and differences may be found in different centres,
based on different recruiters and/or regional differences.
During a recruitment consultation the participant may disclose sensitive data, which may make the
recruiter reluctant to record the recruitment consultations. It may also give the feeling that the recording
is being used for more than its intended purpose, for example to monitor the recruiter. The recruiter may
change his or her behaviour during the recruitment consultations that are being audio-recorded, which
again may not give accurate representation of recruitment consultations (which would have been negated
if more recordings were undertaken).
Conclusion
Throughout the recruitment consultation the recruiter was able to build a personal relationship with each
of the participants. It was the forming of this relationship that allowed the recruiter to discuss the context
of the trial. The relationship and rapport the recruiter had with the participants underpins the whole
information exchange about participation in the VUE trial.
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However, the study was undertaken within one trial centre, analysing a small sample of recruitment
consultations undertaken by one recruiter. To gain a better overall representation it would have been
useful to continue audio-recording the recruitment consultations with more recruiters/centres. If the
VUE-Qual study was extended, this would have allowed for comparisons regionally and between recruiters
to determine if the same themes were consistent throughout the VUE trial as a whole and, in particular,
whether or not the rapport-building is a finding across other sites.
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